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1. Introduction
Sepsis is a major complication of bacterial infections, and is associated with a systemic 
inflammatory response syndrome (SIrS) involving activation and apoptosis of cells and 
activation of the blood coagulation system up to the level of disseminated intravascular 
coagulation (DIC). The mortality rate from sepsis is still high. In an update on the epidemiology 
of sepsis, several studies are cited that report mortality rates of 20–52%1. In more recent 
intervention trials the mortality from sepsis remains high at around 30-50% and apparently, in 
spite of advances in diagnostic procedures, critical care facilities and antibiotic regimens, sepsis 
remains a very complex and severe syndrome2-9. 
one aspect related to the high mortality is the (lack of) timely and accurate assessment of 
high and low risks stages in the individual patient. This relates to the criteria used to classify 
the different stages of sepsis. In the 1991 American Consensus Conference the entities sepsis, 
severe sepsis and septic shock were outlined as progressive phases of sepsis associated with 
increased organ failure and mortality (discussed in10). Nowadays, this staging remains clinically 
useful. Because of a lack of sensitivity and specificity it was proposed to change the term SIrS 
in PIro (predisposing factors, infection, response, organ dysfunction) as a better method for 
staging the continuum of the syndrome of sepsis10. however, so far SIrS remains the preferred 
terminology. In addition to clinical criteria laboratory markers are being used to estimate the 
stage of sepsis and its prognosis, but there are hardly any specific indices available: altered 
white blood cell count, thrombocytopenia or other markers of DIC, elevated C reactive protein, 
increased procalcitonin, hyperglycemia, lactic acidosis, or unexplained alterations in liver or 
kidney function tests are all examples of clinically used but hardly specific assays. Although 
combinations of some of these tests may help to estimate the risk of the individual patient and to 
assist in decision making on therapy, more specific laboratory tools are still missing in clinical 
practice. 
The existing problems with staging of patients according to degree of illness and prognosis may 
in part explain the many negative (lack of clinical benefit) clinical trials with new therapeutic 
agents, such as experimental immunotherapy and treatment with the synthetic Lipid A analog in 
patients with sepsis, in spite of promising preclinical data11-16. Inclusion of very heterogeneous 
patients without further stratification may have contributed to dilution of potentially relevant 
effects of the tested drugs. Another, related factor in the failure of anti-inflammatory agents 
may be insufficient knowledge of the pathophysiology of sepsis and its sequelae such as DIC, 
making it difficult to decide on the appropriate timing of experimental medication. With regard 
to the latter, it appears to be particularly difficult to establish at which stage inflammation is still 
beneficial, in other words at which moment in time is intervention in inflammation beneficial 
and when does it become detrimental17,18? These problems have also been encountered in recent 
studies with anticoagulant agents in patients with sepsis. In these studies, which have yielded 
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negative (antithrombin, tissue factor (Tf) pathway inhibitor) or positive (activated protein C, 
APC, but in follow up studies equivocal) outcomes, there is evidence that the timing of the 
investigative drug is a critical determinant. hence, administration of both antithrombin and APC 
is probably only beneficial in those patients with most severe sepsis while potentially detrimental 
in patients with less severe sepsis18-21. 
The above mentioned considerations about prognosis and staging of sepsis have also played a role 
in the development of assays for measuring endotoxin levels in patients with sepsis. Since infections 
with gram negative bacteria are linked to severe sepsis with high mortality and their confirmation 
by culture is time consuming many investigators have tried to set up laboratory assays for detecting 
the main pathogenic component of these bacteria, the membrane lipopolysaccharide, LPS. Utilizing 
sensitive assays for endotoxin in conjunction with other laboratory markers might be one way by 
which timely diagnosis of gram negative infections becomes feasible. 
A related subject is the laboratory determination of specific markers of disease. Since severe 
sepsis is associated with DIC in at least 50% of the cases22, activation of cells in conjunction 
with activation of coagulation has become a target of investigation. During infection, cells that 
are stimulated or undergo apoptosis release vesicular bodies from the plasma membrane, which 
are called microparticles (mP), also referred to as microvesicles23. After having been considered 
inert cell debris for a long time, mP are now thought to play a role in the pathophysiology of 
inflammatory disorders by presenting specific antigens and by interacting with neighboring 
or remote cells. These mP supply phospholipids and may enhance both inflammation and 
coagulation, constituting an important link between these processes24. from a diagnostic point 
of view determination of mP in a blood sample combines the advantages of a quantitative 
assessment (numbers of particles) with qualitative observations (antigens presented at the 
membrane of particles). In addition, the resuspension of mP in plasma allows for quantitative 
determination of the effects on activation of coagulation (thrombin generation).
In the following paragraphs we present in greater detail two topics related to the diagnosis and 
pathophysiology of sepsis and other inflammatory disorders. first, the importance of LPS as an 
agonist of SIrS in sepsis and the detection of LPS in blood. Second, the role of mP as a cell 
derived source of pro-inflammatory and pro-coagulant activity that trigger and amplify SIrS and 
DIC in sepsis.
2. Endotoxin (or lipopolysaccharides, LPS) 
2.1 Structure and function
The terminology ’endotoxins’ was first used towards the end of the 19th century, to distinguish 
these molecules from ’exotoxins’, which are actively secreted into the environment by gram-
negative bacteria, gram-positive bacteria, as well as a variety of other pathogens25. endotoxins 
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are integral components of the outer membrane of gram-negative bacteria. They have not been 
found in gram-positive cell walls, mycobacterial cell walls, or fungal cell walls. endotoxins (also 
termed lipopolysaccharides (LPS)) are composed of protein, lipid and polysaccharide.
Immunochemically, LPS consists of three parts (figure 1); lipid A, a polysaccharide component 
with an inner and outer core, and the highly variable o-antigen portion composed of 
oligosaccharide subunits26-28. The inner core sugars are added to Lipid A, followed by addition 
of oligosaccharide subunits to the outer core to form the o side chain. Bacterial mutants that 
lack the inner core or the o-specific chain produce ’rough LPS’ and wild-type strains produce 
’smooth LPS’, because of the morphology of the colonies when cultured on medium. Lipid 
A, the minimal structure of LPS, consists of a variable number of C12-14 fatty acids linked to a 
phosphorylated N-acetylglucosamine dimer29. The lipid A variants from most gram negative 
bacteria that exist, as human commensals, pathogens or colonizers, are very similar with regard 
to the indicated structure, also referred to as ’mucosal’ lipid A28. The composition, number and 
acyl side chain are important in immunogenic activity, in combination with different Lipid 
A conformations. The lipid A structures vary considerably in potency. The biological activity 
is associated with the lipid component (Lipid A) and immunogenicity (innate immunity) is 
associated with the polysaccharide components. The structural and conformational parameters, 
endowing lipid A with its potent bioactivity, have been well characterized. The toxic effects 
of endotoxins are initiated by the specific interaction of lipid A with LPS receptors on 
macrophages/monocytes resulting in the production of cytokines like tumor necrosis factor.
The lipid A regions involved in specific binding and cell activation have been characterized. 
The interaction and subsequent mediator production can be specifically and inhibited by lipid 
A antagonists. The composition of LPS varies between different species of bacteria, and some 
bacteria modulate the structure of LPS such that they evade the innate immune system response 
of their host and to maintain the integrity of the outer membrane. 
Figure 1. A schematic diagram of the cell wall from gram negative bacteria. for most purposes the terms 
endotoxin, lipopolysaccharide or LPS are synonymous. 
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Compounds that bind LPS may promote inhibition or neutralization and subsequent interruption 
of the host inflammatory response30. high-, low-, and very low-density lipoprotein bind 
endotoxin, which may reduce endotoxins toxicity by enhanced clearance of the lipoprotein-
endotoxin complex from the circulation31. Bactericidal-permeability/increasing (BPI) protein is 
derived from the azurophilic granules of neutrophils and neutralizes endotoxin after binding with 
high affinity32,33. This binding of endotoxins to BPI results in increased permeability of a variety 
of gram negative bacteria that already have been phagocytosed34. LPS/binding protein (LBP) is 
structurally related to BPI protein, but does not have bactericidal activity. LBP binds to lipid A 
and acts as an opsonin, enhancing the phagocytosis of gram negative bacteria34,35.
extrapolation of data from experimental animal models of infection or endotoxemia to humans is 
complicated by the fact that species differences exist with respect to sensitivity for endotoxin, for 
example the concentration of endotoxin needed to produce an immunologic effect (Table 1) in a 
rat is 25,000 times greater proportionally than what is required to produce the same immunologic 
effects (Table 1) in humans. In humans the sensitivity to endotoxins is primarily dependent on the 
balance of pro- and anti-inflammatory cytokines, where an anti-inflammatory cytokine profile of a 
high ratio of IL-10 to TNf-alpha is associated with fatal outcome in patients with meningococcal 
infection36,37. This suggests that a strong host response to endotoxin may be important in the 
eradication of bacterial infection, which may have been a contributing factor to the many negative 
or untoward outcomes in clinical trials with anti-inflammatory drugs38,39. 
2.2 Immune system and LPS 
The innate immune system has several mechanisms to recognize microbial pathogens; a) the 
complement system, which has specialized receptors that enable nature killer (NK) cells to sense 
non-self, missing-self and induced-self, b) the Toll-like receptors (TLrs) as sensors of discrimination 
Table 1. endotoxin (LPS) induce
a)  fever-leukocytes take up Lipid A which induces the synthesis and secretion of IL-1, which acts on the heat 
regulation centres in the brain to cause fever
b)  Shwartzman reaction - hemorrhagic necrosis at the site of infection following exposure of another part 
of the body to a relatively small amount of Lipid A. This is due to the clearing of fibrin polymers at the 
inflammation site 
c)  Disseminated intravascular coagulation (DIC) – characterized by microvascular fibrin formation, 
thrombosis and organ dysfunction, as well as life threatening bleeding due to consumption of clotting 
factors and cells
d)  macrophage production of tumor necrosis factor alpha (TNf-alpha) which results in various effects 
e)  Activation of complement via the alternative pathway whereby the activator surface (Lipid A) of the 
Gram-negative cell facilitates the combination of factor B and C3b 
f) Stimulation of bone marrow cell proliferation
g) Non-specific enhancement of immune responses (i.e., action as adjuvants)
h) enhancement of radiation resistance
i) Clotting of horseshoe crab amoebocyte lysates (Limulus lysate reaction)
j) engender hypersensitivity reactions
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between self and non-self, a key requirement of any immune system40. The receptor that recognizes 
LPS and other microbial molecules was shown to be dependent on the integrity of a single locus 
known as Lps41. In 1998 the Lps locus was identified as the TLr4 locus. There are 13 mammalian 
TLrs identified, most are known to recognize specific conserved microbial molecules such as Lipid 
A that activates TLr4. The initial uptake and phagocytosis of microbes by antigen presenting cells is 
facilitated by receptor mediated recognition of microbial molecules. It has been suggested that TLr4 
acts to concentrate LPS thereby increasing sensitivity of the receptor complex to its ligand.
Both the scavenger receptors (eg macrophages express several different types of scavenger 
receptors that bind and internalise modified lipoproteins, such as those contributing to foam 
cell formation in atherosclerosis) and receptors of the complement system are important in this 
process40. As one of the monocyte/macrophage receptors CD14 appears to play an important 
role in relation to the complex of TLr4 and mD2 (myeloid differentiation-2=lymphocyte 
antigen 96 (LY96))42. When monocytes/macrophages are activated they release various defense 
regulatory cytokines, including interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor alpha and 
platelet activating factor. These cytokines bind to cytokine receptors on target cells and initiate 
inflammation and activate both the complement and coagulation pathways. These inflammatory 
responses have been employed as a model in which LPS is administered to humans or primates 
to dissect procoagulant and anti-fibrinolytic pathways, as discussed further on43.
2.3 Detection of LPS 
rabbits are similarly susceptible to LPS as humans and this observation has been applied to test 
solutions suspected from LPS contamination in rabbits. Should the rabbit develop a fever after 
inoculation of a test compound, the presence of LPS is likely. Aside from the costs and ethical 
concerns with the use of rabbits for this purpose, this method has other limitations such as the 
long incubation time of up to 48 hours to produce a definitive result.
Bang was studying the circulation of blood using horseshoe crabs when he found that one of 
his crabs died as a result of a Vibrio vulnificus bacterial infection44,45. The infection caused a 
condition in which almost the entire blood volume of the crab clotted into a semi-solid mass. 
other bacterial strains had not produced this sort of reaction. Bang found that not only live 
Figure 2. A horseshoe crab; Limulus Polyphemus.
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gram negative bacteria produced this reaction, but also heat-killed bacteria, suggesting that not 
bacterial activity but rather a bacteria-derived substance was involved46,47. In collaboration with 
Jack Levin, Bang further established the principles of endotoxin induced immune triggering 
in the horseshoe crab or Limulus Polyphemus, a member of the family of arthropods and 
a common inhabitant of the Atlantic coast. With abundant bacteria in the external milieu, 
the horseshoe crab has developed sensitive means for detecting LPS shed by bacteria in its 
environment46,47. Limulus is a cold-blooded animal, without the ability to develop fever or 
other pro-inflammatory networks. Its innate defence mechanism is comprised of a single type 
of blood cell, the amoebocyte, a cell with a number of physiological functions, including 
phagocytosis and clearance of bacteria and dead cells and repair of wound sites47. The cells 
contain small granules that release coagulation proteins called coagulogens upon activation by 
bacterial endotoxin. The clots formed are thought to limit the bacterial invasion and to provide 
a barrier to the outside environment in the case of a severed limb or large incision. This system 
is comparable to the vertebrate blood coagulation system that serves to protect against bleeding 
from trauma and probably also to support innate immunity in vertebrates, where the coagulation 
machinery is triggered by LPS and may also limit bacterial invasion.
The principle of the Limulus amoebocyte reaction to LPS has been extensively explored and 
utilized in the form of a diagnostic assay48,49. In the Limulus Amoebocyte Lysate (LAL) assay 
plasma or other fluid sample is mixed with reconstituted LAL and allowed to clot in a test 
tube. After 45 minutes the tube is inverted and if a clot has formed it will stick to the top of the 
inverted tube; the test is positive48,49. The LAL assay received fDA approval in the 1970’s for use 
in the testing of drugs, blood products, intravenous fluids, and disposable pharmaceutical devices 
and in 1983 was registered in the U.S. Pharmacopoeia50-53.
extracting blood from the crab produces the lysate. This is done using a non-lethal method 
where blood is taken from a large dorsal blood sinus, the pericardium54. The blood can be 
centrifuged to obtain a pellet of amoebocytes that is resuspended with saline. This causes the 
cells to lyse- and to release the coagulogen into solution. The resultant solution is filtered to 
remove cellular debris and then freeze-dried to form a white powder of lysate55,56. 
3. Procalcitonin
Although the endotoxin proven to be useful for screening of solutions for LPS contamination, 
it has never become a suitable test to detect gram negative bacteremia in patients for various 
reasons including poor sensitivity. In human disease there are no reliable parameters 
differentiating acute bacterial infection from other types of inflammation. hence, non specific 
signs like elevated body temperature, or non specific lab tests such as white cell count, 
erythrocyte sedimentation rate or C-reactive protein levels are applied to detect inflammation, 
while blood cultures need to be awaited to confirm a diagnosis of (gram negative) sepsis. of the 
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investigated laboratory biomarkers procalcitonin (PCT) appeared to be a diagnostic parameter 
that is selectively induced during bacterial infection7. PCT is not or only slightly induced by 
viral infections, autoimmune disorders, neoplastic disease or by (surgical) trauma. In contrast, 
PCT promised to distinguish a bacterial from a non-bacterial inflammation, as well as to perform 
as a monitoring parameter in critically ill patients58-60. PCT is a 116 amino acid protein with 
a molecular weight of 13 kDalton. In healthy individuals active calcitonin is produced and 
secreted by C-cells of the thyroid gland after specific intracellular proteolytic processing of 
the prohormone. The plasma concentration of PCT in healthy individuals is very low, in the 
nanogram per millilitre range. PCT is a very stable protein in vivo with a half-life time of about 
25-30 hours. In patients with severe infection or sepsis, plasma concentrations of PCT range 
from 1 tot >1000 ng/ml61. During bacterial infection PCT is probably not primarily produced by 
C-cells of the thyroid, but may originate from neuroendocrine cells of lung or intestine. 
In healthy volunteers PCT induction was stimulated by i.v. injection of bacterial endotoxin 
(4ng/kg body weight)58 and detected in plasma 2 hours after injection, rapidly rising within 
6 to 8 hours and reaching a plateau after approximately 12 hours. Within 2 to 3 days PCT 
concentrations had again assumed basal values58. 
The increase in PCT levels after i.v. injection of endotoxin follows the surge in TNf-alpha and 
IL-6 in blood, which gain peak levels around 90 and 180 minutes respectively. PCT values start to 
increase at 3 to 6 hours after injection reaching a summit at 6 to 8 hours. In contrast to the early rise 
in PCT, C-reactive protein levels were still not increased 6 hours after injection, showing that this 
acute phase protein is a rather slow marker as compared to PCT66,67. Clinically, PCT levels remain 
increased during ongoing infection59 and appear to correlate with the clinical course62-65.
4. Blood coagulation
The principle of the cascade or waterfall mechanism of the coagulation process was described in 
detail in 196468,69. In this model, that is still valid today, coagulation was indicated to be an ordered 
sequence of amplifying reactions70. It encompasses two separate pathways that converge at the 
level of factor X activation. The extrinsic pathway starts with the interaction of phospholipid-bound 
tissue factor (Tf) and factor VII to activate factor X. Activated factor X is also generated by the 
intrinsic pathway, which is initiated by activation of factor XII when it comes in contact with a 
negatively charged surface. The extrinsic system was assumed to be the primitive pathway because 
fewer factors were involved and because birds and reptiles possess only this system. In contrast, the 
intrinsic system was considered more complex and present only in ‘higher’ life forms.
Clinical findings raise confusion regarding the intrinsic route of coagulation as an important 
pathway. While deficiencies in factors VIII and IX, underlying the haemophilias A and B, clearly 
are highly relevant bleeding disorders, a severe deficiency in factor XI is only associated with 
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abnormal bleeding at older age or upon major tissue trauma. more importantly, a major defect in 
the ’contact’ protein factor XII is not associated with bleeding at all, rather with increased risk 
of thrombosis71-75. one possible explanation for these discrepancies is the existence of reactions 
that bypassed factors XII and XI in the activation of factor IX, a route that was indeed first 
demonstrated by Josso76.
Based on these new experimental findings the earlier concept of separate intrinsic and extrinsic 
clotting systems became obsolete. rather, one central Tf driven cascade is postulated to form 
the basis of blood coagulation77,78. Thrombin plays a critical regulatory role with the potential 
to display an anticoagulant action under physiological conditions (thrombomodulin mediated 
protein C activation) and an uncontrolled procoagulant activity under pathophysiological 
conditions (through activating factors XI, V, VIII, fibrinogen and XIII). In addition, thrombin 
may impair fibrinolysis by activating TAfI (thrombin-activated fibrinolysis inhibitor)79,80. The 
long-standing concept that the fXII-induced intrinsic coagulation pathway is not important for 
clotting in vivo was recently challenged. recent studies indicate that arterial thrombus formation 
is impaired in mice with a complete deficiency in factor XII81. Infusion of human fXII into 
fXII-null mice restored injury-induced thrombus formation82. hence, factor XII appears to 
contribute a procoagulant role, probably confined to situations of (arterial) thrombosis, rather 
than in physiological regulation of hemostasis, such as ischemic stroke83 but its specific role 
needs further characterization. A summary of a model of coagulation in indicated in figure 382..
Inhibitors of blood coagulation 
first, antithrombin was discovered in 1965 as a major coagulation inhibitor, deficiency of 
which was associated with an increased risk of venous thrombosis83. Antithrombin binds most 
coagulation enzymes (serine proteases) in a glycosaminoglycan catalyzed 1:1 complex, which is 
Figure 3. The schematic overview of the physiologic 
coagulation cascade is assumed to occur in vivo. The 
coagulation factors denote in roman numerals and the 
active forms are denote as roman number with small 
a. Abbreviations: Tf, PL (phospholipids), hmWK 
(high molecular weight kininogen). The dotted lines; 
positive feedback loops by thrombin: grey dashed-
dotted line; positive feedback by fIXa; grey dashed 
line positive feedback by fXa. – indicated inhibition 
by APC (activated protein C) and TfPI (tissue factor 
pathway inhibitor). It became clear that the hypothesis 
(waterfall hypothesis) of separated pathway – an 
extrinsic pathway dependent upon Tf and an 
intrinsic pathway independent of Tf – to generate 
thrombin, was not able to explain extreme bleeding 
in haemophilia (factor VIII(A) or factor IX(B) 
deficiency) patients, and the absence of abnormal 
bleeding in persons with factor XII deficiency and 
mild bleeding in IX deficiency. reprinted with 
permission from h.m.h. Spronk et al82.
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cleared from the blood. Second, the proteins C and S system was identified 84. This anticoagulant 
system is established by the thrombin dependent activation of protein C upon interacting 
with the endothelial cell receptor thrombomodulin (Tm). Activated protein C interacts with 
endothelial protein C receptor (ePCr) to induce cell signalling pathways and inactivates in 
concert with the cofactor protein S the activated factors Va and VIIIa. The consequence in 
plasma is a down regulation of the rate of thrombin generation, i.e. a net anticoagulant action. 
Third, the Tf pathway inhibitor (TfPI) mechanism was most recently identified. TfPI comprises 
several pools of molecules that inhibit the factor VIIa/Tf pathway, requiring the presence of 
factor Xa, in a quaternary complex at the cell surface85.
Interplay between coagulation activation and – inhibition is now established as a cell surface 
dependent processes82. Blood coagulation is regarded as an integrated mechanism comprising 
three overlapping phases with plasma protease inhibitors modulating the procoagulant response 
at all stages as well as localizing reactions to cell surfaces by inhibiting active proteases that 
diffuse into the fluid phase. These three phases are initiation86, which occurs on Tf-bearing 
cells and results in formation of factor Xa, factor IXa and thrombin; amplification of the 
coagulant response, which occurs as the process moves from the Tf-bearing cell to the activated 
platelet surface, where activated cofactors are accumulated; and propagation in which the 
active proteases assemble with their cofactors on the platelet surface - and a burst of thrombin 
generation resulting in fibrin polymerization occurs.
one of the essential features of these reactions is the generation of thrombin at a phospholipid 
surface. Tf initiates coagulation activity generating small amounts of thrombin that act on cells as 
well as on cofactors. Together activated platelets and cell fragments comprise a catalytic surface on 
which factor X and prothrombin are being converted into enzymes; these enzymatic machineries 
being referred to as the tenase and prothrombinase complexes. held in charge by protease inhibitors, 
mainly antithrombin and activated protein C, under physiological conditions, the amount of 
thrombin is just sufficient to maintain a basal level of protein C activation. In this physiological 
milieu the amount of activated cells is probably low. hypothetically, upon amplification of thrombin 
generation, more cells become activated to shed membrane particles, referred to as microparticles 
(mP), which participate in the process of coagulation activation. These mP may play a distinct and 
prominent role in linking cell activation and apoptosis to inflammation and coagulation.
5. Microparticles 
microparticles are small membrane vesicles (particles) that are released from cells upon activation 
or during apoptosis. The release of mP is thought to be an integral part of the membrane-
remodelling process in which the asymmetric distribution of phospholipids between two leaflets is 
lost. In body fluids cellular mP constitute a heterogeneous population, differing in cellular origin, 
numbers, size, antigenic composition and functional properties24,87,88. After having long been 
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considered ’cell dust’, mP have more recently been postulated to reflect a balance between cell 
stimulation, proliferation and death and it is conceivable that mP play a role in the maintenance of 
homeostasis in multicellular organisms89,90. This may be an explanation for the observation of mP in 
blood from healthy individuals90. however, mP have also been identified as vectors in transcellular 
exchange of biological information88,91-93. The majority of these mP are from platelets90. mPs from 
activated cells can elicit an adverse response from other cells, themselves undergoing membrane 
vesiculation, leading to pathogenic amplification, (as summarized in table 2)92. 
The presence of mP has been known for a long time. Already in the 1940s it was seen that human 
plasma and serum contained a subcellular element that enhanced fibrin formation88,89. Chargaff 
was one of the pioneers who identified the involvement of certain phospholipid substances in 
blood coagulation88. The observation that such phospholipids accelerated the rate of clotting and 
the importance of electrostatic interactions between lipidic anions and cationic groups in proteins 
led to the isolation of cellular macromolecular particles. The study of mP was facilitated by the 
development of the electron microscopy program by Noggle in the 1960s, which facilitated the 
identification of a subcellular factor consisting of small vesicles (’microparticles’)94,95. 
Nevertheless, it is still not clear whether cell activation and apoptosis lead to the formation of 
similar mP, in terms of size, lipid and protein position and (patho-) physiological effects96. 
6.  Endotoxin and microparticles as players in inflammation and 
coagulation
Circulating LPS triggers an array of inflammatory reactions. These involve the release of pro-
inflammatory cytokines, activation of the coagulation system, fibrinolysis (and subsequent 
inhibition of fibrinolysis), activation of complement, as well as activation of different cells including 
neutrophils and monocytes associated with mP formation97. Production of TNf-alpha and IL-1 (as 
part of inflammatory reactions) are both responsible for the loss of normal anticoagulant activity of 
endothelial cells, by cleavage as well as down regulation of thrombomodulin and endothelial protein 
C receptor (ePCr); the result is a procoagulant endothelial surface97-98,110,116. The influence of natural 
anticoagulants in inflammation depends on the strength of the inflammatory stimulus. Whereas in 
low LPS concentrations in human models, the influence of (administered) TfPI and antithrombin 
Figure 4: Light-microscope (50x10) view 
of a lymphnode which shows lymphocytes 
shedding microparticles in haematological 
malignancy (stained with may-Grunwalds/
Giemsa) 
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on coagulation is very limited, the importance emerges at septic conditions in primates where TfPI, 
antithrombin and protein C all have a major protective influence 99,100.
Studies in human volunteers and primates have shown that LPS at low doses induces Tf mediated 
coagulation in an IL-6 dependent manner, while the fibrinolytic response is dependent on TNf-
alpha100-103,105. A second consequence of an increase in pro-inflammatory properties, due to 
adherence of polymorphonuclear leukocytes to the vascular endothelium, is their degranulation and 
the formation of reactive oxygen intermediates such as superoxide anion and hydrogen peroxide. 
This combination of effects promotes tissue necrosis and circulatory collapse.
Thus, it seems likely that in several stages of inflammation, either due to prothrombotic forces 
or to inflammatory mediated cell activation and apoptosis, mP becomes generated. Indeed, in 
addition to sepsis mP are detectable in many other inflammatory diseases106. The mP generated 
become properties of activated cells, and expose membrane antigens from the ’parent cell’, 
enabling the determination of their cellular source. The former include alterations in cell 
membrane composition with a higher degree of negatively charged phosphatidylserine (PS) 
and phosphatidylethanolamine (Pe) residues in the outer membrane as compared to neutral 
phosphatidylcholine (PC) and sphingomyeline (Sm) residues on the inner membrane107. Studies 
showed that the lipid homeostasis is important in the cellular cross-talk of immune cells108. 
Depending on the underlying pathophysiological state, the relative proportions of these mP as 
well as their antigenic and functional determinants may vary. Based on the fact that in clinical 
situations with excessive cell death such as malignancies, autoimmune diseases and following 
chemotherapy high levels of circulating mP might modulate phagocytosing cells, a suppression 
of the immune response which is cell activation and apoptosis related. Sapet and colleagues 
showed a novel signalling pathway that emphasizes the proteolytic activity of caspase 2 in 
endothelial mP generation in response to cell activation108,109.
In vivo, the majority of mP detected are from platelet origin (Table 2)90. A minor fraction of 
mP is derived from other cells present in the vasculature, including erythrocytes, granulocytes, 
monocytes, lymphocytes and endothelial cells. The shift in membrane phospholipid distribution 
forms the basis for a procoagulant surface. This PS enrichment allows coagulation reactions to 
take place at the surface of activated cells, particularly platelets, due to the enhanced exposure 
to the extracellular environment of PS residues87. Platelet mP membranes have a 50- to 100-
fold higher specific procoagulant activity than activated platelets110. Also platelet driven mP 
expose, per unit membrane surface (in vitro), more binding sites for factor Va, VIIIa and IXa 
than the intact platelet membrane. The net procoagulant effect of mP is however also dependent 
on other conditions. for instance, although mP-associated Tf in platelet concentrates may be 
a theoretical source of procoagulant activity, the presence of TfPI neutralizes most thrombin 
generating capacity and this may be just one factor that determines the net procoagulant influence. 
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The difference between in vitro potency of mP and in activity in platelet concentrates may also 
be attributed to the ability of mP to propagate thrombin generation by thrombin-activated fXI111. 
Theoretically, activation through a factor XII dependent way may contribute to some extent.
The procoagulant properties of mP can be mimicked in vitro, by adding mP fractions to plasma 
and measuring thrombin generation111,112. Initiation requires binding or presence of Tf at the 
membrane surface. In two clinical conditions, mP positive for functionally active Tf has been 
identified. first, in a patient with meningococcal sepsis, ex vivo mP-dependent specific antibodies 
against Tf abolished thrombin generation113. Second, these antibodies also inhibited thrombin 
generation in mP derived from pericardial blood aspired during coronary artery bypass grafting 
surgery114. In contrast, in blood from normal volunteers as well as in other clinical conditions, mP 
stimulated thrombin generation in Tf independent ways90,113. 
During the last years many studies have addressed the potential biological roles of mP in vivo.
An intriguing interaction between inflammatory cells, mP and coagulation was derived in the 
ex vivo thrombosis model of the furie group119-122. In a laser induced endothelial injury model 
they studied thrombus formation with real time imaging and observed the co localization of 
P-selectin, Tf and fibrin after platelet localization in the organizing thrombus123. The presence 
of Tf was shown to depend on the availability of P-selectin in this model. mP appeared to 
form a functional bridge between platelets and monocytes as participants in arterial thrombus 
formation134. Wakefield and colleagues observed that mice with the highest levels of P-selectin 
in their blood developed the largest venous blood clots and had more inflammatory cells in their 
vein walls124,125. Blood from mice with high levels of P-selectin also contained leukocyte derived 
mP, but some were derived from blood platelets. Additionally, some mP may have originated 
from endothelial cells lining vein walls126,127. 
mP influence endothelial function in several ways. Several studies show a relationship between 
circulating mP and endothelial function, specifically in diabetes mellitus platelet mP have 
been linked to development of atherosclerosis117,118. moreover, increased mP shedding from 
endothelial progenitor cells may reduce circulating endothelial progenitor cell levels and 
contribute to increased aortic stiffness128,133.
finally, in atherothrombotic disease the induction of vascular cell apoptosis and Tf expression 
may be associated with mP formation that triggers local thrombus formation and contributes 
to micro-embolization causing downstream ischemia due to no-reflow phenomena129-131. mP 
are more abundant and more thrombogenic in human atherosclerotic plaques than in plasma, 
which may be related to their different cellular origin115. e.g. mononuclear cells convert more 
efficiently fVII to fVIIa than platelets do116.
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Vascular smooth muscle cells may become a pathophysiologically relevant source of Tf that can 
be rapidly exposed to the blood in situations of endothelial damage132.
Although many questions remain regarding the involvement of specific mP fractions in 
thrombosis and other diseases, the cumulative evidence suggests that these cell remnants play a 
role of importance in many disease states, as summarized in table 2. 
7. Outline of the thesis
This thesis describes various investigations aimed at aspects of the interactions between 
inflammation and coagulation. This complex interaction is tackled from a diagnostic perspective, 
utilizing three different diagnostic assays: for LPS, for procalcitonin and for mP, respectively. We 
applied these assays to answer specific questions either in animals or in patient populations. 
Table 2. A summary of various diseases, syndromes and symptoms ranged in alphabetical order associated 
with increased numbers of mP and their cellular origin(thesis; 2004 r.J.Berckmans).
Diseases Cellular origin reference
Acute coronary syndrome Platelets, monocytes / macrophages, 135,136,137,168
 endothelial cells, 
Antiphospholipid antibody syndrome monocytes / macrophages 139,140
Arteriosclerosis obliterans Platelets 141
Atherosclerotic plaques  monocytes / macrophages, Lymphocytes 142
Cancer Platelets 143,144
Cerebral infarct Platelets 145,162
Crohn’s disease  Platelets 1467
Cyanotic congenital heart disease with Platelets 147
polycythemia
Diabetes mellitus Platelets, endothelial cells 148,117,149,150, 
  151,152,162
Diabetes mellitus (type 2) monocytes / macrophages, Granulocytes,  150,154, 155
 Lymphocytes
Disseminated intravascular coagulation Platelets 153
hemolytic uremic syndrome Platelets 156
heparin-induced thrombocytopenia Platelets 157,158,159,160
hIV Lymphocytes 161
hypertension (severe) Platelets, monocytes / macrophages, s 162,163,189, 190
 endothelial cell
Idiopathic nephrotic syndrome Platelets 164
Idiopathic thrombocytopenic purpura Platelets 165,166,167,207
Lung cancer monocytes / macrophages 169
meningococcal sepsis Platelets 113,170
multiple organ failure (meningococcal monocytes / macrophages, Leukocytes 113,187,188
sepsis) (granulocytes)
multiple sclerosis endothelial cells 171,172
myeloproliferative syndrome Platelets 173
myocardial infarction Platelets ,endothelial cells 138,174,175,176, 
  177,178
Paroxysmal noctural hemoglobinuria Platelets, endothelial cells  179,180,181
opmaak karin joop_23147.indd   23 12-02-2009   08:46:14
Chapter I
eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIoN AND CoAGULATIoN  eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIo
24
Chapter II: Involves an economic issue in cattle breeding. To maintain a profitable milk 
production it is essential that cows are regularly pregnant. When they develop an intra-uterine 
infection postpartum or even develop dystocia or retain their placenta, the milk production is at 
risk. We studied the relationship between LPS levels and the development of dystocia or retained 
placenta in cows by determining the levels of LPS in plasma and lochia compared with blood 
culture.
Chapter III: Patients undergoing cardiac surgery develop a systemic inflammatory response 
as a result of the cardiopulmonary bypass procedure. The non-physiological perfusion during 
the bypass results in a compromised microcirculation in the intestinal barrier, leading to LPS 
leakage into the systemic circulation. We hypothesized that this same mechanism might occur 
during extreme exercise. In athletes, ischemia of intestines can develop that may initiate the 
release of LPS into the circulation. Therefore, we investigated whether after a long exercise, 
even in healthy and well trained athletes, gastro-intestinal (GI) problems and clinical signs 
resembling to some extent those of septic patients, are related to a LPS-driven rise in cytokine 
levels (TNf-alpha and IL-6). The cytokine-triggered acute phase reaction and characteristic 
variables of this reaction were measured (C reactive protein and pre-albumin). Since tissue 
(muscle) damage can also trigger the cytokine response, creatine kinase was determined as 
indicator of muscle damage.
Chapter IV: Plasma levels of procalcitonin (PCT) and LPS were measured in samples from 
athletes (same group of athletes as in chapter 3). As indicated, PCT was claimed to be a new 
and specific marker for systemic infection and in these subjects it was hypothesized to detect 
translocation of gram negative bacteria or LPS from the digestive tract. 
Chapter V: The efficacy of a new bed-side test for measurements of LPS was determined 
in a group of septic patients. Since the traditional LAL assay has to be performed under 
sterile conditions, is relatively slow (2 hours), is technically demanding, and is too costly to 
be performed on multiple patient samples, we tested a rapid bedside test. This SimplireD® 
endotoxin (Sre) assay was tested in 74 patients with documented SIrS. Sepsis was established 
if the patient also had a positive blood culture. Both the LAL –  and the Sre assay were 
performed and prediction of 28 day-mortality rate was determined.
Chapter VI: Circulating LPS is associated with mortality. Laboratory determination of LPS is 
still difficult, expensive and technically demanding. The additional value of laboratory assays 
for LPS, cytokines and PCT to predict patients at risk for fatal outcome is not known. The 
efficacy of determining these factors on admission to identify patients with a community-
acquired infection, who are at risk for an adverse outcome and may benefit from early preventive 
measures, has not been established. We examined prospectively in febrile patients admitted 
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to the medical emergency Department the relation between clinical data, levels of plasma 
endotoxin, TNf-alpha, IL-6, IL-10 and PCT, and outcome.
Chapter VII: Life threatening complications from bacterial infections form a major clinical 
problem. In severe infections, involving sepsis, the coagulation and fibrinolytic systems are 
targets for modulation. These cascades are normally activated upon tissue injury and/or blood 
vessel damage. During infections, inflammatory mediators perturb the pro-coagulant/anti-
coagulant equilibrium contributing to severe bleeding disorders. We tried to analyze the onset of 
coagulation disequilibrium by investigating the presence of cell-derived microparticles, as well 
as their relationship with in vivo coagulation activation and inflammation, in patients suffering 
from multiple organ dysfunction syndrome and sepsis.
Chapter VIII: Dengue viruses cause a syndrome that varies from mild disease with 
undifferentiated fever, to dengue hemorrhagic fever, or the potentially lethal dengue shock 
syndrome. The differentiation between dengue hemorrhagic fever and dengue shock syndrome 
is made on the basis of clinical and laboratory markers. There is increasing evidence that 
coagulation abnormalities play an important role in dengue related disease, where increased 
vascular permeability due to endothelial dysfunction, might lead to Tf exposure and a 
hypercoagulable state. Since it is thought that circulating mP are discerned as sensors for the 
maintenance of hemostasis they could play a role in dengue shock syndrome. We studied the 
number and cellular origin of microparticles in 8 patients, 4 with dengue hemorrhagic fever and 
4 with dengue shock syndrome.
Chapter IX: Patients with diabetes mellitus type 2 are at relatively high risk for thrombotic 
events. In this population there is a high incidence of cardiovascular disease due to increased 
prevalence of risk factors related to coagulation, inflammation and lipoproteins. Studies have 
shown that increased levels of circulating mP are among the procoagulant determinants in these 
patients. Treatment with pravastatin (a reductase inhibitor hGm-CoA) in patients with diabetes 
reduces cardiovascular complications. We studied if pravastatin has any effect on number, 
cellular origin or antigen composition of microparticles.
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Abstract
A study was conducted to investigate the relationship between intra-uterine bacterial 
contamination, endotoxin levels and the development of endometritis in cows that experienced 
a dystocia or retained their placenta. fifteen healthy cows, 31 cows with retained placenta (rP) 
and 13 cows that had dystocia were clinically examined 1 or 2 days after parturition when 
a uterine swab for bacteriological examination was taken. In addition, plasma and uterine 
lochia samples were collected to determine endotoxin and the plasma IgG anti-endotoxin 
concentrations. Subsequently, 15 rP and 6 dystocia cows were initially left untreated and 
another uterine swab was collected at 2 and 4 wk postpartum. Immediately after calving, rP 
cows had significantly higher endotoxin levels in uterine lochia (average of 2.24 x 104 endotoxin 
Units (eU)/ml) as compared to dystocia and healthy postpartum cows (average of 0.10 and 
0.26 eU/ml, respectively). however, plasma endotoxin levels were below the detection limit 
(<0.036 eU/ml platelet-rich plasma) in all groups of cows. IgG anti-endotoxin levels in plasma 
were not significantly different between the 3 groups immediately postpartum (average of 26, 
16 and 44 median Units (mU)/ml for healthy, dystocia and rP cows, respectively), but they 
were significantly lower when compared to plasma IgG anti-endotoxin levels of healthy cows 
at more than 2 months postpartum (mean 83 mU/ml). high endotoxin levels in lochia at 1 or 
2 days postpartum were significantly related to abnormal cervical discharge, the presence of 
escherichia coli, black pigmented Gram-negative anaerobes and Clostridium spp. shortly after 
calving, and Arcanobacterium-pyogenes and Gram-negative anaerobes in the uterus at 14 days 
postpartum. These results suggest that the presence of e. coli and endotoxin in lochia early 
postpartum favor the development of uterine infections by A. pyogenes and Gram-negative 
anaerobes later postpartum. endotoxin was not observed in plasma, suggesting that either they 
are not absorbed into the blood, or they are efficiently detoxified by IgG anti-endotoxin or other 
detoxification mechanisms. 
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1. Introduction
The period immediately after calving is very important in the reproductive lifecycle of a cow 
because of its vast influence on reproductive efficiency. A normal uterine involution and the 
re-establishment of the ovarian function postpartum are crucial to obtain the short calving to 
conception interval that is required to optimize milk and calf production. Peri- or postparturient 
reproduction disorders most often occur as a complex. Both a difficult calving (dystocia) 
and the retention of fetal membranes (retained placenta (rP)) have adverse effects on several 
reproduction parameters and are predisposing factors for the development of uterine infections 
later postpartum6,13,14,17,20,23,25. 
As shown by others3,18,20,24, intra-uterine infections in rP and dystocia cows are often of a mixed 
nature. During the first 1 to 2 wk after calving, Gram-negative (G-) facultative anaerobes, such 
as escherichia coli, are abundantly present in cows with rP and, to a lesser extent, in cows 
with a history of dystocia. from 2 wk after calving, the most prominent pathogens present are 
Arcanobacterium pyogenes (the former Actinomyces pyogenes) and G- anaerobes, such as 
Bacteroides and fusobacterium4,8,11. The former is generally held responsible for a large part of 
the decrease in reproductive efficiency due to endometritis. The primary question that arises is 
which bacteria and virulence factors during the first 1 to 2 wk postpartum in rP and dystocia 
cows favor the establishment of infections with A. pyogenes later. Therefore, the first objective 
of this study was to characterize both qualitatively and quantitatively the bacteria present 
early postpartum in cows with dystocia and rP and relate these findings to the presence of A. 
pyogenes and signs of sub-acute/-chronic endometritis later postpartum. 
Coliform bacteria are abundantly present in lochia of dystocia and rP cows, and endotoxin 
levels are related proportionally to the numbers of bacteria3,8,9,24,27. Previous work in ruminants21,22 
illustrated that endotoxins are among the most important virulence factors of coliform bacteria 
that can cause complications in cases of dystocia and rP. endotoxins can be described as 
macromolecular complexes of endotoxin, protein and fosfolipids15,16. They are very potent 
inducers of prostaglandin and cytokine release21,22,26,27,29, and they also play an important role in 
periparturient diseases21,22,26,27. moreover, endotoxins have direct cytotoxic effects that likely favor 
the establishment of infections with, for example, A. pyogenes8,11,21,22. Therefore, we hypothesize 
that the development of endometritis later postpartum in dystocia and rP cows is at least partially 
mediated by coliform bacteria and/or endotoxins early postpartum. 
As a second objective we tried to elucidate a possible relationship between bacterial findings 
and endotoxin concentrations in the uterus of dystocia and rP cows, and a possible relationship 
between plasma concentrations of endotoxins and IgG anti-endotoxin, in relation to the 
development of systemic disease in affected cows. IgG anti-endotoxin is an important factor in 
the detoxification of endotoxin and thereby a measure for endotoxin exposure. 
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A better understanding of the early pathogenesis of uterine infections and subsequent 
endometritis in cows with dystocia and rP may help in the design of improved measures to 
prevent uterine infections and also, as a result, fertility disorders.
2. Material and method
2.1 Experimental design
A total of 59 holstein dairy cows were used in this study, of which 15 cows had a normal 
calving without complications (control group), 13 cows had difficulties at calving (dystocia 
cows), and 31 cows retained their placenta for more than 24 h (rP cows). The enrolled animals 
were divided over 23 commercial Dutch dairy farms that had on average 80 dairy cows per farm. 
All the farms took part in a herd health management program that allowed close monitoring of 
the data. The mean milk production was about 7200 kg of milk per cow per year with a mean 
bulk tank somatic cell count of 178,000 cells/ml. The mean calving interval was 380±10 d, and 
the number of calves each cow had (= parity) was noted, with heifers having parity 1 (after the 
parturition of the first calf). Cows that had been treated with antibiotics since parturition, or that 
had a twin delivery, a fetotomy or serious injuries of the birth canal or reproductive tract were 
not enrolled in the study. All cows were housed under field conditions and were fed commercial 
concentrated pellets, corn silage and hay.
Within 2 d after calving, all cows were clinically examined, rectal temperature was taken, and 
their general condition was noted. emphasis was put on the appearance of signs of systemic 
illness. The course of delivery was specified as being ‘normal’ (hardly assisted by a maximum 
of one person), ‘heavy’ (assistance of at least 2 persons needed), and whether or not obstetric 
actions were necessary or a dead calf was born (stillbirth). The cows were palpated per rectum 
to check the status of the reproductive tract. The aspect of the cervix and the present vaginal 
discharge were evaluated during vaginoscopy. In addition, a blood and a lochia sample were 
taken for endotoxin and IgG anti-endotoxin determination (the latter in plasma only). A uterine 
swab for bacteriological examination was aseptically collected.
Subsequently, half of the dystocia (6 cows) and rP (15 cows) cows were randomly left 
untreated, whereas the other half was treated with antibiotics to fulfill a concurrent protocol 
(data not given). Decision upon treatment was made at random following table random digit 
numbers30. To exclude bias of treatment on the outcome of the clinical and bacteriological 
findings, the treated cows were not included in the follow up of this study. The 21 untreated 
cows were further sampled as depicted in figure 1.
2.2 Collection of lochia,  plasma and blood samples
Lochia samples were aseptically collected using an empty 50-ml syringe and a sterile disposable 
catheter. Before sampling, the vulva was carefully washed and disinfected with a nonirritating 
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relationship betwee intra-uterine bacterial contamination
59 Holstein Dairy cows/heifers:
– 15 had normal calving (controls)
– 13 had dystocia
– 31 retained their placenta (RP)
<2 d postpartum: clinical
examination, vaginoscopy,
blood and lochia sample,
uterine swab for bacteriology (I)
6 dystocia and 15 RP cows:
initially
UNTREATED
7 dystocia and 16 RP cows:
TREATED (data not given)
14 d postpartum: clinical examination,
vagionoscopy, uterine swwab for
bacteriology (II)
30 d postpartum: clinical examination,
vaginoscopy, uterine swab for
bacteriology (III)
± 150 d postpartum: incidence of 
endometritis, pregnancy and culling
rates (pregnancy checks 45 days after
AI), calving to conception  intervals
Figure 1. Diagram of the chronology of the sampling events described in the experimental design.
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ethylalcohol solution (Citopogeen® mycofarm BV, Boxmeer, The Netherlands) and dried. The 
catheter was carefully inserted in the vagina, avoiding contamination by contact with the vaginal 
wall. Then it was passed through the cervix into the uterine lumen under rectal guidance by 
means of the conventional artificial insemination technique. A lochia sample was collected in the 
catheter by exerting a negative pressure on the syringe after which the sample was transferred 
immediately into a 6 ml sterile tube35 and stored on ice. The samples were stored at –20°C 
within 8 h after collection, until the endotoxin levels were determined.
Blood samples for endotoxin and IgG anti-endotoxin determinations were collected using 4 ml 
pyrogen-free heparin containing vacuum tubes (endotube, Chromogenix AB, mölndal, Sweden) 
after the sampling site had been cleaned with 70% alcohol. A 4 ml blood sample was drawn 
from the jugular vein using a sterile disposable needle. Blood and heparin were gently mixed 
and stored on melting ice. Within 8 h, tubes were transported to the laboratory and centrifuged at 
540 x g for 10 min at 4°C. In preliminary experiments, this centrifugation procedure was found 
to provide an optimal concentration of trombocytes in the plasma with simultaneous removal 
of the erythrocytes. Platelet-rich Plasma (PrP) demonstrated to be the material of choice to 
measure endotoxin concentrations31. The plasma was then transferred into 2 pyrogen-free vials 
with a sterile disposable pipette, avoiding contamination, and stored at –20°C until tested for the 
presence of endotoxin and IgG anti-endotoxin.
2.3 Endotoxin assay
Lochia and plasma samples were quantitatively tested for the presence of endotoxin using the 
Limulus Amebocyte Lysate (LAL) test. In this assay, endotoxin activates the coagulation system 
obtained as a lysate from the amebocyte (i.e., circulating cell) of Limulus polyphemus (the 
horseshoe crab). The activated coagulation factors can then be measured with a chromogenic 
substrate. however, in plasma, noncharacterized inhibitory factors of the activation reaction are 
present. They may include hDL, albumin, anti-endotoxin antibodies, and others. Therefore, plasma 
samples need to be diluted and heat treated32,33. first, the frozen plasma samples were thawed at 
37°C for 5 min and stored on ice (<1 h). Then, they were diluted ten-fold (v/v) with sterile pyrogen-
free water (Chromogenix AB, mölndal, Sweden) or with pyrogen-free water containing 0.24 
endotoxin Units (eU)/ml endotoxin-standard (= spike). The results were expressed in endotoxin 
Units (eU) per milliliter PrP. The potency of the standard expressed in this eU is provided by the 
manufacturer and is based upon primary standards of purified e. coli endotoxin manufactured by 
the federal Drug Administration. The method was validated for bovine plasma with an endotoxin 
detection limit of 0.036 eU/ml PrP (= 0.0036 eU/ml taken into account the dilution). In addition, 
endotoxin was added to samples of normal blank human plasma to establish calibration curves. 
human plasma was used because this was more readily available at the site of endotoxin testing 
and because the preliminary experiments with cow plasma indicated that the standard curves were 
negligibly different. Samples were heat treated at 75°C for 15 min to remove plasma inhibitory 
activity and then cooled down to room temperature within ±45 min.
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The method for the detection of endotoxin in lochia was slightly different. The frozen lochia 
samples were thawed as described for plasma. Subsequently, dilutions were performed for lochia 
samples with very high endotoxin levels. Because of the slimy aspect of the lochia, samples 
were centrifuged at 2750 x g (4°C, 10 min). Supernatants were diluted (10-100-1000-10000 
times) by adding pyrogen-free water. Several dilutions of each lochia sample were measured, 
and the lowest dilution giving an extinction that fitted on the calibration curve was used. The 
results were expressed as endotoxin Units per milliliter with a detection limit for endotoxin in 
lochia of 0.036 eU/ml. The standard curves were performed in pyrogen-free water.
The endotoxin assay was performed in microtitre plates, according to the prescriptions of 
the supplier of the chromogenic assay (Biowhittaker Inc., Walkersville, maryland, USA). In 
short, samples were incubated with Limulus Amoebocyte Lysate (37°C, 30 min), and then 
with substrate (37°C, 6 min). The cascade reaction was stopped by adding 25% acetic acid. 
Absorbences were measured at 405 nm in a microtitre plate reader (Spectra max 250, molecular 
Devices, Sunnyvale, California, USA).
2.4 Assay for IgG anti-endotoxin
IgG anti-endotoxin in plasma was assayed by eLISA with endotoxin-precoated microtiter plates 
and dilution buffer (endoCab kit, Chromogenix AB, mölndal, Sweden). Briefly, plasma samples 
were thawed at room temperature and diluted 200-fold in the dilution buffer. Then, 100 µL of 
this diluted sample or standards was added to the microtitre plate to allow the anti-endotoxin 
antibodies in the plasma to bind to the endotoxin on this microtitre plate. After incubation (37°C, 
60 min), the plate was washed 3 times with PBS-Tween 0.1% to remove plasma components that 
are likely to interfere in the subsequent steps of the assay. Then 100 µL of an antibody to bovine 
IgG was added, which had been conjugated to peroxidase (Kirkegaard & Perry Laboratories 
Inc., Gaithersburg, maryland, USA). After incubation (37°C, 60 min) to allow the anti-bovine 
IgG to bind to the IgG on the microtitre plate, the plate was washed 3 times with PBS-Tween 
0.1% and 5 times with distilled water to remove nonbound anti-bovine IgG. finally, 100 µL of a 
freshly prepared substrate solution of o-phenylenediamine dihydrochloride (2.2 mm) was added 
to measure the peroxidase in the complex endotoxin – anti-endotoxin – anti-IgG – peroxidase 
on the microtitre plate. Incubation was continued for 60 min at ambient temperature in the dark, 
after which the reaction was stopped by adding 50 µL of 4 N h2So4, and the absorbance was 
read at 492 nm. endoCab is expressed in median Units (mU) (i.e., the median level observed 
in a group of 100 human volunteers tested by the manufacturer). To get a reference value for 
healthy cows, plasma samples of 23 healthy lactating non-pregnant cows that were more than 2 
month after calving were included in the assay.
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2.5 Bacteriological examination of uterine swabs
Uterine swabs for bacteriological examination were collected using a sterile double-sheathed 
swab apparatus (Nifa Instrumenten B.V., Leeuwarden, The Netherlands). The protected swab 
was carefully introduced into the uterus, avoiding contamination. Swabs were immediately 
placed in transport medium (Port-A-Cul, Becton Dickinson B.V., etten Leur, The Netherlands) 
and transported to the laboratory at 4°C within 1 day after collection. Immediately upon receipt, 
uterine swabs were resuspended in 2 ml thioglycolic broth that was partly diluted 100 times by 
adding more broth. Both suspensions were inoculated on 5 different media: aerobic blood agar, 
Levine-emB agar (oxoid Ltd, Basingstoke, hampshire, UK), anaerobic blood agar, anaerobic 
blood agar with metronidazole, and fAA agar with vitamin K3 and kanamycin. The blood agar 
plates contained 5% sheep blood. Inoculated plates were incubated for 2 to 7 days at 37°C in 
aerobic or anaerobic atmosphere. All colonies that could macroscopically be determined as 
A. pyogenes, e. coli, f. necrophorum, Bacteroides spp. and/or black pigmented G- anaerobes 
together with the colonies that were present in O5% of the total number of colonies were 
counted and recorded separately. If necessary, these colonies were further identified up to 
species level, or up to genus level in the case of A. pyogenes, e. coli and f. necrophorum, using 
appropriate tests (API system). A bacteriological score varying from 0 to 4 was assigned to these 
bacteria, which corresponded respectively to ’no growth’ (Score 0), 0 to 105 Colony forming 
Units (CfU) per ml (Score 1), 105 to 106 CfUs per ml (Score 2), 106 to 107 CfUs per ml 
(Score 3), and 107 to 108 CfUs per ml (Score 4).
2.6 Statistical analysis
Collected data were compared between the different groups of cows and statistically analyzed 
with the Chi-square test and Student’s two-sample t-test using the software program Statistix  
(Statistix® 4.0, Analytical Software, St. Paul, mN, USA).
3. Results
3.1 Findings immediately postpartum
As shown in Table 1, significantly more heifers were found in the dystocia group (62%) as 
compared to the rP group (19%; P <0.01). At 1 to 2 d postpartum, rectal temperatures for the 
rP cows were significantly increased (average of 39.3°C; P <0.05) compared to healthy and 
dystocia cows. A total of 5 cows (4 rP cows, 1 dystocia cow) showed signs of systemic illness.
Lochia of rP cows were abnormal in 29% of the cases (Table 1), and these cows generally 
harboured bacteria more frequently and often in a higher number than dystocia and healthy cows 
(Table 2). In particular, e. coli, G-anaerobes (predominated by black pigmented bacteria) and 
Clostridium spp. were isolated in a significantly higher frequency in rP cows than in dystocia or 
healthy cows. The bacteriological score of e. coli was positively correlated with both the number 
of black-pigmented G-anaerobes (r=0.40; P< 0.01) and the number of Clostridium spp.  
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(r=0.44; P< 0.001). The bacteriological score of black-pigmented G-anaerobes was positively 
correlated with the bacteriological score of A. pyogenes (r=0.60; P<0.001). 
Although variation in endotoxin levels in lochia within the groups was large, levels were 
significantly (P< 0.05) higher in the rP group (2.24x104±4.94x104 eU/ml) compared to the 
healthy and dystocia groups (maximum levels of respectively 2 and 0.6 eU endotoxin per ml; 
see figure 2).    
Table 1. Clinical findings in heifers and cows at 1 to 2 days postpartum.
 healthy cows Dystocia cows rP cows
 n=15 n=13 n=31
Parity (mean±SD) 2.5±1.7 1.7±1.0a 3.2±1.9b
Percentage of heifers 27% 62%c 19%d
Course of delivery:
Normal(m1 person) 100% 0 78%
heavy (M2  persons) 0 77% 16%
obstetric actions 0 15% 3%
Still birth 0 8% 3%
Percentage of cows with discharge:
Normal 100%a 92% 71%b
Abnormal* 0a 8% 29%b
foul-smelling discharge 0a 0a 26%b
rectal temperature (°C): 38.6±0.3a 38.8±0.5a 39.3±0.6b
* Abnormal discharge is red-brown watery with or without necrotic material.
a,b
 Values in the same row with different superscripts differ (P<0.05).
c,d
 Values in the same row with different superscripts differ (P<0.01).
Table 2. frequency rate (freq.) and mean bacteriological score (score) of uterus isolates in healthy, 
dystocia and retained placenta (rP) cows at 1 to 2 days postpartum.
 healthy cows Dystocia cows rP cows
 n=15 n=13 n=31
 freq. score freq. score freq. score
A. pyogenes 7% 1.0 0 – 10% 3.0
e. coli 33%a 2.6 38%a 1.2a 97%b 3.1b
Coliforms (no e. Coli) 27% 1.3 8% 1.0 13% 2.5
Streptococci 0 – 8% 1.0 6% 2.0
Staphylococci 0 – 8% 4.0 3% 3.0
Black pigmented anaerobes 13%c 1.5 0c – 45%d 2.1
Bacteroides spp. 0 – 8% 1.0 20% –
f. necrophorum 7% 1.0 0 – 3% 3.0
Clostridium spp. 7%a 4.0 8%a 1.0 65%b 3.0
a,b
 Values in the same row with different superscripts differ (P<0.001).
c,d
 Values in the same row with different superscripts differ (P<0.05).
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Despite the high endotoxin levels in lochia of rP cows, endotoxin concentrations in plasma were 
below the detection limit (<0.036 eU/ml) in all cows. No significant differences  
(P >0.05) between the different groups of postpartum cows were observed for the IgG anti-
endotoxin levels in plasma. however, IgG anti-endotoxin levels in plasma of cows at 1 to 2 days 
postpartum were significantly lower (P<0.05) than IgG anti-endotoxin plasma levels of healthy 
cows later postpartum (figure 3).
higher endotoxin concentrations in lochia were found to be positively correlated with the 
presence of abnormal and foul-smelling discharge, the rectal temperature, and especially 
the presence of e.coli, black pigmented G-anaerobes and Clostridium spp (P<0.05). The 
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Figure 2. Individual endotoxin levels in lochia (logarithmic scale) at 1 or 2 days postpartum in healty (h, 
n=11), dystocia (Dys, n=11) and retained placenta (rP, n=31) cows. Average values between healty and 
dystocia cows, and rP cows differ significantly (P < 0.05).
Figure 3. Individual IgG anti-LPS levels in plasma at 1 to 2 days postpartum in healthy (h, n=15), dystocia 
(Dys, n=11), retained placenta (rP, n=30) and healthy cows later postpartum (h (later pp), n=23). Average 
values between healthy, distocia and rP cows and healthy cows later postpartum differ significantly 
(P<0.05).
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bacteriological score of e. coli was also positively correlated with the endotoxin levels (r =0.35; 
P <0.05). Parity did affect not endotoxin and IgG anti-endotoxin levels.
3.2 Follow-up cows
The 6 dystocia and 15 rP cows randomly left untreated immediately after calving were 
subsequently part of a follow-up study up to 150 days postpartum. The isolation frequencies of 
A. pyogenes, e. coli and black pigmented anaerobes from these cows are given in Table 3. After 
an increase at 14 d postpartum, prevalence rates of all bacteria for both dystocia and rP cows 
had decreased at 30 days postpartum. Streptococci and staphylococci were hardly isolated at 14 
and 30 days postpartum (data not given, maximum 1 cow infected per group per time point). 
At 14 d postpartum, abnormal discharge (i.e., (muco)purulent) was observed in 33% of the dystocia 
group and 92% of the rP group. At 30 d postpartum, all cows except one had normal discharge. In 
total, 8 of the 21 cows had been treated because of endometritis: 4 rP cows already in the first week 
postpartum, and the other 4 between 14 and 33 d after calving (Table 3). At 150 d after parturition, 4 
out of 15 rP cows had been culled. four out of 6 dystocia cows (67%) and 6 out of 11 rP cows (55%) 
were pregnant after on average 1.8 and 1.2 inseminations per cow, respectively. The average calving to 
conception intervals were 78 days for the dystocia and 94 days for the rP cows.
Presence of abnormal cervical discharge at 1, 14 and 28 d postpartum was positively related to the 
presence of A. pyogenes (P<0.05) and, except for day 1 postpartum, also with G-anaerobes  
(P<0.05). The presence of e. coli was not related to the aspect of the discharge (P>0.1). however, 
a positive relationship between the presence of e. coli at 1 day postpartum and the presence of A. 
pyogenes and G-anaerobes at 14 d postpartum was found (figure 4, P<0.05). An even stronger 
relation was present between endotoxin levels in lochia of 1 day postpartum and the presence of 
both A. pyogenes and G-anaerobe bacteria at 14 d postpartum (P<0.01). No significant relationships 
between endotoxin levels and bacteriological data at 30 d postpartum were observed, possibly 
because the number of available cases at this time had decreased due to treatments.
Table 3. frequency rates (%) of uterus isolates at 14 and 30 days postpartum in untreated cows.
 Dystocia cows (n=6) rP cows (n=15)
 14 d pp 30 d pp 14 d pp 30 d pp
Treated for endometritis1 0% 17% 27% 40%
A. pyogenes 40% 0% 89% 29%
e. coli 60% 33% 44% 11%
Black pigmented anaerobes 0% 0% 44% 14%
Bacteroides spp. 0% 0% 56% 17%
f. necrophorum 0% 0% 33% 0%
Clostridium spp. 0% 0% 11% 0%
1
 Cows which had been treated in the mean time for endometritis. No additional uterine swabs of these cows 
were collected. pp=postpartum
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4. Discussion
having studied qualitative and quantitative aspects of intra-uterine bacterial contamination, 
we could not only confirm previous reports7; 8; 24 on this topic, but also demonstrate some 
valuable interrelationships on the appearance of certain pathogens and endotoxins in the course 
of the development of endometritis in cows that had dystocia or rP. our findings show that 
immediately after calving, rP cows were more often infected with various bacteria like e. coli, 
Clostridum spp. and G-anaerobes (prevalence rates up to 97%) than cows without periparturient 
disorders. results also confirm that e. coli is mainly present during the first days postpartum, 
whereas A. pyogenes and G-anaerobes are present in the uterus for a longer period7; 8; 24. our 
results allow us to show a positive relationship between the presence of e. coli and endotoxins 
in the uterus at 1 to 2 d postpartum and the presence of A. pyogenes and G-bacteria at 14 d 
postpartum. This suggests that the bacterial contamination present in the uterus shortly after 
parturition favors the development of uterine infections by A. pyogenes and G-anaerobes later 
postpartum. As a consequence, advice on optimal calving conditions and hygiene around 
parturition can be substantiated.
Although acute endometritis is known to be related to high endotoxin levels (Intervet data, 
on file) and the presence of both A. pyogenes and G- bacteria in the uterus9; 28, little is known 
about their role in the establishment of uterine infections later postpartum except that they act 
Figure 4. relationship between the precence of e. coli at 1 day postpartum (pp) and the prevalance of A 
pyogenes and G-anaerobes at 14 days ppabcd. Values with different superscripts differ significantly  
(P<0.05).
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synergistically, causing a significant negative effect on reproduction1; 4; 8; 11. Because they lack 
the ability to invade intact epithelium, these are usually considered facultative pathogens and 
therefore require a damaged epithelium to establish infection19, which can be the case shortly 
after a dystocia. Later postpartum, an e. coli infection was needed to damage the endometrium, 
enabling absorption of endotoxins12; 27. Although the variation within the group was large, rP 
cows had significantly higher endotoxin levels in uterine lochia shortly after calving compared 
to dystocia and healthy postpartum cows. Despite these high endotoxin levels and a significant 
increase in body temperature, only 5 cows were systemically ill at the time of sampling. 
moreover, these sick cows did not have the highest endotoxin concentrations in their lochia. 
endotoxin levels in plasma on the other hand were below the detection limit in all groups of 
cows, suggesting that either they are not absorbed into the blood, which is contradicted by the 
work of Peter et al.27 and Gilbert et al.12, or they are sufficiently detoxified by IgG anti-endotoxin 
or other detoxification mechanisms such as the acyloxyacyl hydrolase (AoAh) system10. This 
can explain why some cows get sick and others do not, depending on the normal function of 
their detoxification mechanisms. 
An important mechanism to detoxify endotoxin is the IgG anti-endotoxin system. According 
to Barclay2, the IgG anti-endotoxin levels steadily increase in humans until they stabilize at 
the adult median around the age of 7 yr. We found no relationship between parity and IgG 
anti-endotoxin, suggesting that IgG anti-endotoxin levels in cows reach the maximum range 
within 1 yr. In the case of endotoxemia, IgG anti-endotoxin levels generally fall, but will soon 
be recovered from a reservoir that is present in the interstitial fluid2. This was partly confirmed 
by Troedsson et al.34, who saw a drop in the concentration of total IgG during the first 24 h 
after an intra-uterine challenge infection with Streptococcus zooepidemicus in mares. however, 
between 24 and 36 h after infection, the total IgG levels in resistant mares were re-established 
at the baseline levels, suggesting that these mares cleared the infection within 24 h, after 
which IgG was not needed anymore to opsonize residual bacteria. In contrast, IgG levels in 
susceptible mares continued to decline. Despite the high endotoxin levels found in lochia, IgG 
anti-endotoxin levels in the plasma of rP cows were not significantly different from the IgG 
anti-endotoxin levels in the other groups of cows immediately postpartum. Striking however are 
the significantly lower IgG anti-endotoxin levels in all groups of cows shortly after parturition 
when compared to healthy cows later postpartum. This decrease in IgG anti-endotoxin levels 
can possibly be caused by their binding to endotoxin that seep from the uterine lumen into the 
systemic circulation through a damaged endometrium. Consequently, the decline in the IgG 
anti-endotoxin levels can be seen as an indirect measure for the amount of endotoxins involved. 
Brenner and colleagues5 saw a drop of about 25% in the total serum IgG levels of healthy 
cows when comparing levels measured at 7 to 11 d before parturition with those measured at 
parturition. The decline in IgG anti-endotoxin levels could therefore be caused by the decline in 
the total IgG concentration. Brenner et al.5 hypothesized that IgG is transferred to the colostrum 
at the start of lactation, explaining the low concentrations in all postpartum cows. Additional 
opmaak karin joop_23147.indd   49 12-02-2009   08:46:24
50
Chapter II
eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIoN AND CoAGULATIoN  eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIo
differential analysis of both IgG anti-endotoxin and total IgG levels is needed to elucidate the 
cause of this marked decline.
The main conclusion of our study is that the presence of large numbers of e. coli and high 
concentrations of endotoxin/endotoxins in lochia of dystocia and rP cows shortly after 
parturition favor the development of uterine infections by A. pyogenes and G- anaerobes later 
postpartum. Despite the high endotoxin levels in lochia, no endotoxin was detected in the plasma 
of healthy, dystocia or rP cows. The normal function of the uterine wall and the detoxification 
mechanisms will determine whether the cow will show signs of systemic illness. results of 
this study indicate that measures to prevent and treat intra-uterine infections with e. coli in the 
immediate postpartum period may aid in reducing endometritis later.
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Abstract
The aim of the present study was to establish whether the gastro-intestinal (GI) complaints 
observed during and after ultra-endurance exercise are related to gut ischemia-associated leakage 
of endotoxins into the circulation and associated cytokine production. 
Therefore we collected blood samples from 29 athletes before, immediately after, and 1, 2 and 
16 hours after a long-distance triathlon for measurements of endotoxin, tumour necrosis factor 
(TNf-alpha and interleukin-6 (IL-6). As the cytokine response would trigger an acute phase 
response, characteristic variables of these responses were also measured as well as creatine 
kinase (CK) to obtain an indicator of muscle damage. 
There was a high incidence (93% of all participants) of gastro-intestinal (GI) symptoms, 45% 
even reported severe complaints and 7% of the participants abandoned the race because of severe 
GI-distress. 68% of the athletes had mild endotoxemia (5-15 pg/ml) immediately post-race, as 
also indicated by a reduction in IgG anti-endotoxin antibody levels. In addition, we observed 
a production of IL-6 (27 fold increase immediately after the race), leading to an acute phase 
response (20-fold increase in CrP and 12% decrease of pre-albumin 16 hours after the race). 
however, the extent of endotoxemia was not correlated to the GI-complaints. 
It is therefore concluded that endotoxin does enter the circulation after ultra-endurance 
exercise but in view of the absence of a correlation between the extent of endotoxemia and 
GI-complaints, this endotoxin leakage does not seem to be responsible for the observed GI-
problems in these athletes. 
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1. Introduction
Prolonged exercise at high intensities leads to a quantitative redistribution of blood flow. The 
blood flow to the exercising muscle is increased (exercise hyperaemia) in proportion to the 
energy demand in order to increase the supply of oxygen and substrates. In addition, during 
intense exercise the blood flow to the skin is increased to facilitate heat dissipation. As a 
consequence the blood flow to central tissues (gut and liver) is reduced during exercise1; 2. 
Clausen3 reported that during maximal exercise in man blood flow to the gut is reduced by about 
80%. exercise in the heat leads to an extra loss of total body water and a greater reduction in 
plasma volume. The blood flow to the gut may even be further reduced during such extreme 
conditions4; 5. A similar redistribution of blood flow is seen in patients with major trauma and/
or sepsis and various forms of shock6. In this situation a serious under perfusion of the gut often 
leads to shock-induced mucosal damage and invasion of gram-negative intestinal bacteria and/
or their toxic constituents (endotoxins) into the blood circulation7. endotoxins are highly toxic 
that form part of the outer cell wall of gram-negative bacteria. The shock-induced damage to 
gut mucosa is probably mediated by an excess production of oxygen-derived free radicals in 
the reperfusion stage following ischaemia8; 9. Increased circulating endotoxin levels in patients 
lead to various symptoms such as fever, shivering, dizziness, nausea, various gastro-intestinal 
complaints such as vomiting and diarrhea, and ultimately sepsis10. Similar symptoms may 
be found in athletes involved in ultra-endurance exercise in combination with heat stress and 
dehydration.
There is a very high prevalence of gastro-intestinal complaints during exercise among long-
distance runners and athletes involved in other types of strenuous long lasting exercise11-13. These 
symptoms include high body temperature, dizziness, nausea, and vomiting and are very similar 
to the symptoms seen in patients with systemic endotoxemia. In addition, ultra-endurance 
athletes often report gastro-intestinal problems like stomach cramps or stomachache, intestinal 
cramps and diarrhea. Prevalences of 30-50% have been reported among marathon runners14-16. 
marathon runners occasionally develop serious gut complaints (blood loss in faeces) in the hours 
following a marathon. Schaub et al.17 observed epithelial surface changes known to occur during 
ischemia upon colonoscopic inspection of one such athlete following a marathon and suggested 
that ischemia of the lower gastrointestinal tract induced the problems. Øktedalen et al.18 reported 
increased intestinal permeability after a marathon. Despite the high prevalence, the etiology of 
these gastro-intestinal complaints in endurance athletes is still incompletely understood.
As discussed above, decreased splanchnic blood flow may lead to ischemic damage to the 
intestinal wall. In addition, during intense exercise under extreme conditions mucosal damage 
may also be caused by thermal and mechanical damage to the mucosal layer of the gut and 
thus to a partial loss of the immunological barrier function of the gut. If this is the case, gram-
negative bacteria, present in the gut, may penetrate the mucosal layer and enter the lymph nodes 
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in the sub mucosal tissues. This may lead to the entrance of endotoxin in the portal vein and 
under extreme conditions maybe even in the main circulation (as observed in shock patients). 
Indeed, endotoxemia after strenuous ultra-endurance exercise has been reported. Brock-Utne 
et al.19 reported that 81% of 89 ultra-marathon runners in the Comrades marathon (90 km) 
demonstrated elevated plasma endotoxin concentrations. Two percent showed endotoxin 
concentrations above 1.0 ng/ml, a value reported in patients with meningococcal sepsis and 
considered to be extremely high if one considers a value of 5 pg/ml the limit for endotoxemia 
to predict or exclude oncoming sepsis20. however, in that study, resting levels of endotoxin also 
were in the range usually observed in critically-ill septic patients. In another study endotoxin 
concentrations increased and the anti-endotoxin IgG levels markedly decreased after a triathlon 
(3.2 km swim, 140 km cycling, 42.2 km run)21. Again, the reported resting levels of endotoxin 
were in the range usually observed in critically ill septic patients, which raise doubt about 
the validity of those results. Studies in race horses after short distance 1000-2800 m races22, 
cyclists with post-exertional illness after a 100 mile ride in the heat23 and more recently after a 
marathon24 showed only minor or no systemic endotoxemia. 
endotoxins are in vivo a main trigger for the host immune response via the induction of the 
cytokine network. TNf-alpha (tumor necrosis factor), one of the cytokines is presumed to be 
the central inflammatory mediator25. TNf-alpha is produced by macrophages and monocytes. 
It stimulates the production of other cytokines by the monocyt and other cells, including 
endothelial cells. other pro-inflammatory cytokines include interleukin-1 (IL-1) and IL-6. Upon 
intravenous administration of a bolus of 2-4 ng endotoxin/kg body weight to human volunteers, 
TNf-alpha first appeared 45 min post-infusion in the circulation, peaked at 90 min and then 
rapidly declined towards pre-infusion levels after 6 hours26,27. IL-1 could not be detected 
while IL-6 appeared at 60 min in the circulation, peaked at 120 min and then also disappeared 
rapidly26,27. TNf-alpha, IL-1 and IL-6 have many biological effects, including the triggering 
of the acute phase response28-31. This involves substantial changes in plasma concentrations of 
many proteins in response to bodily harm, e.g. an increased inflammatory or surgical situation. 
Both increases and decreases in plasma protein concentrations, the so-called positive and 
negative acute phase responses, occur due to a change in their synthesis in the liver28. IL-6 
induces the full spectrum of the acute phase reaction whereas IL-1 and TNf-alpha only lead to 
a partial acute phase reaction29-31. Pre-albumin and C-reactive protein (CrP) are good examples 
of negative and positive acute phase reactants, respectively. After the onset of inflammation or 
tissue injury, the CrP concentration starts to increase after 4-6 hours and peaks at 36-50 hours32. 
The development of the pre-albumin concentration is not well known.
The first aim of the study was to investigate whether there is endotoxemia in the 16 hours after 
a long distance triathlon. We also measured IgG-anti-endotoxin antibody concentrations, as they 
are expected to decrease over a time period more prolonged than that of a potential endotoxin 
peak, due to formation of endotoxin-anti-endotoxin complexes and subsequent breakdown of 
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the protein complex. furthermore, decreases in anti-endotoxin may also be seen when endotoxin 
would be produced locally only (e.g. in gut and portal vein) without appearing in the systemic 
circulation. We also measured the cytokines TNf-alpha and IL-6 as possible mediators of the 
endotoxin-induced effects, and C-reactive protein and pre-albumin as indicators of the acute 
phase reaction induced by those mediators.
A second aim of the study was to study the relation between gastro-intestinal complaints and the 
measured indirect markers of the gut barrier function: endotoxemia, the cytokine and the acute 
phase response.
In order to study the effects of extreme exercise we have chosen for a long distance triathlon 
(3.8 km swimming, 186 km cycling and 42.2 km running) in embrun, france. This triathlon is 
believed to be one of the most challenging worldwide. The conditions of this race are extreme 
(high temperatures, altitude, long duration) and thus the prevalence of gastrointestinal symptoms 
and possibly endotoxemia were expected to be high.
2. Methods
2.1 Subjects and protocol 
Twenty-nine male triathletes and 1 female triathlete were recruited for this study. All subjects 
were instructed and informed about the procedures of the study and they signed a consent form. 
Subject’s age and weight were 33.0±6.0 years and 72.3±7.3 kg, respectively. The Ironman 
distance triathlon in embrun (embrunman) in france helt on the 15th of August 1996 was 
chosen because this is supposed to be one of the most challenging long distance triathlons. After 
the swim (3800 m) in open water, athletes cycled a course of 185 km in the mountains (Alps) 
with an altitude difference of 3600 m. Subsequently the athletes ran 42.2 km, partly on unpaved 
roads. The environmental conditions were 9.4°C in the morning at the start (6.00 Am) with a 
high of 32.1°C around 14.00 Pm. The water temperature was 18.6°C at the start.   
The day before the start a blood sample was collected as well as immediately after the finish, 
one hour, two hours and 15-20 hours after the finish. The blood was used for the measurement of 
endotoxin, anti-endotoxin, TNf-alpha, IL-6, CrP and pre-albumin. The day before the triathlon, 
one hour before the start and immediately after the triathlon body mass was measured. Before 
and immediately after, the athletes completed a questionnaire.  
2.2 Questionnaire
A questionnaire (20 items) was provided two or three days prior to the race with questions 
regarding training background, performance level, experience, preparation and the use of 
supplements. A second questionnaire (96 items) was provided directly after the race and 
athletes were asked to complete the questionnaire within 2 hours after finishing. This second 
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questionnaire contained questions regarding the occurrence of gastro-intestinal symptoms during 
swimming, cycling, running and in the hours after the race. In case subjects abandoned the race 
questions were included to obtain the reason of abandoning.
fluid loss was estimated from weight loss and corrected for fluid intake. 
2.3 Body mass and fluid balance 
Weight was recorded the day before the triathlon, one hour before the start and immediately 
after the race. Subjects were carefully instructed to report fluid and solid food intake during the 
race as accurately as possible. fluid intake was estimated from the reported beverage (and solid 
food) intake. Immediately after the race, athletes were also asked to write down as accurately as 
possible what beverages and solid food they consumed during the race and in which amounts. 
The nutritional composition of dietary intake during the race was calculated through information 
from producers of particular products or the Dutch Nutritional (NeVo) tables. 
2.4 Analyses 
At each time point three samples of 4.0 ml heparin-anticoagulated blood was collected (endo 
Tube, Chromogenix AB, mölndahl, Sweden) and 5.0 ml non-anticoagulated blood. The tubes 
with the heparinised blood were immediately placed on melting ice. one was centrifuged at  
180 x g and 4°C for 10 min to prepare platelet-rich plasma (PrP) for the endotoxin assays. 
The PrP samples were divided in two aliquots and stored at -20°C. The two other tubes were 
centrifuged at 3000 x g and 4°C for 10 min to prepare platelet-poor plasma (PPP) for the TNf-
alpha and IL-6 assays. The PPP was divided in 500 µl aliquots. The 5 ml non-anticoagulated 
blood was allowed to clot for at least 30 min at ambient temperature to prepare serum, 
centrifuged at 3000 x g at 4°C for 10 min, and aliquots of 500 µl stored at -20°C. The serum was 
used for the anti-endotoxin, pre-albumin and CrP assays.
Blood was also collected from 20 healthy untrained male volunteers (mean age 38 years, 
range 20-55) to determine reference ranges of anti-endotoxin, IL-6, pre-albumin and CrP. The 
reference ranges were determined in male volunteers because 29 of the 30 athletes were also 
male.
2.5 Endotoxin
endotoxin was assayed with chromogic assays obtained from Boehringer Ingelheim Whittaker 
(Verviers, france, the β-glucan insensitive endotoxin assay) and Chromogenix Am, mölndal, 
Sweden, the more β-glucan sensitive endotoxin assay), as described previously33-35. Briefly, 
the PrP samples were thawed 5 min at 37°C, dilluted 10-fold with pyrogenfree water and 
heated for 15 min at 75°C to remove inhibitory activity from the plasma. After cooling to room 
temperature for 1 hour, 50 µl aliquots were transferred to a microtiterplate. After incubation at 
37°C with 50 µl LAL reagent (Biowhittaker 30 min, Chromogenix 12 min) and the subsequent 
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chromogenic substrate (Biowhittaker 6 min and Chromogenix 8 min) the reaction was stopped 
with acetic acid and the yellow colour read at 405 nm. readings were compared with a standard 
curve prepared in human PrP with the e.coli 0111:B4 standard provided by the manufacturers 
according to the same procedure and treated simultaneously with the test samples. With this 
standard 1.2 eU/ml corresponds to approximately 120 pg/ml.
2.6 IgG anti-endotoxin
IgG anti-endotoxin was assayed by eLISA with reagents (endocab) that were kindly provided 
by Chromogenix AB, mölndal, Sweden. Briefly, serum samples were thawed at room 
temperature and diluted 200-fold in the sample buffer provided in the kit. Then 100 µl of this 
diluted sample or standards were added to a microtiterplate. This microtiterplate had been 
precoated with a mixture of endotoxin by the manufacturer. After incubation at 37oC for 60 min 
to bind the endotoxin antibodies in the serum to the plate, the plate was washed three times with 
wash-buffer. Then 100 µl of an antibody to human IgG was added, which had been conjugated 
to alkaline phosphatase. After incubation for 60 min at 37oC, the plate was washed three times 
with wash buffer and five times with destilled water. Then 100 µl of a freshly prepared substrate 
solution of 800 µm p-nitrophenyl phosphate was added, incubation continued for 60 min at 
ambient temperature and in the dark, the reaction was stopped by addition of 50µl 6N h2So4 
and the absorbance read at 405 nm. endocab is expressed in median Units/ml (mU/ml), i.e. the 
median level observed in a group of 100 volunteers tested by the manufacturer.
2.7 TNF-alpha and IL-6
In the assays for TNf-alpha and IL-6, endo tube eT collection tubes were used to avoid any 
contamination with endotoxin and thus to avoid higher levels of TNf-alpha and IL-6 due to 
in vitro activation of blood cells. TNf-alpha and IL-6 were determined by eLISA (Pelikine 
Compact™ TNf-alpha and IL-6 eLISA kits; Central Laboratory of the Netherlands red Cross 
Blood Transfusion Service; The Netherlands).
2.8 CRP
CrP was determined by nephelometry on a hitachi 911 analyser (Boehringer mannheim, 
mannheim, Germany) with reagents and according to the instructions provided by this supplier.
2.9 Pre-albumin
Pre-albumin was determined by nephelometry on an auto-analyser (ArrAY, Beckmann 
Instruments Inc., Breda, The Netherlands), with reagents and according to the instructions 
provided by this supplier.
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2.10 CK
Creatine kinase (CK) was determined by spectrophotometry on a hitachi 747 analyser 
(Boehringer mannheim, mannheim, Germany) with the NAC-activated CK reagent kit and 
according to the instructions provided by this supplier.
2.11 Statistics
The gastro-intestinal symptoms were divided in two categories: severe symptoms and less 
severe symptoms. Severe symptoms included nausea, vomiting urge, vomiting, stomachache 
and intestinal cramps. Nausea, stomachache, intestinal cramps and urge to vomit were only 
registered as severe symptoms when a score of 5 or higher out of 10 was given. Less severe 
symptoms included eructation, flatulence, urge to defecate, heartburn and abdominal pressure 
(bloating). Nausea, stomachache, intestinal cramps and urge to vomit were registered as non-
severe symptoms when a score below 5 was given.
Symptoms reported during cycling and running were compared to endotoxin and anti-endotoxin 
concentrations as well as with the parameters of the cytokine and acute phase response using a 
Spearman rank Correlation test. Gastro-intestinal complaints reported during swimming were 
ignored because it is unlikely that these complaints would be related to endotoxemia.
A one-way ANoVA was used to detect changes over time. In case of significance, the difference 
was located with a Tukey post-hoc test. To study the difference in measured blood parameters 
between the triathletes and untrained healthy control subjects an unpaired t-test was applied. In 
all cases the level of significance was set at P<0.05 and all results were expressed as mean  
± Sem.
3. Results
3.1 Study group
Because of incomplete data collection, one subject was discarded. four out of the remaining 29 
participants abandoned the race (14%). The reasons for abandoning varied among athletes. Two 
of them could not continue because of gastro-intestinal problems, two abandoned because of 
muscle cramping and muscle soreness or lower back problems.
3.2 Gastro-intestinal complaints
The vast majority of the subjects (93%) reported some gastro-intestinal symptoms, most of them 
being non severe. The most reported complaints were flatulence and eructation. There was also 
a relatively high prevalence of severe symptoms (Table 1). Six subjects (21%) reported an urge 
to vomit during either cycling or running and these subjects also vomited. one athlete reported 
diarrhea during cycling and one during running. Two athletes abandoned the race because of 
severe gastro-intestinal problems including diarrhea, stomach cramping, vomiting and nausea.
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3.3 Assays
The mean endotoxin concentration as measured with the β-glucan insensitive assay showed an 
increase immediately post-exercise and was more pronounced 1 hour after the race (figure 1). 
The highest measured value was 15.0 pg/ml. When it is assumed that endotoxemia is present 
at endotoxin concentrations >5.0 pg/ml20,24, at 1 hours after the race, 68% of the athletes had 
endotoxemia. At 2 hours after the race only 19% of the athletes had endotoxemia which was 
increased again 16 hours after the race (79%). With the β-glucan sensitive assay a similar pattern 
in the endotoxin concentrations was observed, but the highest level of endotoxin-active material 
was measured immediately after the race.
IgG anti-endotoxin levels did not change directly and 1 hour after the race but showed a 
tendency to decline after 2 hours. After 16 hours anti-endotoxin had declined significantly 
compared to the levels at rest and the first 2 hours after exercise. The TNf-alpha, IL-6, CrP and 
pre-albumin concentrations are presented in figure 2.
The TNf-alpha concentration was 0.84±0.20 pg/ml before the race and did not change 
significantly at any of the study periods.
The IL-6 concentration showed a significant average 27-fold increase immediately after the race 
and then decreased slowly. The day after the race (16 h) IL-6 had returned to pre-race levels.
The CrP concentration was elevated 2 h after the race compared to rest (1.53±0.11 µg/ml) and 
was on average increased 20-fold 16 hours after the race to a mean of 30.2±3.0 µg/ml. one 
subject had a CrP concentration of 62.4 µg/ml.
Table 1. Gastro-intestinal and related complaints during the triathlon.
Complaints n % Complaints n %
Stomach problems 9 31 Stomach cramps 3 10
Nausea 6 21 Intestinal cramps 4 14
Dizziness 2 7 Urge to vomit 6 21
head ache 3 10 Vomiting 6 21
flatulence 11 38 Diarrhea 2 7
Urge to urinate 19 66 Side ache left 1 3
Urge to defecate 4 14 Side ache right 3 10
Belching 10 35 muscle cramps 6 21
heartburn 2 7 Cold shivering 3 10
Bloating 7 24 
Nausea, stomachache, intestinal cramps and urge to vomit were only registered when a score of 5 or higher 
(out of 10) was given.
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The pre-albumin concentration was slightly elevated immediately after the race and started to 
decrease in the hours after the race. At 16 hours after the race the pre-albumin concentration was 
significantly lower than the concentrations on the day of the race. 
Plasma CK concentrations were significantly elevated after exercise and continued to 
increase the hours after the race. This increase however, was not correlated with changes in 
IL-6 concentration (Spearman rank correlation coefficient (r
s
) 0.174 p=0.366). Similarly, no 
correlation was found between CK and changes in TNf-alpha concentration (r
s
 –0.139 p=0.473), 
between CK and changes in CrP concentration (r
s
 0.363 p=0.053), and between CK and 
changes in pre-albumin concentration (r
s
 0.244 p=0.220).   
Figure 1: endotoxin measured with a β-glucan insensitive and a more β-glucan sensitive endotoxin assay 
and IgG anti-endotoxin before and at several time points after the triathlon. Values are presented as mean  
± Sem.
a indicates a significant (P<0.05) elevation compared to the pre-race values.
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Increases in endotoxin and IgG anti-endotoxin were not correlated with any of the gastro-
intestinal symptoms during running and cycling (data not shown). The change in IL-6 
concentration from rest to directly after the race showed a significant correlation with vomiting 
and diarrea during running (Table 2). markers of the acute phase response (CrP and pre-
albumin) also showed a significant correlation with the incidence of diarrea during running. 
Additionally, these two markers of the acute phase response were correlated with the score for 
Figure 2: IL-6, TNf-alpha and the positive and negative acute phase response proteins CrP and pre-
albumin concentrations before and at several time points after the triathlon. Values are presented as mean  
± Sem.
a indicates a significant (P<0.05) change compared to resting values
b indicates a significant (P<0.05) change compared to 2 hours after the race.
opmaak karin joop_23147.indd   63 12-02-2009   08:46:29
eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIoN AND CoAGULATIoN  eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIo
64
Chapter III
intestinal cramps during running. The responses for the two athletes who abandoned the race 
because of GI-problems were similar to those of athletes with little or no GI-complaints.
reference values were obtained in healthy untrained control subjects for anti-endotoxin (mean 
242 MU/ml, range 65-470 mU/ml), IL-6 (mean 1.1 pg/ml, range 0.7-6.5), pre-albumin (mean 
322 µg/ml, range 200-494 µg/ml) and CrP (mean 2.47 µg/ml, range 0.74-6.21 µg/ml) (Table 3). 
Figure 3: CK response after the triathlon. Values are 
presented as mean±Sem. 
an indicates a significant (P<0.05) change compared to 
pre-race values. 
Table 2. Correlations between changes in CrP, IL-6 and pre-albumin versus gastro-intestinal complaints.
 ∆ CrP ∆ IL-6 ∆ pre-albumin
Nausea 0.259 0.155 0.223
Dizziness 0.350 0.264 0.503* 
Intestinal cramps 0.397* 0.174 0.533**
Vomiting 0.381 0.268* 0.165
Diarrhea 0.511* 0.504* 0.529**
The presented values are Spearman rank correlation coefficients (rs) and * indicates P<0.05 (** indicates 
P<0.01). The changes in CRP, IL-6 and pre-albumin were expressed as a ∆ value of each athlete between rest 
and the value at the time point of maximum response; for IL-6 immediately after the race, for CRP and pre-
albumin 16 hours after the race.
Table 3. resting values of endotoxin, IgG anti-endotoxin, IL-6, TNf-alpha, CrP and pre-albumin in triathletes 
and untrained controls.
 Control Triathletes P-value
IgG anti-endotoxin (mU/ml) 242±28 146±14* 0.0013
IL-6 (pg/ml) 1.1±0.2 1.5±0.3 0.3444
CrP (µg/ml) 2.47±0.34 1.53±0.11* 0.0033
Pre-albumin (µg/ml)  322±15 326±7 0.8238
* indicates statistical significance (P<0.05).
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Compared to a group of healthy but untrained individuals, the athletes had lower concentrations 
of anti-endotoxin and lower CrP concentrations at rest (Table 3). No differences were observed 
in IL-6 and pre-albumin concentrations. 
4. Discussion
The athletes in the present study showed some symptoms usually seen with endotoxemia, 
i.e., dizziness, nausea, and vomiting during and after the race. one third of the athletes had 
stomach problems, 21% of the athletes were nauseous, 7% experienced dizziness, 6 athletes 
(21%) vomited and two had diarrhea. Two athletes had to abandon the race because of severe 
gastro-intestinal distress (vomiting and diarrhea). These gastrointestinal (GI) problems are often 
reported by endurance athletes during long races, especially in the heat and especially when 
running is involved as shown by numerous surveys and case studies14-16. Although there was 
a high incidence of gastro-intestinal complaints in the present study, including several severe 
symptoms, only mild endotoxemia was observed in the athletes investigated (i.e, endotoxin just 
above the 5 pg/ml threshold used to define endotoxemia). The degree of endotoxemia was not 
related to the incidence or the severity of the complaints. however, the cytokine response, which 
might have evolved from the endotoxemia, was correlated with gastro-intestinal complaints. 
especially the IL-6 concentration was correlated to severe complaints (diarrhea and vomiting) 
(Table 2). No correlation, however, was observed between IL-6 and endotoxin.
The finding of mild endotoxemia in these extreme conditions is seemingly in contrast with 
two other studies19-21, which reported a high incidence of extreme endotoxemia in athletes 
participating in a 90 km run (Comrades marathon) and a long distance triathlon, respectively. In 
the study by  Brocke-Utne et al.19, 81% of the investigated athletes had endotoxin levels above 
100 pg/ml whereas in the present study the highest measured endotoxin level was 15 pg/ml. one 
explanation for the discrepancies may be the fact that the athletes studied by Brocke-Utne et al.19 
were exhausted runners who had to abandon the race because of gastro-intestinal complaints, 
dehydration and heat shock, whereas in the present study 86% of the participants in the study 
were able to finish the race. 
however, similar observations to Brocke-Utne et al.19 were made by Bosenberg et al.21, who 
studied 18 triathletes and observed that plasma endotoxin rose from a mean of 81 ng/ml to 294 
ng/ml. It must be kept in mind, however, that the reported resting endotoxin concentrations in 
those studies were already higher than those observed in patients with a septic shock and thus 
analytical differences may be responsible for the discrepancies between the two abovementioned 
studies and the present study. When a similar endotoxin assay was performed by Camus et 
al.24 the results seem to be in agreement with our findings. In that study very mild endotoxemia 
(between 5 and 14 pg/ml) was observed after a marathon in 8 of 18 athletes whereas one athlete 
had a high endotoxin level of 72 pg/ml24.
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The analysis of endotoxin in plasma is critically dependent upon several issues, which may 
be responsible for the discrepancy in the findings in the present study and those of Brocke-
Utne et al.19 and Bosenberg et al.21 endotoxin are usually determined with the LAL (Limulus 
Amoebocyte Lysate) assay34; 35. This assay is based on the property of endotoxin to activate the 
clotting cascade, which is present in the circulating cell (amoebocyte) of Limulus polyphemus, 
the horseshoe crab. With this assay it is possible to detect very low levels of endotoxin in plasma 
(3 pg/ml or 0.036 eU/ml), which is essential because endotoxemia in man is already considered 
to be present above 5 pg/ml20. A first critical issue is the fact that plasma contains inhibitory 
substances that have to be removed prior to the endotoxin assay. A dilution and heating 
procedure is usually the method of choice36. Details of the method to remove the inhibitory 
activity in plasma are not always indicated. This makes it difficult to estimate the validity 
of the methodology. however, an inappropriate method would result in too low endotoxin 
concentrations and therefore cannot be the reason for the relatively high reference values 
obtained by the investigators reporting high endotoxin concentrations19-21.
Secondly, the reference ranges in the other studies19-21 are rather high, i.e. between 64 and 100 
pg/ml, and would therefore be in the range of septic patients. The articles are not providing 
sufficient details of their methodology. for instance, if the other investigators used a standard 
curve prepared in water instead of PrP, a factor 10 difference in results will be obtained due to a 
lesser endotoxin activity in water. Also, the factor 10 dilution of the PrP is frequently not taken 
into account if the results are expressed as pg/ml. We therefore always prepare the standard 
curve in PrP and express our results in pg/ml PrP (or eU/ml PrP).
Thirdly, the LAL reagent may not only react to endotoxin but can also be sensitive to β-glucan 
if a chloroform extraction procedure is used to prepare the LAL reagent, which is usually the 
case. β-Glucan is present in fungi and can be present in the membranes used in hemodialysis and 
other cardio pulmonary bypass devices36. In the present study both a β-glucan insensitive and a 
more β-glucan sensitive endotoxin assay were used. The two assays gave similar patterns of the 
endotoxin levels, but immediately post-race the β-glucan sensitive assay gave higher results than 
the β-glucan insensitive assay. This could indicate that fungal material, also likely to originate 
from the intestine, is especially present in the circulation at that study period. It is unclear 
whether the LAL in the other two studies19-21 was β-glucan sensitive.
Another method to investigate whether endotoxin has appeared in the circulation is to measure 
the plasma anti-endotoxin concentration. In a study in racehorses, the IgG anti-endotoxin 
concentration was significantly reduced after the race22. Also, both the pre- and post-race IgG 
anti-endotoxin levels were lower than the values measured in untrained horses, which could 
indicate that training and competition leads to endotoxin leakage into the circulation and 
subsequent increase in the specific antibody production21. Similarly, serum IgG anti-endotoxin 
concentrations were negatively correlated to the endotoxin concentrations in the circulation in 
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long-distance runners19. In agreement with the findings in racehorses we observed 40% lower 
IgG anti-endotoxin levels in our trained subjects compared to untrained controls. It can not be 
excluded that the lower anti-endotoxin level in trained athletes may be due to some endotoxin 
leakage during training sessions in the weeks preceding the race, leading to the formation of 
endotoxin – anti-endotoxin complexes, which may be rapidly broken down, thereby decreasing 
the levels of anti-endotoxin. The observed reduction in IgG anti-endotoxin 16 hours following 
the triathlon suggests that there is a continuous leakage of endotoxin into the circulation in the 
first hours after this extreme exercise.
It is known that endotoxin is a potent activator of the cellular and humoral host-defence systems. 
Blood monocytes and tissue macrophages secrete several cytokines like TNf-alpha and IL-6 
upon activation by bacterial endotoxins27,37. TNf-alpha did not change after the race, whereas 
the IL-6 concentration increased substantially. In this study the cytokine response to endotoxin 
was partly detected. TNf-alpha did not change, which is in agreement with some38; 39 but not all24 
studies. Northoff and Berg38 were unable to detect TNf-alpha at the completion of a marathon 
whereas TNf-alpha also stayed below the levels of detection in a study by rohde et al.39, both 
measured by an eLISA assay. our failure to detect TNf-alpha is not surprising if one considers 
the much more serious conditions of sepsis. In studies involving 97 to 146 patients with sepsis, 
only 4-54% of the patients had detectable levels of TNf-alpha in the circulation40. This may be 
due to the rapid clearance of TNf-alpha in the circulation40.
Increased IL-6 levels were demonstrated in 28 of the 29 athletes in this study, which confirms 
observations by other investigators after various exercise conditions41 including a marathon24. 
Upon activation by bacterial endotoxins, blood monocytes and tissue macrophages secrete 
several cytokines including IL-627,37. The increased IL-6 levels observed here may thus be 
another indication that endotoxemia occurred during and after the triathlon. however, there 
seemed to be no direct correlation between IL-6 and endotoxin and it cannot be excluded that 
the elevated IL-6 levels were caused by the exercise itself or by muscle damage as a result of 
exercise. Bruunsgaard et al.42  recently showed that serum IL-6 was significantly increased after 
2 hours eccentric exercise but not after 2 hours concentric exercise. IL-6 may thus be related 
to muscle damage, especially since serum IL-6 concentrations were significantly correlated 
with creatine kinase (CK), a parameter often used to indicate muscle damage. The athletes in 
the present study encountered a fair amount of downhill running and thus eccentric exercise. 
however, in the present study we could not find a correlation between the cytokine- and acute 
phase response and plasma CK levels (figure 3). CK was significantly increased after the race, 
as were IL-6 and pre-albumin but the magnitude of the increase in IL-6 and pre-albumin was not 
related to the CK levels. Although there was a tendency for the increase in CrP to be correlated 
with CK, the correlation was not strong and statistically not significant.
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Camus et al.24 concluded that the relationship between alterations in gut-barrier function, 
endotoxin translocation and the cytokine responses after exercise is, at least in quantitative 
terms far from being established. As in the present study, these authors did not find a correlation 
between endotoxin or anti-endotoxin and the concentration of cytokines after strenuous exercise. 
IL-6 is one of the main stimuli of the acute phase reaction, which was indeed present in these 
athletes. CrP as participant of the positive acute phase reaction, and pre-albumin representing 
the negative acute phase reaction, were especially increased and decreased, respectively, in the 
samples collected 16 hours after the race. elevations of positive acute phase proteins have been 
reported by others43-46. Dufaux et al.43 and Liesen et al.44 reported a 6-fold increase in CrP one 
day after a 2 hour and 3 hour run, respectively, while a peak may be observed 24 hours after 
a strenuous exercise46. Castell et al.45 reported a 4-fold increase in CrP levels 16 hours after a 
marathon. These results seem to be in agreement with the results of this study in which we found 
CrP to be increased 20-fold and pre-albumin decreased 12% 16 hours after the race.
It is possible that the long training background and the large number of training hours before 
participation increased the endotoxin resistance and reduced the pro- and anti-inflammatory 
responses. rats that were repeatedly injected with endotoxin, show a significantly improved 
survival rate when exposed to the heat, which has been attributed to increased circulating anti-
endotoxin antibodies, increased reticulo-endothelial phagocyte capacity, increased tolerance 
to TNf-alpha toxicity, and reduced inflammatory reactions by endotoxin-stimulated cells47. 
however, here we did not see a relation between training background or the amount of training 
and the concentrations of endotoxin, anti-endotoxin, IL-6 or TNf-alpha. however, we did 
observe 40% lower IgG anti-endotoxin levels in our trained subjects compared to untrained 
controls. This may indicate that previous training resulted in endotoxin leakage into the 
circulation. resting CrP levels were lower in the athletes. however, this may be attributed to 
the high CrP levels of three of the control subjects, possibly caused by smoking behaviour or an 
infection. 
These results suggest that endotoxin leakage is a situation that is inherent to the large training 
loads as applied by these endurance athletes and may occur frequently without causing systemic 
endotoxemia.
In conclusion, mild systemic endotoxemia was observed in some athletes in the hours after 
exercise while anti-endotoxin levels were significantly decreased 16 hours after exercise 
suggesting that there was portal vein endotoxemia during and after exercise. however, there was 
no correlation between the extent of systemic endotoxemia and the severity of GI-complaints 
suggesting that systemic endotoxemia is not a direct cause of GI-complaints. There was a clear 
cytokine response immediately after exercise and a clear acute phase response the day after 
exercise, and both of them did positively correlate with some of the severe GI-complaints (e.g. 
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diarrhea, vomiting) during exercise. As both responses may have evolved from portal vein 
endotoxemia, we conclude that we find evidence in support of the hypothesis that the gut barrier 
function for bacterial endotoxins and potentially also for fungal beta glucans is lost during 
severe prolonged exercise and may lead to GI-complaints. Although it cannot be excluded that 
other exercise-induced inflammatory processes (e.g. muscle damage) also play a role in cytokine 
and acute phase activation, we did not find a correlation between CK and this activation.
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Abstract
Previously, we investigated whether gastro-intestinal (GI) complaints during an ultra endurance 
exercise, the embrun Ironman triathlon, are related to gut ischemia-induced leakage of 
endotoxins into the circulation. We observed a mild endotoxemia and muscle damage13. 
recently, procalcitonin was found in high concentrations in patients with bacterial infection 
or sepsis, and at lower concentrations in non-infectious conditions. The aim of the present 
study was to determine procalcitonin levels before and after the ultra endurance exercise, and 
to determine whether changes were due to the release of endotoxins. from 30 athletes venous 
blood samples were collected before and at various time intervals after the exercise. Plasma 
procalcitonin concentrations before the exercise were low, increased approximately 4-fold 
after the exercise (p<0.01) and did not correlate with endotoxin levels (r=0.10; p=0.61). The 
significantly increased plasma concentrations of creatine kinase also did not correlate with 
the procalcitonin increases (r=0.30, p=0.11). The procalcitonin concentrations correlated with 
interleukin 6 levels (IL-6, r=0.49) and the acute phase reactant C-reactive protein (CrP, r=0.35), 
which was statistically significant for IL-6 but not for CrP (p<0.01 and p=0.06, respectively).
We conclude that during and after ultra endurance exercise the rise in procalcitonin is not likely 
to be induced by the endotoxemia, or muscle damage. The exercise-induced cytokine alterations 
are likely to be responsible for the mildly increased levels of procalcitonin.
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1. Introduction
endotoxins are constituents of the gram negative bacterial cell wall. endotoxins are released from the 
bacteria and then trigger the immunologic response7. elevated levels of endotoxin in the circulation 
cause symptoms such as fever, shivering, dizziness, nausea and various gastro-intestinal (GI) 
complaints28. These symptoms are also frequently observed in ultra endurance athletes during and 
after their extreme exercise23. In an earlier study, we hypothesized that GI-complaints in athletes are 
caused by leakage of endotoxin due to gut ischemia6;23. Therefore, we determined concentrations 
of endotoxin in blood samples collected from athletes before and after a long-distance triathlon. 
Almost all athletes suffered from GI-complaints during and after the triathlon, and 74% had mild 
endotoxemia after the ultra endurance exercise. Although endotoxin evidently entered the circulation, 
no correlations were found with the observed cytokine- and acute phase responses after the triathlon. 
Procalcitonin (PCT) gained much interest as a potential marker for systemic infection. PCT is 
a 13 kDa polypeptide of 116 amino acids, which is the precursor of calcitonin14. Injection of 
endotoxin into healthy individuals increased the PCT concentrations from <0.1 ng/ml to 5 ng/ml 
within 24 hours1. elevated PCT levels were more sensitive and specific than C-reactive protein 
(CrP) or interleukin 6 (IL-6) for differentiation between bacterial and viral infections 9;10;12;17;20;21. 
Boeken and colleagues found that elevated concentrations of PCT could distinguish between 
SIrS (systemic inflammatory response syndrome) and sepsis5.  In contrast to CrP no elevated 
levels of PCT were found in patients with trauma and without infections8;19;29. The function of 
the PCT increase is still unknown, since no subsequent rise in plasma calcitonin antigen levels or 
activity are observed24. 
To further characterize the systemic inflammatory response of these athletes, concentrations of 
PCT were determined and correlations were established with endotoxin, cytokines and acute 
phase responses, and muscle damage. 
2. Methods
2.1 Athletes
Twenty-nine males and 1 female were recruited for this study. All subjects were instructed, 
informed and signed consent form. Subjects aged 33.0 ±6.0 years. The subjects particated in the 
Ironman Distance Triathlon in embrun (1996). four athletes abandoned the race and data from 
one subject were deleted because of incomplete data collection.
2.2 Blood collection
Blood samples were collected the day before the triathlon, immediately after the finish and 1, 
2 and 15-20 hours thereafter. At each time point blood was collected and prepared as described 
previously 13. 
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2.3 PCT
PCT was determined as described by Assicot  et al.4 with the LUmI test PCT; BrAhmS 
Diagnostica, Berlin, Germany)4. In brief, 20 µL of plasma (or standards or controls) were mixed 
with 250 µL luminescent-labeled antibody in precoated tubes and incubated for 2 hours at room 
temperature on an orbital shaker (170-300 rotations per minute). The tubes were washed four 
times with 1 ml washing solution. Luminescence was determined in a luminometer (Lumat LB 
9507; BG & G Berthold, Bad Wildbad, Germany) after injection of 300 µL buffer plus enhancer. 
The lower detection limit is 0.1 ng/ml. Inter-assay and intra-assay variation coefficients at low 
and high PCT concentrations were 10% and 6%, respectively. The mean plasma PCT levels of 
healthy adult subjects was 0.2 ng/ml (n=7, SD0.02).
2.4 Endotoxin
endotoxin was determined by chromogenic assay from Boehringer Ingelheim Whittaker 
(Verviers, france)26.  Brie fly, PrP samples were thawed for 5 minutes at 37ºC and then diluted 
10-fold with pyrogen-free water (NPBI, emmen, The Netherlands) and heated for 15 minutes 
at 75ºC. This diluted and heated PrP was kept at ambient temperature for 1 hour. from 
this suspension, 50 µL samples were transferred to a 96-wells microtiterplate (type 655161 
Greiner Gmbh, frigkenhausen, Germany). After 30 minutes incubation with 50 µL Limulus 
amoebocyte lysate at 37ºC and subsequent incubation with chromogenic substrate for 6 minutes, 
the reactions were stopped by addition of 100 µL acetic acid (20%). The optical density was 
determined at l=405 nm (Spectra max 250, molecular Devices, Sunnyvale, Ca, USA). With the 
standard provided by the manufacture, 1.2 eU/ml corresponds to 120 pg/ml endotoxin.
2.5 IL-6
Serum IL-6 concentrations were determined by eLISA (IL-6 Pelikine CompactTm  eLISA kits; 
Central Laboratory of the Netherlands red Cross Blood Transfusion Service Amsterdam; The 
Netherlands). 
2.6 CRP
Plasma CrP concentrations were determined by nephelometry  (hitachi 911 analyzer, 
Boehringer mannheim, mannheim, Germany) with reagents and according to the instructions 
supplied by this manufacturer. 
2.7 CK
Creatine kinase (CK) was determined by spectrophotometry on a hitachi 747 analyser 
(Boehringer mannheim, mannheim, Germany) with the N-acetylcystine-activated CK reagent 
kit and according to the instructions provided by this manufacturer.
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2.8 Statistics
Statistical analyses were performed using nonparametric Spearman’s rho correlations 
(Nonparametric test was used to correct for skewed distribution), and one way ANoVA (Post 
hoc Test Bonferroni; SPSS 8.0; SPSS Inc., Chicago, Ill). Since the kinetics of PCT, endotoxin 
and cytokine- and acute phase proteins are different, maximum response values were compared.
3. Results
figure 1 shows the concentrations of PCT before and after the triathlon. Before the triathlon, the 
PCT levels were low (median 0.2 ng/ml; range 0.1-0.5). Already immediately after the exercise, the 
concentrations of PCT had increased to 0.9 ng/ml (range 0.3-4.8; p<0.01). No further statistically 
significant increases were observed, although the median level of PCT after 16 hours was about 1.5 
higher (median 1.4 ng/ml; range 0.2-6.4) than immediately after the triathlon.
Lines represent median with range (minimum-maximum). PCT concentrations immediately after 
exercise were significantly elevated compared to the PCT levels before exercise. (p<0.01), but 
did not increase significantly further after the race.
To determine whether the increases in PCT levels are due to leakage of endotoxin into the 
circulation, the highest PCT levels were correlated to the highest concentrations of endotoxin 
(figure 2A). No correlation was found (r=0.10, p=0.61).
Correlations were present between the highest PCT concentrations and highest concentrations 
of IL-6 (r=0.49; p<0.01; figure 2B). A correlation was also found between the highest PCT 
concentrations and the highest CrP concentrations (r=0.35), but this did not reach statistical 
significance (p=0.06) (figure 2C).
Figure 1. Plasma PCT concentrations 
in highly trained athletes (n=30) 
before and after ultra endurance 
exercise
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No correlation could be determined between the maximum levels of CK and PCT (r=0.30 
p=0.11, figure 2D).
3. Discussion
Severe generalized bacterial infections with systemic manifestation are associated with increased 
concentrations of PCT11;15. for example, in children without infection PCT levels were very low 
(<0.1 ng/ml), they were very high in those with severe bacterial infections (6-53 ng/ml) and only 
moderately increased by inflammatory response of non-infectious origin (0.3-1.5 ng/ml)4. for 
adults similar data have been obtained1. moulin and coworkers found that a low threshold of 1 
ng/ml PCT was more sensitive, specific and had greater positive- and negative predictive values 
than CrP or IL-6 for differentiating bacterial and viral causes of community pneumonia2;17;20;21.
In the present study we measured concentrations of PCT in athletes and determined whether or 
not changes in PCT paralleled the observed increase in endotoxin levels. Immediately after the 
exercise the levels of PCT increased 4-fold compared to the levels before exercise, but these 
changes did not correlate to the observed increase in endotoxin levels. 
Immediately after the race the athletes showed five-fold increased CK levels and after some 
16 hours the CK levels had increased nine-fold. This illustrates the muscle damage due to the 
Figure 2. Correlations of the maximum values of PCT levels compared with maximum values of endotoxin 
(figure 2A), IL 6 (figure 2B), CrP (figure 2C) and CK (figure 2D). 
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exercise13. however, no correlation was found between the highest PCT and the highest CK 
levels, indicating the PCT response to be unlikely due to the muscle damage.
In the present study the PCT levels ranged between 0.3-6.4 ng/ml after exercise. These 
concentrations are comparable to those found in polytrauma patients (<0.5-10 ng/ml), i.e. 
patients without infection, and in post-operative patients3;18;22;27. 
It was found that SIrS triggered by a cardiac surgical procedure caused a moderate and transient 
increase in PCT levels on the first post-operative day2;3. Also it was found that patients with 
perioperative myocardial infarction and undergoing cardiac surgery developed high levels of 
PCT16. Not only cardiac surgery but also oesophagectomies gave post-operative increased levels 
of PCT27. Therefore it may concluded that in early postoperative periods elevated levels of PCT 
should be interpreted with caution regarding infection diagnosis. Also, no additional value was 
found for PCT to differentiate between mild and severe pancreatitis22.
Somech and coworkers report a highly significant correlation between PCT and CrP in diverse 
clinical conditions. They concluded that PCT  is in part an acute phase reactant25. evidently in 
these athletes there was a correlation between PCT and CrP (r=0.35) albeit just not significant 
(p=0.06).
from the present study we conclude that the endotoxin entering the circulation of these athletes, 
or their muscle damage, are unlikely to be the cause of the observed PCT increases. Instead, 
we propose the acute phase response as triggered by IL-6 and reflected by CrP increases, to be 
responsible for the PCT increase.
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Abstract
Although the presence of endotoxin in the systemic circulation has been reported to be an 
important risk factor for fatal outcome, the detection of endotoxin by the regular chromogenic 
Limulus Amoebocyte Lysate (LAL) assay is too expensive and labour intensive to perform on 
only a few patient samples per day. A simple bedside test for use upon whole blood, the SImPLY 
reD®  endotoxin (Sre) assay, has been reported to be of clinical value in critically ill patients. 
In the present study we evaluated the LAL and Sre assays for their ability to predict mortality 
in 74 (APAChe II score 6-31) patients clinically suspected to have sepsis. In 13 patients, sepsis 
could not be confirmed. of the 61 septic patients 6 died as result of sepsis, of which one patient 
was positive for the LAL assay and another patient for the Sre assay. of the 55 survivors, 5 
were positive for the LAL, 12 for the Sre and 2 for both assays. Thus, the positive predictive 
values in all septic patients were low for both assays (13% and 7%, respectively), and the 
negative predictive values (91% and 89%, respectively) were also considered too low to be 
clinically useful. If applied to the 17 patients with APAChe II score >19 (the 75 percentile), 
sensitivity and positive predictive values both increased to 17%-20% but specificity and negative 
predictive value both decreased to 58-67% for the two assays. This performance of the two 
endotoxin assays to predict 28 day mortality due to sepsis was similar to the results of the blood 
and local cultures regarding the PPV (10%-38%) and the NPV (80%-100%), but inverse for the 
sensitivity (80%-100%) and the specificity (22%-37%), both in the subgroup of 61 patients with 
sepsis and all 74 patients (15-10%, 100-95%, 100-83%, 49-34%, respectively). We conclude 
that neither the Sre nor the LAL assay is useful in predicting or excluding mortality in patients 
clinically suspected of having sepsis.  
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1. Introduction
Despite antibiotic treatment, there still is a high mortality in patients who develop sepsis7. When 
endotoxin, i.e. lipopolysaccharides (LPS) derived from the outer wall of Gram-negative bacteria, 
are present in the circulation of patients, the risk for fatal outcome increases1. Concentrations 
of endotoxin can be determined with the Limulus amoebocyte lysate assay (LAL assay)17, in 
which endotoxin activates the clotting cascade present in the amoebocyte of the horseshoe 
crab (Limulus polyphemus) and the activated enzyme(s) are measured with a chromogenic 
substrate. In this type of assay even low concentrations of endotoxin can be detected (>3 pg/ml 
or 0.036  eU/ml platelet rich plasma (PrP)16. This is essential because patients with even low 
concentrations of endotoxin, i.e. concentrations ranging between 0.06 to 0.12 eU  
endotoxin/ml PrP, are already considered to have endotoxemia19. The LAL assay, however, has 
to be performed under sterile conditions, is relatively slow (2 hours), is technically demanding, 
and due to the necessity of including a standard curve with each assay, too costly to be 
performed on only a few patient samples per day. Nevertheless, circulation of endotoxin is still 
considered a risk factor for mortality and contributes to predict mortality in febrile patients who 
were in shock at admission20.
A rapid bedside test has been reported for the measurements of endotoxin in whole blood, the 
SImPLY reD®  endotoxin (Sre) assay13. In this assay, the erythrocytes agglutinate upon the 
addition of blood containing endotoxin. The active agent in this assay is a chemical conjugate 
of a monoclonal antibody, which binds to the surface of the erythrocytes of the patient but itself 
does not cause agglutination, and the cyclic peptide antibiotic polymyxin B. Upon addition of 
blood containing endotoxin, this endotoxin binds to polymyxin B and induces the agglutination 
of the conjugate-coated erythrocytes. The Sre assay predicts sepsis with high specificity (90%) 
in critically ill patients2. In the present study we compared the LAL and Sre assays for their 
ability to predict fatal outcome in a broad range of patients clinically suspected to have sepsis. 
2. Patients and Methods
The study was performed at the Leiden University medical Center (Leiden, The Netherlands) 
and was approved by the local medical ethical committee (protocol number 13/97-5/ymo/en).
2.1 Patients
The SIrS (systemic inflammatory response syndrome) criteria for sepsis were established 
according to the guidelines recommended by the American College of Chest Physicians/Society 
of Clinical Care medicine Consensus Conference, 19923. The criteria for SIrS were: (i) a 
temperature >38°C or <36°C; (ii) a heart rate >90 beats/minute; (iii) tachypnea (respiratory 
rate >20 breaths/minute or PaCo2 <32 mm hg); and (iv) a white blood cell count >12x109/L or 
<4x109/L; or the presence of >10% immature neutrophils. These changes should represent an 
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acute alteration from baseline in the absence of other known causes for such abnormalities, such 
as chemotherapy-induced neutropenia or leukopenia. Sepsis was established if patients fulfilled 
two or more of the criteria for SIrS and had a positive blood and/or local culture. 
Seventy-four consecutive patients (46 men and 28 women; median age 60 years (range 16-90)) 
were included in the study at the moment that they were clinically suspected to have sepsis by 
their attending physician and fulfilled the SIrS criteria. Thus, from the 74 patients blood was 
taken the day they were admitted to the hospital in 23% of the cases (1 intensive care patient), on 
the day after admission to the hospital in 26% (3 intensive care patients) and at several days after 
hospitalization in 51% (8 intensive care patients). 
At 28 days after study entry, 8 patients had died. however, only 6 patients died due to the sepsis 
or complications thereof: 2 from the sepsis itself, 2 from the adult respiratory distress syndrome 
and 2 from multiple organ dysfunction syndromes. The other 2 patients died of a heart failure or 
at home, without it being likely that those deaths were sepsis related. We therefore calculated all 
efficacy parameters based upon the 6 deaths related to the sepsis. 
2.2 Collection of blood samples
from each patient a heparin-anticoagulated (30 IU heparin final concentration, endo Tube, 
Chromogenix Am, mölndal, Sweden), a non-anticoagulated and an eDTA-anticoagulated blood 
sample (BD Biosciences, franklin lakes, NJ, USA) was collected. heparin-anticoagulated blood 
was immediately placed on melting ice until centrifugation (10 minutes 180 x g; 4ºC) to prepare 
PrP. Immediately before centrifugation, 30 µl of the heparin-anticoagulated blood was removed 
and used for the Sre assay. The other blood samples were used for routine assays. Aliquots 
of PrP were stored frozen at –70ºC prior to the LAL assay. In the instructions provided by the 
manufacturer eDTA is proposed as the anticoagulant to be used in the Sre assay. however, 
at the start of the study the manufacturer informed us that heparin can also be used. We then 
decided to use the heparinized blood for both assays, to exclude contamination of the eDTA 
tube as a source of possible discrepancy between the LAL and Sre assays.
2.3 LAL assay
The LAL assay was obtained from Boehringer Ingelheim Whittaker (Verviers, france). Briefly, 
PrP samples were thawed for 5 minutes at 37ºC, diluted 10-fold with pyrogen-free water (NPBI, 
emmen, The Netherlands) and then heated for 15 minutes at 75ºC. Subsequently, PrP was 
kept at ambient temperature for 1 hour. from this suspension, 50 µl samples were transferred 
to 96-well microtiterplates (type 655161 Greiner Gmbh, frigkenhausen, ger). After 30 minutes 
incubation with 50 µl LAL at 37ºC and subsequent incubation with chromogenic substrate 
for 6 minutes, the reactions were stopped by addition of 100 µl acetic acid (20%). The optical 
density was determined at λ=405 nm (Spectra max 250, molecular Devices, Sunnyvale, CA, 
USA). With the standard (escherichia Coli; 0111:B4) provided by the manufacturer, 1.2 eU/ml 
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corresponds to 120 pg/ml endotoxin. The detection limit of this assay is 0.036 eU/ml PrP17. The 
LAL used in this assay is not sensitive to (1.3)-β-D-glucan, i.e. fungal infections, because factor 
G has been extracted from this reagent8,11,12.
2.4 SRE assay
The Sre assay was obtained from Agen Biomedical Ltd. (Acacia ridge, AUS). Ten µl of 
heparin-anticoagulated blood aliquots were pipetted in duplicate into reaction wells containing 
only buffer reagent (control) or test reagent. The suspensions were mixed by gently swirling 
for 2 minutes at ambient temperature. When visible agglutination occurred in duplicate wells, 
a result was considered positive. When agglutination occurred in only one well of the test 
reagents, the experiment was repeated. If agglutination still occurred in only one test reagent 
well, the outcome was considered negative. When agglutination occurred in duplicate, the 
outcome was scored as positive. The lower cut-off value reported by rylatt et al. is 1.56 ng/ml, 
but Ng et al. suggest 25 pg/ml2,13.
2.5 Statistics
Correlation analyses were performed using the nonparametric Spearman’s rho test (SPSS 8.0; 
SPSS Inc., Chicago, Ill). Sensitivity was defined as the number of non-survivors that had a 
positive endotoxin test (true positive) divided by the total number of non-survivors. Specificity 
was defined as the survivors that had a negative test result (true negative) divided by all 
survivors. The number of non-survivors with a positive endotoxin test (true positive) divided by 
the total number of patients with a positive test result was designated as the positive predictive 
value (PPV). The negative predictive value (NPV) was calculated by dividing the number of 
survivors with a negative test (true negative) by the total number of patients with a negative test 
result. 
3. Results
3.1 Microbiological data of the patient population
The results of the bacterial cultures are provided in table 1. Blood cultures were performed 
of 71 patients, of which 39 (55%) had bacteremia and 30 (42%) gram-negative sepsis. Local 
cultures were performed in 70 patients. of these, 48 (69%) had a positive culture and 46 (66%) 
had a gram negative infection. The cultures originated from the urinary tract (47%), respiratory 
tract/sputum (26%) and skin/ joints, cerebrospinal fluid, gastrointestinal tract, ear and nose and 
throat (11%). In 13 patients sepsis could not be confirmed since blood- and/or local cultures 
were negative or not performed. These patients suffered from cholangitis (5), sinusitis (1), 
pneumococcal pneumonia (1), focus of infection located from skin biopsy (1), excudative 
pleuritis (1), during chemotherapy (3) and an unknown focus for infection (1). of the 61 septic 
patients, 13 patients only had a positive blood culture, 22 patients only had a positive local 
culture and 26 patients had both positive blood and positive local cultures.
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3.2  APACHE II score, mortality and their relation with microbiological and endotoxin 
assays
of the 61 septic patients, 56 (92%) had a gram negative infection based on blood- and/or local 
cultures (Table 1). Three patient subgroups were identified based on the 25-75 percentiles of 
the APAChe II score: <11 (n=9), 11-19 (n=35) and >19 (n=17). for each of these subgroups, 
the outcome of the microbiological data, endotoxin assays and mortality are summarized 
(Table 2). The majority of the patients were negative in the LAL (87%) and Sre (82%) assays. 
The patients with APAChe II score >19 showed the highest mortality (29%). The highest 
percentages of patients positive in the LAL and Sre assays were also found in this patient group 
(29 and 35%, respectively), including 2 patients that were positive for both assays.  
of the total of 6 non-survivors due to the sepsis (Table 3), only one patient was positive for the 
LAL assay and one for the Sre assay, and 4 patients had no positive reactions in either the LAL 
or Sre assay. of the 55 surviving patients, 5 were positive in the LAL assay, 12 in the Sre 
assay and 2 in both assays.
3.3 Prediction of mortality
The negative- and positive- predictive values (NPV and PPV, respectively), sensitivity and 
specificity were calculated for the two endotoxin-assays and compared with the values for 
culture results for (i) the total number of septic patients and (ii) the patients with APAChe II 
score >19 (Table 4). With the inclusion of all septic patients the NPV and specificity for the two 
endotoxin assays were 91%-89%, but both the PPV (13-7%) and sensitivity (both 17%) were 
low. When applied only to the patients with APAChe II score >19, the sensitivity (both 20%) 
and PPV (20%-17%) slightly improved for both assays, but the specificity (67%-58%) and NPV 
(67-64%) decreased. To estimate the performance of the culture results for the prediction of 28 
day mortality, the data obtained in all 74 patients were calculated (Table 4), i.e. including the 
13 non-septic patients. This was done because the culture result is part of the definition sepsis 
and thus a proper evaluation requires the analysis of the complete group of patients. results are 
presented in table 4. We found for, blood and local culture NPV 100%-95% PPV 15%-10% and 
sensitivity 83-100%, respectively, but a very low specificity, 49%-34%.
Table 1. The result of the blood and local cultures in all patients (n=74) clinically suspected to have sepsis
Blood culture
  Not done Sterile Gram-pos Gram-neg Gram-pos + neg Total
 Not done 0 4 0 0 0 4
 Sterile 0 9 3 9 1 22
 Gram-pos 0 0 2 0 0 2
 Gram-neg 3 14 3 17 0 37
 Gram-pos + neg 0 5 1 2 1 9
 Total 3 32 9 28 2 74Lo
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Table 2. relation between the clinical status (APAChe II score), mortality, culture results and endotoxin 
assays of the septic patients (n=61)
  APACHE II score
  <11 (n=9) 11-19  (n=35) >19 (n=17)
Sterile  1 15 3
Gram negative 5 13 10
Gram positive 1 6 2
Both gram negative and positive  0 1 1
Not done  2 0 1
Sterile  3 5 5
Gram negative 5 24 8
Gram positive 0 2 0
Both gram negative and positive  1 4 4
Not done  0 0 0
LAL assay Negative (<0.036 eU/ml PrP) 8 33 12
 Positive (M0.036 eU/ml PrP) 1 2 5
SRE assay Negative 7 31 12
 Positive 2 7 6
Mortality (28 days) 1* 2* 5
* one patient did not die due to the sepsis in each group.
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Table 3. results of LAL and Sre assays compared with mortality (as result of sepsis) in the septic patients 
(n=61)
 APACHE II score
 < 11 11 - 19 > 19
Non-survivors
LAL assay positive 0 0 1
Sre assay positive 0 0 1
LAL and Sre assay positive 0 0 0
LAL and Sre assay negative 0 1 3
Subtotal 0 1 5
Survivors
LAL assay positive 1 2 2
Sre assay positive 2 7 3
LAL and Sre assay positive 0 0 2
LAL and Sre assay negative 6 25 5
Subtotal 9 34 12
Total 9 35 17
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4. Discussion
Although endotoxin plays an important role in the pathophysiology of the sepsis syndrome 
and multiple organ dysfunction syndromes, several difficulties have limited its measurement 
in clinical practice thus far. Danner et al. have demonstrated that endotoxemia was present in 
43% of the 100 septic shock patients admitted to the intensive care unit and suggested that 
endotoxin was an important mediator of septic shock5. moreover, we have reported that of 
the febrile patients who were in shock on admission to our hospital, 71% of the non-survivors 
had endotoxemia20. These data suggest that measurements of endotoxin might help to identify 
patients at risk for mortality who require additional treatment at an early stage. In the present 
study we compared the classical chromogenic LAL assay and a bedside test for whole blood, 
the Sre assay, for their ability to predict fatal outcome in a broad range of patients that were 
clinically suspected to have sepsis.
In the present study 74 patients suspected of sepsis were included and 13 (18%) had no proven 
sepsis, 23 (31%) had detectable levels of endotoxin (with the LAL and/or Sre assay), and our 
(28 day) mortality rate was 8 (13%). In comparison, in one of the first clinical studies using 
the LAL assay, Levin et al.10 showed that of 218 patients, 39 (14%) patients had detectable 
endotoxin levels and 18 (8%) had no positive culture. The mortality rate in this study was 52 
(24%). We found a lower mortality rate and more patients with detectable endotoxin levels, 
which may be caused by different detection limits of the assays used in those two studies, i.e., 
0.5 ng/ml (Levin et al.) and 3 pg/ml (our LAL assay)10;17. however, leaving out the Sre positive 
Table 4. The positive predictive value (PPV), negative predictive value (NPV), sensitivity and specificity for 
endotoxin assays and culture results in all septic patients (score 6-31), in the
septic patients with APAChe II score >19 and in all included patients. 
 MORTALITY FOR SEPSIS (28 days)
 NPV (%)  PPV (%) Sensitivity (%) Specificity (%)
LAL assay  91 13 17 87
Sre assay  89 7 17 75
Locale culture   92 10 83 22
Blood culture   100 15 100 37
LAL assay  67 20 20 67
Sre assay  64 17 20 58
Locale culture   80 33 80 33
Blood culture   100 38 100 27
Locale culture (n=70)  95 10 83 34
Blood culture (n=71)  100 15 100 49
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patients and considering only the positive LAL patients in our study (8 i.e.11%), the findings 
are comparable, which could indicate false positive Sre assay results. rylatt et al. found that 
samples from healthy donors of the Brisbane blood bank gave 10% false positive Sre tests13. 
They also found 8% false positive Sre results in healthy laboratory personnel. This trend is 
confirmed by culture results in our patients. All patients who had a positive LAL assay also had 
a positive (gram negative) blood culture. In contrast, 7 of the 15 patients that were positive in the 
Sre assay had a sterile blood culture. Thus, there is no clear correlation between the Sre assay 
and (gram negative) bacteremia. 
our conclusion that the Sre assay provides false positive results contrasts those by Ng et al., 
who compared the LAL and Sre assays for their ability to predict systemic gram negative 
infection in 73 critically ill patients, and who also determined 50 healthy blood donors. The 
authors found no positive Sre in the healthy donors, and a much higher incidence of positive 
LAL and Sre assays, 47% and 49%, respectively and positive culture results (67%)13. The 
patient population under investigation by Ng et al. may possibly explain the different findings in 
that study. only patients were included that were admitted to the intensive care unit, in contrast 
to the patient group in our study, of which 12 patients were admitted to the intensive care and 49 
were not, so our group of patients was in general less ill2. 
Kollef and eisenberg demonstrated in intensive care patients (APAChe II score 8-32), that the 
Sre assay predicted the development of multiple organ dysfunction syndrome but the LAL 
assay did not 9. They performed the endotoxin assay daily and found a significant predictive 
value on day 2 after admission to the intensive care unit. In agreement with our findings they 
reported that the Sre assay could not predict hospital mortality. 
from the paper of Brandzaeg and Taveira it became clear that longitudinal measurement of 
endotoxin (using the LAL assay) gives a higher percentage of patients with detectable endotoxin 
levels than single measurements4,18. however, Taveira18 found that after intravenous endotoxin 
injection detectable endotoxin levels were measured in only 50% of the tested individuals. 
Apparently, rapid clearance of endotoxin from the circulation had occurred and was not caused 
by insufficient sampling. In the study of Shenep et al. patients were sampled 7 times and thus, 
from the 26 patients clinically suspected to have sepsis 10 (38%) had detectable levels of 
endotoxin and 3 (14%) died14,4,18. Compared to Shenep et al. we have found a similar percentage 
of endotoxin positive samples (31%), although we sampled only once.
The percentage of endotoxin positive samples is also similar to the findings of Smith et al.15, who 
also compared the incidence of endotoxemia in gram negative bacteremia over the last years and 
found a range of 43%-90%, when endotoxin measurements were taken 11 times over 72 hours15. 
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our finding that several samples were positive in the LAL but not the Sre test is likely to be 
explained by the difference in reported sensitivity of the two assays. We previously determined a 
cut-off level for endotoxemia of 0.06-0.12 eU endotoxin/ml PrP (5-10 pg/ml with the endotoxin 
standard used) for the LAL assay19,17.  Such data are not available for the Sre assay, which only 
provides an estimate of the endotoxin concentration by the extent of agglutination (according to 
the literature 1.56 ng/ml13 or 25 pg/ml2). one of our aims in the present study was to investigate 
at which endotoxin concentration, determined by the LAL assay, the Sre assay would become 
positive. In view of the small overlap in positive LAL and Sre assays, this aim could not be 
fulfilled. only 2 of 15 patients with a positive Sre test had a positive LAL assay result. This 
may be due to false positive Sre assays or false negative LAL assay results. 
Although the Sre assay was easy to perform practically, its interpretation was cumbersome, 
i.e. agglutination was sometimes hardly visible, and one patient, who had an extremely high 
endotoxin concentration in the blood (44.8 pg endotoxin/ml PrP), was negative in the Sre 
assay. At present we cannot exclude that high levels of endotoxin may block the erythrocyte-
agglutination in the Sre assay (high-dose hook effect). of course, we can also not exclude the 
possibility that the high LAL test result is due to a contamination occurring at the stage of the 
heating and dilution step of the PrP in the LAL assay. 
of the 61 patients with sepsis in this study 30 (42%) had gram negative bacteremia, of which 
13 (43%) had detectable levels of endotoxin with either the Sre or the LAL assay (including 2 
patients with both assays positive). our study population was heterogeneous, with an APAChe 
II score of (ranging from 6-31). Comparing the PPV, NPV, sensitivity, and specificity from 
the culture results and the endotoxin assays, the cultures are more sensitive but less specific in 
predicting mortality.
In summary, based upon the sensitivity of 7–13% and the specificity of 75-87%, we conclude 
that neither the LAL nor Sre assay are useful in predicting or excluding mortality in a broad 
range of patients known to have sepsis according to the definition of Bone3.
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Abstract
endotoxemia, cytokinemia and elevated levels of procalcitonin are considered risk factors for 
a complicated course in patients with an infection. however, the efficacy of determining these 
factors on admission to identify patients with a community-acquired infection who are at risk 
for an adverse outcome and may benefit from early preventive measures is not known. We 
examined prospectively in febrile patients admitted to the medical emergency Department of a 
800-bed academic medical center the relation between clinical data, levels of plasma endotoxin, 
TNf-alpha, IL-6, IL-10 and procalcitonin, and outcome. We included 464 consecutive patients 
(median 61 year, range 18-97, 59% male). Blood cultures were positive in 90 (19%) patients; 
more than 85% of all patients were febrile due to infection. In 345 patients no underlying illness 
was present, whereas 97 had an ultimately fatal disease and 22 a rapidly fatal disease. Predictors 
of in-hospital death were identified through unvaried and multivariate logistic regression using 
clinical data (age, underlying disease, duration of fever, chills, shock on admission), and plasma 
endotoxin, cytokines and procalcitonin. 
Thirty-three patients (7.1%) died. The mortality rate was 4.6-fold (95% CI: 1.8-12) higher in 
31 patients who were in shock on admission (7 nonsurvivors). In these patients with shock, the 
strongest association with mortality was the endotoxin concentration (endotoxin 5 pg/ml, rr 
13.7, 95% CI: 1.4-136) that identified 5 of the 7 nonsurvivors (i.e., over 70%) at the cost of a 5% 
false-positive rate. In 433 patients not in shock on admission, a high relative risk of mortality 
was associated with age, underlying disease, and to a lesser degree, IL-6 and procalcitonin. 
In these patients without shock on admission, clinical data alone identified up to 30% of the 
nonsurvivors, whereas the additional measurement of IL-6 and procalcitonin identified an extra 
10%, at the cost of a 5% false-positive rate. In conclusion, when febrile patients are screened on 
hospital admission to identify those with a high mortality risk and who may benefit from early 
preventive measures, sound clinical judgement based on age, underlying disease and recent 
history outweigh the predictive value of endotoxin, cytokine and procalcitonin levels. only in 
patients who present in shock, measurement of endotoxin will help detect most nonsurvivors at 
the cost of few false-positives.
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1. Introduction
Despite a vast body of evidence implicating cytokines as mediators of sepsis, results of clinical 
trials with cytokine-based strategies are disappointing1. Though this has led to skepticism that 
immunotherapy would have a role in the management of sepsis, it has been suggested that 
cytokine-based strategies may be beneficial in specific subsets with a high mortality risk rather 
than in all patients with sepsis1. If this is indeed the case, a crucial question is whether such 
subgroups can be identified prospectively.
The reaction to infection can clinically be manifested by the systemic inflammatory response 
syndrome progressing to septic shock and multiple organ dysfunction syndrome1. This chain 
of events is triggered by bacterial components such as endotoxin, peptidoglycan, lipoteichoic 
acid, lipoprotein and exotoxins, and executed through many mediators2-4. The predictive value 
of circulating endotoxin and mediators including various pro- and anti-inflammatory cytokines 
for the clinical outcome has been studied in highly diverse groups of critically ill patients 
and yielded variable results. Interpretation of many studies on the role of such parameters in 
assessment of patients outcome in intensive care units may have been hampered by the nature 
of the underlying illnesses modulating the response to a superimposed, acute infection2,5-9. 
recently, another marker, procalcitonin, the propeptide of calcitonin, was introduced and shown 
to be strongly associated with severity of sepsis8. 
Although high circulating levels of inflammatory mediators like endotoxin, cytokines and 
procalcitonin are associated with an adverse outcome2,5-9, the efficacy relative to clinical 
judgment of determining these factors on admission to identify patients with an infection 
who are at risk for a complicated course and may benefit from early preventive measures, is 
not known. To assess the predictive value of plasma endotoxin, cytokine and procalcitonin 
concentrations relative to clinical judgement in a group of patients with an acute community-
acquired infection of whom only a few suffered from an active underlying disease, we measured 
these concentrations on admission in a group of febrile patients with a community-acquired 
infection, and followed their clinical course.
2. Methods
The study was performed at the Leiden University medical Center, an 800-bed secondary and 
tertiary referral hospital. Patients 18 years and older, consecutively referred to the medicine 
emergency Department because of a febrile illness (rectal temperature 38.2°C) were enrolled. 
following institutional approval and patients oral consent, clinical and microbiological data were 
obtained and registered10. Circulatory shock was defined as hypotension (systolic blood pressure 
<90 mmhg; mean arterial tension <65 mmhg) for more than 1 hr with signs and symptoms of 
end-organ failure, despite fluid resuscitation; multiple organ dysfunction syndrome (moDS) 
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was considered when a patient had ∅3 organ system failure during at least 24-hr period1,11,12. Two 
blood cultures were collected that were incubated under aerobic and anaerobic conditions. In 309 
of the 464 patients attending physicians ordered cultures from sites deemed to be responsible for 
the febrile illness. During clinical follow-up, antibiotic treatment, culture and serology data were 
recorded, as were the diagnoses of the attending physicians and infectious diseases consultant. Also, 
the duration of hospital stay and clinical course with respect to development of circulatory shock, 
moDS, and outcome (i.e. discharge or death) were recorded. Severity of underlying disease was 
documented according to the classification of mcCabe and Jackson13.
four hundred sixty four patients (272 men and 192 women) were entered in the prospective 
study10. The median age was 61 yr (range 18-97). Patients were admitted at a median of 1 
day (IQr 0-3) after the onset of fever. Infection as cause of fever was definite on clinical and 
microbiological evidence (clinically identified focus of infection and positive blood and/or local 
culture from a normally sterile body site) in 223 (48%) patients. Infection was judged highly 
probable on clinical grounds (e.g. by identified focus of infection and serology data) in another 
141 (30%) and was uncertain in 35 patients. The sites of infection and sources of bacteremia 
and endotoxemia are given in table 1. Ninety patients (19%) had bacteremia, of which 4 had 
both Gram-negative and Gram-positive bacteria in the blood. Gram-positive bacteremia was 
mainly caused by pneumococci (n=27) and various species of streptococci (n=15); the most 
common source of infection in these patients was the lower respiratory tract. In Gram-negative 
bacteremia, enterobacteriaceae (n=40, including 17 e. coli and 13 Klebsiella) dominated over 
non-enterobacteriaceae (e.g., 2 P. aeruginosa and 2 enterobacter spp); the most common focus 
of infection was the urinary tract. Seven cases had malaria (P. falciparum 5; P. vivax 2). empiric 
antibiotic treatment (according to hospital protocol) was judged adequate, i.e., at least one 
antibiotic to which the causative organism was susceptible and anaerobic coverage in abdominal 
infection, in 95% of the patients including all cases with bacteremia.
of the 464 patients, 33 (7.1%) died after a median hospital stay of 11 days; all but 2 died within 
28 days. Seven of 31 patients who were in circulatory shock on admission died, of whom 4 
after having developed moDS. Another 24 patients had a normal blood pressure on admission 
but became hypotensive during the first 24 hr. In this group 5 died, including 3 patients who 
developed moDS after the episode of shock. overall, 19 patients developed moDS, of whom 
14 died. In 28 of the 33 patients who died, an infection as cause of fever was certain: pneumonia 
(10), urosepsis (5), peritonitis (6), cholangitis (1), primary bacteremia (4), and meningococcal 
sepsis and pneumococcal meningitis (1 each). The other nonsurvivors died of a cerebrovascular 
accident (3) or myocardial infarction (2).
2.1 Endotoxin, cytokines (IL-6, TNF-alpha, IL-10) and procalcitonin assays
endotoxin was determined in platelet-rich plasma by a quantitative photometric assay with end-point 
measurement as described10,14; concentrations 5 pg/ml were considered to indicate endotoxemia9.  
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IL-6 and IL-10 concentrations were determined with a standard eLISA technique and TNf-alpha 
by a competitive inhibition radio immunoassay (medgenix diagnostics, floury, Belgium)10,15; the 
detection limit for cytokines was 5 pg/ml. Procalcitonin was measured by the immunoluminometric 
assay adapted from the immunoradiometric assay; the detection limit was 0.1 ng/ml. Blood was 
available for assay of endotoxin in 452 (98%), of TNf-alpha in 462 (99%), of IL-6 in 379 (82%), 
of IL-10 in 419 (91%) patients, and of procalcitonin in 381 (82%); loss of completeness was due to 
incomplete sampling. Assay results were not available during the hospital stay of the patients.
2.2 Analysis of data
Logistic regression analysis was used to assess an association between endotoxin, cytokines 
and procalcitonin levels with outcome of hospitalization. Data of endotoxin, cytokine and 
procalcitonin levels were used after log-transformation10. Underlying disease was entered as 
categorical variable, as described by mcCabe and Jackson13.  When indicated, endotoxemia 
and elevated levels of procalcitonin (0.5 ng/ml) were entered as categorical variable. multiple 
logistic regression was used to identify variables that were independently related to fatal 
outcome. The model included patient and laboratory data that can be obtained within hours 
after admission. The following characteristics were evaluated: gender, age, underlying disease, 
duration of fever prior to hospitalization, chills, prior use of antibiotics, vital signs on admission, 
circulatory shock, and endotoxin and cytokines. The multivariate analysis was performed by 
entering the variables one by one into the model, starting with the clinical variables and next 
selecting the strongest predictors. Statistical significance was tested two-tailed, with the p set to 
0.05. To study screening potential, the mortality risk was estimated separately for each patient 
from the values for the variables listed above obtained on admission, as modelled previously16. 
The detection rate of nonsurvival was defined as the proportion of patients who died during 
follow-up and who had a screening result above the false-positive rate, i.e. the proportion who 
did not die and who had a positive screening result. The false-positive rate was set arbitrarily at 
5% or 10% by choosing appropriate risk cut-off values.
3. Results
3.1 Clinical risk factors of mortality 
Age and underlying disease were significantly associated with mortality (Table 2); these 
associations were largely independent of each other. furthermore, circulatory shock on 
admission was strongly associated with mortality (rr 4.6, 95% CI: 1.8-11.6). The duration 
of fever before admission showed a trend towards association with mortality (p=0.10). The 
occurrence of chills correlated with bacteremia (p=0.04) which itself showed a trend (p=0.06) 
towards association with mortality. Since microbiological confirmation of bacteremia is 
not available within hours of admission, chills rather than bacteremia was included in the 
multivariate analysis as a basic clinical characteristic available on hospital admission, together 
with age, underlying disease and duration of fever.
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3.2 Endotoxemia as risk factor of mortality 
on admission, 98 of 452 patients (21.7%) had a plasma endotoxin level O5 pg/ml (Table 1). of 
these patients 16 died (17.2%), compared with 16 (4.6%) of 346 patients without endotoxemia 
(rr 4.0, 95% CI: 1.9 to 8.4; Table 2). In 44 patients with Gram-negative bacteremia, only those 
with concomitant endotoxemia died, i.e. 5 (23%) out of 22 endotoxemic patients in contrast 
to none of 22 without endotoxemia (p=0.02). of the 4 patients with polymicrobial bacteremia 
including Gram-negatives, only the 2 patients with endotoxemia died. overall, of the 119 
patients with a culture-proven Gram-negative infection, 12 died of whom 10 were endotoxemic.
3.3 Cytokines as risk factors of mortality
Plasma IL-6 and IL-10 levels were significantly associated with mortality, whereas TNf-alpha 
only showed a trend towards such an association (p=0.10). Dichotomized around the median, the 
mortality risk was 2.9 (95% CI 1.2-7.1) and 2.5-fold (95% CI 1.1-5.9) higher in those patients 
with a plasma concentration of IL-6 or IL-10 above the median, respectively, compared with 
those with values below the median. These mortality risks were not different between patients 
with a high or low plasma TNf-alpha.
3.4 Procalcitonin as risk factor of mortality 
on admission, 207 of 381 patients (54%) had an elevated level of procalcitonin, i.e. O0.5 ng/ml. 
of these patients 22 died (10.6%), compared with 4 (2.3%) of 174 patients, respectively, without 
an increased procalcitonin (rr 5.0, 95% CI: 1.7 to 15). In 82% of patients with bacteremia 
the procalcitonin was ∅0.5 ng/ml, as were 49% of the patients without bacteremia. however, in 
bacteremic patients a positive test for procalcitonin was not associated with mortality (p=0.15). 
In the subgroup with a culture-proven gram-negative infection, a positive test of procalcitonin 
was associated with mortality (rr 6.8, 95% CI 0.8-56), but -though more sensitive- proved less 
specific than endotoxin. 
3.5 Screening performance of clinical and laboratory variables. 
rather than to try to identify by endotoxin and cytokine measurements those patients in the 
whole group who were on admission in such a poor condition that they are easily identified on 
clinical grounds (e.g. those in shock), the value of screening for endotoxemia, procalcitonin 
and cytokinemia was assessed in patients who on admission were in shock and compared with 
those who were not (Table 3). In the prediction model, clinical data concerning age, underlying 
disease and recent history with respect to the febrile episode are entered first, reflecting a ’real 
life’ encounter between patient and physician in the emergence room.
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3.6 Patients in shock on admission 
of the 31 patients who were in shock on admission, 7 (23%) died. The clinical data did not 
identify more than 15% of the nonsurvivors at the false-positive rates of 5 and 10%. Unlike 
TNf-alpha, IL-6 and IL-10, the endotoxin level alone identified 6 (i.e., over 81%) of the 7 
nonsurvivors, beit at the cost of a 10% false-positive rate, and 5 (i.e., 71%) of the nonsurvivors at 
a 5% false-positive rate (Table 4). With the exception of measurement of TNf-alpha that slightly 
raised the detection of a fatal outcome, other cytokines or procalcitonin values did not improve 
the detection rate of the model any further. 
3.7 Patients not in shock on admission
of 433 febrile patients without shock on admission, 26 (6%) did not survive. Clinical data 
alone already predicted 30-50% of total mortality, beit at the cost of a 5 or 10% false-positive 
rate (Table 4). for instance, at a 10 % false-positive rate in patients not in shock on admission 
(n=433), the table 4 demonstrates that a multivariate model including age, mcCabe and fever 
will identify correctly 12 of 26 (46%) patients with fatal outcome on top of 43 false-positives 
(i.e., 10% of 433 patients). Thus, 55 (12+43) patients are screen-positive, but only 12 (i.e., 22%, 
representing 46% of all fatalities) will die. Combining the clinical data with measurements of 
IL-6 and procalcitonin improved detection to about 41% at a 5% false positive rate, but did not 
improve detection at a 10% false-positive rate. Addition of TNf-alpha and IL-10 values did not 
improve the results of the multivariate model, whereas endotoxin measurements contributed 
Table 2. results of univariate analyses of clinical and laboratory data of 464 febrile patients.
Characteristic relative mortality risk
 (95% CI)
Clinical data
 Age (yr) 1.05 (1.03-1.1)
 Dichotomized at M65 years 7.2 (2.9-17.8)
 male sex 0.8 (0.4-1.7)
 Ultimately fatal or rapidly fatal underlying disease 3.0 (1.5-6.1)
 Duration of fever (d) 1.04 (1.0-1.1)
 Chills 1.3 (0.7-2.9)
 Circulatory shock present on admission 4.6 (1.8-11.6)
Laboratory data
 endotoxemia  4.0 (1.9-8.4)
 endotoxemia in 119 culture-proven, 
  gram-negative infections 10.6 (2.2-51)
 TNf-alpha 1.6 (0.8-3.4)
 IL-6  2.9 (1.2-7.1)
 IL-10 2.6 (1.1-5.9)
 hyperprocalcitonemia 5.1 (1.7-15)
 Bacteremia 1.9 (0.9-3.9)
Note: Underlying disease was classified according to mcCabe and Jackson13. endotoxemia was defined by an 
endotoxin level M5 pg/ml, hyperprocalcitonemia was defined by a procalcitonin level M0.5 ng/ml. Cytokines 
were dichotomized around median.
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only modestly to the model in these patients (Table 4). of note, these results were not affected 
by the loss of completeness of procalcitonin and IL-6 measurements (i.e., data available in 82% 
of the patients), and tested patients were not different from the patients who did not have the 
procalcitonin and IL-6 values determined.
4. Discussion
The association between mortality in patients with a community-acquired infection and 
plasma endotoxin, cytokine and procalcitonin levels is important in terms of the reduction 
in mortality that would follow a successful identification of those patients who might benefit 
from early intervention strategies. The present findings indicate that measuring on hospital 
admission plasma endotoxin, cytokine and procalcitonin levels in febrile patients can help only 
moderately to identify those patients. In this respect, the efficacy of a model that includes basic 
clinical data that can readily be obtained on admission, and endotoxin, IL-6 and procalcitonin 
measurements, appears to outweigh that of other combinations that include TNf-alpha and 
IL-10. At best, however, such a model will allow at the cost of a 10% false-positive rate only 
Table 4. Screening detection rates (%) for nonsurvival in febrile patients 
 Detected with fatal outcome (%)
 in shock not in shock
 on admission on admission
false-positive rate (n=31) (n=433)
10% false-positive rate
 Age 0/7 (-) 7/26 (27%)
 Age, mcCabe 0/7 (-) 12/26 (46%)
 Age, mcCabe, fever 1/7 (14%) 12/26 (46%)
 Age, mcCabe, fever, chills  1/7 (14%) 13/26 (50%)
 Age, mcCabe, fever, chills, endotoxin 6/7 (81%) 13/26 (50%)
 Age, mcCabe, fever, chills, endotoxin, procalcitonin 6/7 (81%) 14/26 (54%)
 Age, mcCabe, fever, chills, endotoxin, procalcitonin, cytokines 6/7 (81%) 14/26 (54%)
5% false-positive rate
 Age 0/7 (-) 4/26 (15%)
 Age, mcCabe 0/7 (-) 5/26 (19%)
 Age, mcCabe, fever 0/7 (-) 6/26 (23%)
 Age, mcCabe, fever, chills  0/7 (-) 7/26 (27%)
 Age, mcCabe, fever, chills, endotoxin 5/7 (71%) 7/26 (27%)
 Age, mcCabe, fever, chills, endotoxin, procalcitonin 5/7 (71%) 9/26 (35%)
 Age, mcCabe, fever, chills, endotoxin, procalcitonin, cytokines 6/7 (81%)a 11/26 (41%)b
Note: Data are proportion (%) of patients. Chills, accurrence of cold chills before admission; cytokine, plasma 
concentration (in log pg/ml); fever duration of fever prior to admission (in days); mcCabe, underlying disease 
classified according to mcCabe Jackson13.
endotoxemia was defined by an endotoxin level M5 pg/ml; hyperprocalcitonemia was defined by a 
procalcitonin level M0.5 ng/ml.
a only TNf-alpha contributed to prediction model, at 5% false-positive rate
b
 only IL-6 contributed to prediction model, at 5% false-positive rate
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to identify about half of all patients who will have a fatal outcome. Thus, because the mortality 
rate in febrile patients with a community-acquired infection is quite low, i.e. less than 10%, 
determining endotoxin, cytokine and procalcitonin levels performs too poorly to discriminate 
between those patients who might benefit from early preventive measures and who will not. 
moreover, clinicians should realise that they will miss about half of the target group because 
it is screen-negative. Therefore they cannot take false reassurance about the clinical course in 
screen-negative febrile patients. An exception to this disappointing situation is the small group 
of patients who are in shock on admission and have a substantially higher mortality risk. In these 
patients, risk assessment using basic clinical data appears to be grossly inferior to that based on 
plasma endotoxin levels.
rather than in the whole group identify patients who already are in an extreme phase of 
their illness on admission, the value of screening for endotoxemia, cytokinemia and hyper 
procalcitonemia was investigated in patients who on hospital presentation were clinically 
stable separately from those who presented in shock. In patients who were already in shock, 
nonsurvival appeared mainly associated with the severity of the acute host response to infection 
and not with age, activity of underlying disease or other clinical data. In this particular situation, 
endotoxemia proved a strong predictor of nonsurvival that greatly outmatched the predictive 
value of the cytokines, and in fact, most patients in shock who died had endotoxemia on 
admission. By contrast, in patients who on admission were clinically stable and normotensive, 
the main factors associated with a fatal outcome were high age and certain characteristics 
of underlying disease, and largely independent from these parameters, levels of IL-6 and 
procalcitonin as well. We found little influence of microbiological findings on the prognosis 
after adjustment for other significant risk factors for nonsurvival, which is in accordance with 
published data12,18.
As the efficacy of an intervention is generally judged by its effect on the mortality rate, one 
should be able to identify these high-risk patients preferably on admission, because at that 
moment they should be considered for specific measures or inclusion in trials for treatment of 
severe sepsis. readily available information such as age and activity of underlying diseases as 
well as the vital signs help the clinician to estimate the severity of illness. As demonstrated in 
the present study, however, such clinical data in combination with measurement of endotoxin 
and selected cytokine and procalcitonin levels will help the clinician to identify only about halve 
of the patients with a high mortality risk and this at the cost of an even larger number of false-
positives. Thus, even when a rapid and reliable endotoxin and cytokine test would be available, 
out of every 100 patients only 4 of the 8 expected nonsurvivors can be identified at the cost of 10 
false-positives, i.e. patients with a positive screening result who will not die.
In this study the outcome of infections caused by gram-negative microorganisms was determined 
to a large extent by the presence of endotoxemia. In patients with gram-negative bacteremia those 
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who died had both endotoxemia and bacteremia. This finding underscores the predictive value of 
data on endotoxemia in patients with gram-negative infections. Until now a substantially increased 
risk of mortality in endotoxemic patients appeared from meta-analyses2,19-24. Though in this study 
we focussed on the predictive value of endotoxin and cytokine levels rather than underlying patho-
physiological mechanisms10, the findings illustrate that distinction must be made with respect to 
the inflammatory response elicited by circulating free endotoxin and that by intact gram-negative 
bacteria, even though in the latter a high amount of bacterial cell-bound endotoxin is present. our 
data add to previous studies showing that septic shock occurs more frequently among patients 
with both endotoxemia and gram-negative bacteremia compared with those with only bacteremia2, 
and confirm that bacteremia in itself is a weak predictor of clinical outcome. Strong associations 
between endotoxemia and outcome were observed in patients with meningococcemia, plague and 
leptospirosis, but not in a number of studies on hospitalized patients with sepsis syndrome due to 
other causes6,9,22-29. In many studies intensive care patients were included and in most of these the 
presentation of the acute illness was complicated by an active underlying condition. As our study 
sample included only few patients with active underlying disease, the sample size may have limited 
the power to detect the impact of predictors of outcome in patients in whom the severity of illness 
was comparable to that in the intensive care patients.
In our study only patients admitted because of a community-acquired febrile illness were eligible 
for inclusion. Although the population was heterogenous in terms of age, site of infection, etc, in 
general patients were acutely ill and few had an underlying disease. The mixture of patients with 
community-acquired infection in our study represents that seen in many university and large 
community hospitals17,18. Since we did not evaluate the predictive potential of the parameters in 
already hospitalized critically-ill patients after referral to an intensive care unit, our findings do 
not exclude that such measurements of endotoxin, cytokines and procalcitonin may be relevant 
in such a selected patient group.
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Abstract
Aim. We investigated the occurrence and thrombin generating mechanisms of circulating 
microparticles (mP) in patients with multiple organ dysfunction syndrome (moDS) and sepsis. 
methods. mP, isolated from blood of patients (n=9) and healthy controls (n=14), were stained 
with cell-specific monoclonal antibodies (moAbs) or anti-tissue factor (anti-Tf) moAb and 
annexin V, and analyzed by flow-cytometry. To assess their thrombin-generating capacity, mP 
were reconstituted in normal plasma. The coagulation activation status in vivo was quantified by 
plasma prothrombin fragment f1+2 and thrombin-antithrombin (TAT) measurements. 
results. Annexin V positive mP in the patients originated predominantly from platelets (PmP), 
and to a lesser extent from erythrocytes, endothelial cells (emP) and granulocytes (GmP). 
Compared to healthy controls, the numbers of annexin V-positive PmP and Tf exposing mP 
were decreased (P=<0.001 for both), emP were decreased (e-selectin, P=0.003) or found equal 
(CD144, p=0.063), erythrocyte derived mP were equal (P=0.726), and GmP were increased 
(P=0.008). GmP numbers correlated with plasma concentrations of elastase (r=0.70, P=0.036), 
but not with C-reactive-protein or interleukin-6 concentrations. Patient samples also contained 
reduced numbers of annexin V negative PmP, and increased numbers of erythrocyte derived 
mP and GmP (P=0.005, P=0.021 and P<0.001, respectively). Patient mP triggered thrombin 
formation, which was reduced compared to the healthy controls (P=0.008) and strongly inhibited 
by an anti-factor XII moAb (two patients), by anti-factor XI moAb (eight patients) or by anti-Tf 
moAb (four patients). Concentrations of f1+2 and TAT were elevated (P=0.005 and P=0.001, 
respectively) and correlated inversely with the number of circulating mP (and r=-0.51, P=0.013, 
and r=-0.65, P=0.001, respectively) and their thrombin generation capacity (f1+2: r=-0.62, 
P=0.013). 
Conclusions.  In patients with moDS and sepsis relatively low numbers of mP are present that 
differ from controls in their cellular origin, numbers and coagulation activation mechanisms.
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1. Introduction
Cells undergoing activation or apoptosis release small parts of their outer membrane, the 
so-called microparticles (mP). extensive studies have been reported on mP generated from 
blood platelets (PmP) in vitro1,2. These mP expose negatively charged phospholipids, thereby 
providing binding sites for activated coagulation factors V (factor Va), VIIIa, IXa and XIa1-4. 
As a consequence, these PmP are procoagulant by providing ’phospholipid cofactor’. In vitro, 
other cell-types such as monocytes, endothelial cells and erythrocytes also release mP upon 
appropriate stimulation5-7.
In vivo, increased numbers of PmP are found in the circulation of patients with an increased risk 
for thromboembolic events, i.e. patients with diabetes8,9, patients undergoing cardiac surgery10, 
or patients suffering from acute coronary ischaemia11, heparin-induced thrombocytopenia12, 
myocardial infarction13, uremia14, idiopathic thrombocytopenic purpura15 and disseminated 
intravascular coagulation (DIC)16,17. Previously, we reported elevated numbers of PmP and 
erythrocyte derived mP in the pericardial fluid of patients undergoing cardiopulmonary bypass 
surgery, and demonstrated that the isolated mP facilitated thrombin generation via the extrinsic 
pathway, i.e. tissue factor (Tf)/factor VII dependent18. Subsequently, we reported elevated 
numbers of PmP and mP derived from monocytes and granulocytes in the circulation of patients 
with meningococcal septic shock and provided evidence that exposure of Tf on mP might be 
involved in the pathogenesis of DIC17. finally, we were also able to measure low numbers of mP 
especially from platelets and erythrocytes- in the circulation of healthy individuals. Those mP 
triggered low levels of thrombin generation in vitro via a Tf/factor VII-independent mechanism. 
This thrombin generation was partially inhibited by blockade of factors XII or XI19. recently, 
Combes and coworkers reported elevated numbers of endothelial cell-derived mP (emP) in 
the circulation of patients with systemic lupus erythematosus (SLe) when compared to healthy 
individuals20.
meningococcal septic shock is a very severe, rapidly progressive disease, which may not be 
representative for other more protracted septic conditions. In the present study we investigated 
the cellular source and thrombin generating capacity of mP in patients with multiple organ 
dysfunction syndrome (moDS) and sepsis, and a possible relation of those mP to the activation 
status of the coagulation system in vivo. We also investigated a possible relation between the 
number of mP in the circulation and the extent of the inflammatory response, as indicated by the 
plasma concentrations of interleukin-6 (IL-6), elastase and the acute phase reactant C-reactive 
protein (CrP).
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2. Patients, materials and methods
2.1 Patients and healthy individuals
Patients with moDS and sepsis were investigated. The patients entered the study between July 1998 
and march 1999 and were hospitalized in the Intensive Care Unit of the Leiden University medical 
Center (LUmC). of the nine patients (2 female and 7 male; age: 60 years (median), range 26-71), 
six had bacteremia whereas the others had a local bacterial infection. Patients developed moDS 
and sepsis after surgery (six patients), pancreatitis (one), multitrauma (one) or escherichia (e) coli 
meningitis (one). Patients were considered to have sepsis if they fulfilled the criteria for a systemic 
inflammatory response syndrome (SIrS) and had evidence for a systemic and/or local bacterial 
infection21. The criteria to establish SIrS were more than one of the following: (I) a temperature 
>38ºC or <36ºC; (II) tachycardia (>90 beats/minute); (III) tachypnea (respiratory rate >20 breaths/
minute or PaCo2 <32 mm hg); and (IV) a white blood cell count >12x109/L or <4x109/L, or the 
presence of >10% immature neutrophils21. The diagnosis SIrS was made by the attending physician 
and checked by one of the study clinicians. moDS was defined as a failure of 3 or more organ 
systems for at least 24 hours21. of the nine patients, five patients died within 28 days. Individual 
patient characteristics, including platelet- and white blood cell counts, are presented in table 1. 
of the nine patients, 7 had elevated numbers of white blood cell counts (>10x109/L), whereas 5 
patients were thrombocytopenic (<150x109/L). As controls, 14 adult healthy individuals were also 
investigated for the presence, cellular source and thrombin generating capacity of mP. The healthy 
individuals had not taken any medication for at least ten days prior to the blood collection. The study 
was approved by the medical ethical committee (234-94/5/DPe/eN) of the LUmC.
2.2 Collection of blood samples
Blood was collected into 3.2% trisodium citrate (BD, San Jose, CA, USA). Blood cells were 
removed within 5 minutes after blood collection by centrifugation for 20 minutes at 1550 x g 
and room temperature. for flow cytometry, mP were isolated (see below) from fresh plasma 
Table 1. Patient characteristics.
Patient Age 1Gender 2Platelet 2WBC count Cause of sepsis Positive 3mortality
  count    culture
1 67 m 54 14.3 Post-operative Blood Survivor
2 35 m 193 15.8 Post-operative Blood Survivor
3 55 m 102 6.0 Post-operative Blood Non-survivor
4 43 f 223 25.3 Post-operative Blood Non-survivor
5 71 m 113 29.6 Pancreatitis Blood Survivor
6 61 f 63 9.3 e. coli meningitis 4CSf Non-survivor
7 26 m 167 18.1 multi trauma Blood Non-survivor
8 60 m 166 15.4 Post-operative Sputum Non-survivor
9 62 m 121 13.9 Post-operative Aneurysm Survivor
1m=male, f=female; 2Whole blood platelet- and white blood cell counts (x109/l); 3Within 28 days after onset of 
sepsis; 4Cerebrospinal fluid.
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samples. The concentrations of prothrombin fragment f1+2, thrombin-antithrombin complex 
(TAT), IL-6, elastase and CrP, and thrombin generation experiments were determined in 
aliquots of plasma that were first snap frozen in liquid nitrogen, and then stored at -80°C until 
use. 
2.3 Reagents and assays 
reptilase was obtained from roche (Basel, Switzerland) and the chromogenic substrate S2238 
from Chromogenix AB (mölndal, Sweden). murine normal serum was obtained from the 
Central Laboratory of the Netherlands red Cross Blood Transfusion Service (CLB; Amsterdam, 
The Netherlands), anti-Glycophorin A-fITC (JC159, IgG1) and CD61-fITC (Y2/51, IgG1) from 
Dako A/S (Glostrup, Denmark), IgG1-fITC (X40) from BD (San Jose, CA, USA), CD62e-
fITC (1.2B6, IgG1) from Serotec Ltd (oxford, england), CD66b-fITC (80h3, IgG1k) from 
Coulter/ Immunotech (marseille, france), CD144-fITC (BmS158fI, IgG1) from medSystems 
Diagnostics Gmbh (Vienna, Austria), annexin V-APC from Caltag Laboratories (Burlingame, 
CA, USA) and annexin V-Pe from Pharmingen (San Jose, CA, USA). oT-2 (0.71 mg/ml), a 
moAb which inhibits the activity of factor XII(a), was prepared as described earlier22. moAb 
directed against factor XI (clone XI-1 (0.92 mg/ml)) was also from the CLB. Anti-Tf-fITC 
(4508CJ, IgG1) and polyclonal rabbit anti-human Tf (1 mg/ml; clone 4502) were from American 
Diagnostics, Inc. (Greenwich, CT, USA). Plasma concentrations of f1+2
 
and TAT (Behring 
Diagnostics Gmbh, marburg, Germany), elastase (DPC, Nauheim, Germany) and IL-6 (CLB) 
were determined by eLISA as described by the manufacturers. CrP was measured on a hitachi 
911 analyzer (roche, Basel, Switzerland) by immunoturbidimetric assay as described by the 
manufacturer.
2.4 Isolation of microparticles
After removal of cells, 250 µl plasma were centrifuged for 30 minutes at 17570 x g and 20°C. 
Subsequently, 225 µl of (mP-free) plasma were removed. The remaining (mP-enriched) plasma, 
25 µl, was diluted with 225 µl of phosphate-buffered saline (PBS; 154 mmol/l NaCl, 1.4 mmol/l 
phosphate, ph 7.4), containing 10.9 mmol/l trisodium citrate to prevent coagulation activation. 
mP were resuspended and centrifuged for 30 minutes at 17570 x g at 20°C. Again, 225 µl of the 
supernatant were removed and mP were resuspended in the remaining 25 µl. for the thrombin 
generation experiments, 20 µl of this suspension were used. for flow-cytometry, 25 µl mP 
suspension was diluted fourfold with PBS/citrate buffer, of which 5 µl were used per incubation 
with moAb and annexin V. 
2.5 Flow cytometric analysis
mP analysis was performed as described previously17,18. Briefly, mP (5 µl) were diluted in 35 µl 
PBS containing 2.5 mmol/l CaCl2 (ph 7.4) and 5 µl of 1 to 500 diluted  (in PBS) normal mouse 
serum. After incubation for 15 minutes at room temperature, 5 µl annexin V-Pe and 5 µl fITC-
labeled cell-specific moAbs or isotype-matched control antibody were added. The mixtures were 
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incubated in the dark for 15 minutes at room temperature. Subsequently, 200 µl PBS/calcium 
buffer were added and the suspensions centrifuged for 30 minutes at 17570 x g and 20°C. 
finally, 200 µl of (mP-free) suspension were removed. The mP were resuspended with 300 
µl PBS/calcium buffer before flow-cytometry. All samples were analyzed for 1 minute during 
which the flow cytometer analyzed approximately 150 µl of the suspension. To estimate the 
number of mP/L plasma, the number of mP (N) found in the upper right (marker positive and 
annexin V positive) and lower right (marker positive and annexin V negative) quadrants of the 
flow-cytometry analysis (fL1 versus fL2, corrected for isotype control and autofluorescence) 
was used in the formula: Number/l=N x [100/5] x [355/150] x [106/250]. The lower detection 
limit of the particle count was established in the samples with the IgG control as 5x106 mP/l. 
The samples were analyzed in a fACScan flow cytometer with CellQuest software (BD, San 
Jose, CA, USA). forward scatter (fSC) and sideward scatter (SSC) were set at logarithmic gain. 
To distinguish mP from events due to noise, mP were identified on fSC, SSC and binding of a 
moAb directed against a cell-specific antigen. To identify annexin V positive events, a threshold 
was placed in a mP sample prepared without any additions to correct for autofluorescence. To 
identify mP that bound cell-specific moAbs, mP were incubated with identical concentrations 
of isotype-matched control antibodies to set the threshold. fITC-fluorescence was measured in 
the fL-1 channel and Pe-fluorescence in the fL-2 channel. The anti-CD144 antibody became 
only recently available to us, once we had started to perform our analysis on a fACSCalibur flow 
cytometer from Becton Dickinson (San Jose, CA, USA). This antibody was used in conjunction 
with annexin V-APC and anti-CD62e-Pe. In all other aspects the CD144 analysis was performed 
as described for the other antibodies.
2.6 Thrombin generation assay
The thrombin generation test (TGT) as described by Béguin et al.23 was used to assess the 
thrombin generating capacity of the mP. In brief, isolated mP were reconstituted in defibrinated, 
mP-free normal plasma. mP were isolated from stored (-80°C) plasma from patients (n=9) 
and healthy controls (n=6). Defibrinated plasma was prepared by incubating mP-free normal 
plasma (a pooled plasma from 20 healthy individuals, that had been centrifuged for 30 
minutes at 17570 x g and 20°C) with reptilase for 10 minutes at 37°C and, subsequently, for 
10 minutes on melting ice. The fibrin clot was removed by centrifugation for 30 minutes at 
17570 x g and 20°C. Since mP adhere to fibrin, the plasma aliquots from which mP were 
isolated were not defibrinated24. mP (20 µl) was added to 120 µl of defibrinated plasma in all 
experiments. At t=0, thrombin generation was triggered by the addition of 30 µl CaCl2 (16.7 
mmol/l final concentration) to a prewarmed (37°C) mixture of plasma, mP and buffer A (10 
µl; 50 mmol/l Tris-hCl, 100 mmol/l NaCl, 0.05% bovine serum albumin, ph 7.35). At fixed 
intervals after t=0,3 µl aliquots were removed from this mixture and added to 147 µl prewarmed 
(37°C) chromogenic substrate S2238 in buffer B (50 mmol/l Tris-hCl, 100 mmol/l NaCl, 20 
mmol/l eDTA and 0.05% bovine serum albumin, ph 7.90). After 3 minutes, the conversion of 
S2238 was stopped by the addition of 90 µl citric acid (1.0 mol/l) and the generated amount 
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of p-nitroaniline was determined at λ=405 nm. In the inhibition experiments, the mixture of 
plasma plus buffer A, and separately the mP, were incubated with 20 µl and 10 µl of antibodies, 
respectively. In preliminary experiments the concentration yielding maximal inhibition was 
determined for each antibody. These were anti-Tf (1 mg/ml initial concentration), anti-fXI 
(0.92 mg/ml) and anti-fXII (0.71 mg/ml). After 30 minutes pre-incubation at room temperature, 
the mP were added and incubated for 10 minutes at 37°C, whereupon the thrombin generation 
was started by addition of CaCl2. for quantitative analysis, the results were determined as 
the area under the curve and expressed as milligram (mg) of the graph paper being weighed. 
Compared to unfrozen mP from healthy controls, after freeze/thawing these mP generate more 
thrombin as the area under the (thrombin generation) curves increases about two fold, but the 
proportion of inhibition by individual antibodies (such as anti-fXI, anti-fXII, anti-Tf or anti-
fVII) is unaffected by freeze/thawing. In preliminary experiments, we observed that the increase 
in the area under the curve of the thrombin generation experiments upon freezing/thawing may 
be somewhat dependent upon the composition of the mP in the plasma sample. This indicates 
that the absolute thrombin generation capacities of stored microparticle preparations have to be 
interpreted with some caution. however, the freezing/thawing did not influence the percentage 
of inhibition by the various antibodies regardless of the composition of the microparticle 
populations, and thus the pathways observed to initiate the thrombin generation seem to be 
unaffected by the freezing/thawing process19.
2.7 Statistical methods
Data were analyzed with SPSS for Windows, release 9.0. The data obtained in the healthy 
individuals were log transformed to calculate the 2.5 and 97.5 percentiles of the reference range. 
Dependent upon the parameter under investigation, individual patient values either below or 
above those percentiles is indicated. Differences in microparticle numbers between the groups 
of patients and healthy individuals were tested with the mann Whitney U test. Correlations were 
determined with the Spearman’s rho test.
3. Results
3.1 Flow-cytometry
Number and cellular origin of microparticles in patients with moDS and sepsis
A representative flow cytometric analysis of mP circulating in a patient is presented in figure 
1. The patient plasma mainly contained platelet- and erythrocyte derived mP, but also mP from 
endothelial cells (emP) and granulocytes (GmP). for the detection of emP, antibodies directed 
against e-selectin and Ve-Cadherin (CD62e and CD144, respectively) were used. Also Tf 
(CD142) was measured. 
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A similar analysis of a healthy individual is presented in figure 2. here, the absence of GmP and 
the higher number of PmP are noteworthy. remarkably, a larger number of emP were measured 
with the anti-CD62e antibody as compared to the anti-CD144 antibody in both patients and 
healthy controls (figures 1 and 2, respectively). 
Quantitative data are presented in table 2, in which not only mP numbers of the marker- or Tf-
positive and annexin V positive populations are summarized (upper right quadrants of figures 
1 and 2), but also annexin V negative events that were marker- or Tf-positive (lower right 
quadrants of figures 1 and 2). on average, the numbers of annexin V positive mP of platelet 
origin were decreased and those of endothelial cell origin either decreased (CD62e) or similar 
(CD144). The numbers of erythrocyte derived mP were similar and the numbers of GmP were 
elevated. The numbers of annexin V negative PmP were decreased, emP were comparable and 
the numbers of erythrocyte derived mP and GmP were increased.  figure 3 shows the numbers 
of PmP, erythrocyte derived mP, emP and GmP in the individual patients. The number of 
annexin V and Tf positive mP, not specified per cell type, was reduced in the patient group, but 
numbers of annexin V negative and Tf positive mP were equal for this antigen. There was a 
considerable overlap in the ranges of the number of mP between the healthy volunteers and the 
patients, but, dependent upon the cellular origin of the mP, 0 to 8 of the patients had numbers 
of mP below the 2.5 or above the 97.5 percentile of the range in the healthy controls (Table 2). 
mP of T helper cells (CD4), T suppressor cells (CD8), B-cells (CD20) and plasma cells (CD38) 
were below the detection limit in both patients and controls (data not shown).
Table 2. Numbers and cellular origin of circulating mP in patients with moDS and sepsis (n=9) and healthy 
individuals (n=14).
 marker Patients Controls N
x
/Nt3 P
Platelets CD61 114 (65 - 208)1 237 (116 - 547)1 3/9 (lower) 0.0011
  50 (17 - 185)2 126 (32 - 381)2 2/9 (lower) 0.0052
erythrocytes Glyco A 24 (<5 - 165) 28 (13 - 46) 4/9 (higher) 0.174
  94 (26 - 293) 46 (19 - 84) 4/9 (higher) 0.021
endothelial cells CD62e 93 (57 - 309) 336 (87 - 721) 2/9 (lower) 0.010
  17 (8 - 66) 14 (<5 - 42) 1/9 (higher) 0.238
Granulocytes CD66b 12 (<5 - 145) <5 5/9 (higher) < 0.001
  43 (<5 - 110) <5 8/9 (higher) < 0.001
(Tf-positive) (CD142) 14 (5 - 30) 47 (15 - 108) 4/9 (lower) 0.001
  16 (<5 - 36) 20 (11 - 49) 1/9 (lower) 0.238
1Cell-marker- or Tf-positive and annexin V-positive mP (x106/l); 2Cell-marker- or Tf positive and annexin 
v negative mP (x106/l);  Nt3: total number of patient samples tested, Nx: number of patient samples with 
microparticle numbers below the 2.5 or above the 97.5 percentile of the reference range in the healthy controls.
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Figure 1. representative dot plots of mP in plasma of a patient with moDS and sepsis. mP were isolated, double 
labeled with annexin V (Pe-labeled) and a moAb directed against a specific cell marker or Tf (both fITC-
labeled), and analyzed by flow-cytometry as described in the Patients and methods section. The binding of annexin 
V is indicated on the y-axis, and the expression of the cell marker on the x-axis. The fluorescence thresholds were 
set as described in the Patients and methods section, i.e., with a isotype-identical control antibody for the cell 
marker and in the absence of annexin V for annexin V binding. Data of patient 7 is presented.
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Figure 2. representative dot plots of mP in plasma of a healthy individual. for details see legend figure 1.
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Thrombin generating capacity, initiation pathways and relation to in vivo coagulation activation 
status
3.2 Thrombin generation
figure 4 shows thrombin generation curves obtained with mP from two patients and a 
representative healthy individual in the absence and presence of inhibitory moAb. The curves 
from patients 1 and 7 are provided, because patient 1 demonstrated extreme inhibition with anti-
factor XII, in contrast to patient 7. 
overall data are provided in figure 5. As represented in this figure, the thrombin generating 
capacity, expressed as the area under the curve in the assay, varied widely between the patients 
but was overall reduced compared to the controls (P=0.008). Thrombin generation by mP from 
Figure 3. microparticle numbers in the individual patients. Numbers of platelet-, erythrocyte-, endothelial-, 
granulocyte derived mP are shown as well as the number of Tf-positive mP (x106/l plasma). for each 
individual patient the numbers of marker- and annexin V positive (light gray bars) as well as marker positive 
but annexin V negative mP (hatched bars) are shown. The data in the healthy controls are depicted as 
median with range.
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healthy individuals was on average not inhibited by anti-Tf, slightly inhibited by anti-factor 
XII (on average 12%) and by anti-factor XI (36%). Three patients had a significantly reduced 
thrombin generation capacity of the mP; four had an increased inhibition by anti-Tf, two by 
anti-factor XII and all but one of the nine with anti-factor XI (figure 5). 
3.3 Congulation activation status
In vivo coagulation activation status and relation to the number of circulating mP.
Concentrations of both f1+2
 
and TAT were determined to assess the activation status of the 
coagulation system in vivo. As shown in figure 6A, concentrations of both f1+2 and TAT 
were significantly elevated in the patients compared to the healthy controls (f1+2
 
in patients 
1.20 (median), range 0.46-3.48 and controls 0.59 (0.32-1.91), P=0.005; TAT in patients 5.50 
(2.20-14.70) and controls 1.04 (0-3.63), P=0.001), indicating that the coagulation system in the 
patients was activated. 
Next, we determined correlations between the in vivo activation status of the coagulation system 
and the number of circulating mP as well as their thrombin generating potential in plasma. As 
Figure 4. Thrombin generation by isolated mP from two patients and from a representative healthy 
individual in defibrinated normal plasma. Thrombin generation was performed in the absence (L) or 
presence of antibodies to Tf (m), factor XII (P) or factor XI (q), as described in Patients and methods. The 
background, i.e. recalcified mP-free plasma, is depicted by (r).
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shown in figure 6B and 6C, the numbers of circulating, annexin V binding mP in patients and 
controls inversely correlated with the concentrations of both f1+2 and TAT (r=-0.51, P=0.013, 
and r=-0.65, P=0.001, respectively). A negative correlation trend was present between the 
thrombin generation capacity (area under curve) and TAT (r=-0.43, P=0.106), and a significant 
negative correlation of this capacity with f1+2
 
(r=-0.62, P=0.013, figure 6D).
3.4 Inflammatory response and relation to circulating MP
To assess the extent of the inflammatory response in the patients, plasma concentrations of 
the cytokine IL-6, the acute phase reactant CrP and the granulocyte product elastase were 
determined. figure 7 (A-C) shows the individual concentrations in each patient and median plus 
range values in the healthy controls. The plasma concentrations of IL-6 and CrP were clearly 
elevated in all patients as expected. elastase concentrations were also above the 97.5 percentile 
of the control range in 6 out of 9 patients. The number of GmP found in patient plasma samples 
correlated with their plasma elastase concentrations (r=0.70, P=0.036; figure 7D), but not with 
the concentrations of CrP (r=0.05, P=0.898) or IL-6 (r=-0.14, P=0.787).
Figure 5. The effect of inhibitory antibodies on thrombin generation by mP from patients and from healthy 
individuals. median and range of the data in the healthy individuals (n=6) are presented, together with 
the individual data of patients 1-9. Note that the data in the upper left figure represent absolute values of 
thrombin generation, expressed as the area under the curve (mg). Those in the other figures are relative 
values, i.e. the percentage remaining thrombin generation in the presence of the antibody compared to the 
uninhibited value in that patient. The * indicates findings lower than the 2.5 percentile of the reference 
range in the healthy controls.
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4. Discussion
The present study shows that patients with moDS and sepsis have relatively low numbers of 
circulating mP. reconstitution of these mP in normal plasma evoked less thrombin generation 
than mP from controls, and the mechanisms of thrombin formation clearly differed from healthy 
individuals.
Coagulation in vivo is generally believed to be initiated by the complex of Tf-alpha and factor 
VIIa25, which results in the conversion of prothrombin (factor II) -via factor X(a)- into active 
thrombin (factor IIa). There is extensive evidence supporting the relevance of this coagulation 
activation pathway in vivo: (i) the bleeding tendency in persons with hereditary deficiencies,  
(ii) infusion of activated factor VII into baboons increases the concentrations of the activation 
peptides of factors IX, X and II, which increases are blocked by infusion of anti Tf-alpha26, 
Figure 6. relationship between in vivo thrombin generation and number and thrombin generating capacity 
of circulating mP. A. median and range of concentrations of prothrombin fragment f1+2 (gray bars) 
and TAT (white bars) from patients (n=9) and controls (C; n=14). B. Correlation between the number of 
circulating, annexin V positive mP and plasma TAT concentrations. C. Correlation between the number 
of circulating mP and the plasma f1+2 concentrations. D. Correlation between the extent of thrombin 
generation by the mP and plasma concentrations of f1+2. Patients are depicted as q and controls as P 
in figures 5B-D, *P<0.05 and #P<0.001 are indicated in figure 5A. Spearman’s rank correlation analysis 
is provided in figures 5B-D.  Two of the controls are not depicted in figure 5B, because their plasma 
concentration of TAT was below 0.1 µg/l.
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and (iii) infusion of anti Tf-alpha prevents the development of DIC in baboons that receive 
lethal doses of e. coli28. In our previous studies we also found that thrombin generation 
induced by mP, isolated from either material of the pericardial cavity of patients undergoing 
cardiopulmonary bypass18 or from the systemic circulation of a patient with meningococcal 
septic shock and DIC17, occurred via a Tf-alpha/factor VII(a) dependent mechanism. In the 
present study, however, anti-Tf-alpha partially inhibited thrombin generation in only four 
patients. In two patients, thrombin generation was strongly inhibited by anti-factor XII, which in 
our previous studies was completely ineffective17,18, despite the fact that this antibody completely 
blocks kaolin-induced generation of thrombin in normal plasma19. The role of factor XII in 
coagulation is still obscure. Patients with hereditary factor XII deficiency do not have a bleeding 
tendency29,30  and administration of anti-factor XII does not prevent the development of DIC in 
baboons after administration of lethal doses of e. coli27. our present findings suggest that mP 
can activate factor XII. Whether this factor XII-activating property is explained by differences 
in composition or cellular origin of the mP remains to be determined. We can only speculate 
on the cellular origin of the mP involved in activation of factor XII. factor XII is present on 
the neutrophil membrane surface27,31,32. Interestingly, the two patients that showed by far the 
strongest inhibition of thrombin generation by anti-factor XII (patients 1 and 5) also had the 
highest numbers of GmP and the highest plasma elastase concentrations of the nine patients 
Figure 7. Inflammatory response and relation to GmP. median and range of the data in the healthy 
individuals (n=14) are presented, together with the individual data of patients 1 - 9. Plasma concentrations 
of A. IL-6, B. CrP, C. elastase and D. Correlation between the number of GmP and plasma concentration 
of elastase
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studied. A relation between the GmP and the factor XII activation in an in vitro thrombin 
generation assay could therefore be hypothesized. 
In eight of the nine patients, anti-factor XI moAb strongly inhibited thrombin generation, more 
than observed with the healthy controls. The role of factor XI in coagulation, as with factor XII, 
has long been debated. Patients with hereditary factor XI deficiencies suffer in various extents 
from bleeding abnormalities33. factor XI can be activated by factor XIIa and by thrombin34. 
once activated, factor XIa induces more extensive thrombin formation -via factors IXa and 
Xa- and then also indirectly inhibits fibrinolysis in plasma35. factor XI can be activated on the 
platelet surface in the absence of factor XII36. Despite the fact that in patients the numbers of 
PmP were decreased, they still comprise about 40% of the total number of circulating mP and 
possibly provide an efficient surface for activation of factor XI. Platelets contain a unique form 
of factor XI, platelet factor XI, which is an alternative splicing product of the plasma factor XI 
gene37 and which is present on the platelet surface38. To our knowledge, it is unknown whether 
platelet factor XI and plasma factor XI differ in their sensitivity for activation via either factor 
XIIa or thrombin. It is equally unknown whether mP differentially causes activation of plasma 
and platelet factor XI.
Development of moDS may be due to hypercoagulation and platelet deposition, leading to 
obstruction of blood vessels and finally organ dysfunction39. The platelet count in the patients 
was significantly lower than in the controls (patients 121x106/l (median), range 54-223; controls 
238x106/l, range 172-276; P<0.01), whereas the numbers of PmP per platelet were comparable 
(P=0.477). This could suggest that the number of PmP in the circulation of patients and healthy 
individuals are simply a reflection of the number of platelets. Alternatively, the low numbers 
of PmP in the patients may be due to deposition of platelets- and/or PmP in the organs24,40. 
Deposition of PmP has been observed in the microvasculature after porous balloon delivery41 
and in atherosclerotic plaques42.
The numbers of PmP found in the controls in the present study (237x106/l) are much higher than 
those reported previously by us (41x106/l)17. In the earlier study, we used eDTA-anticoagulated 
plasma that had been frozen and stored for 5-9 years at -70°C but that had not been snap frozen 
prior to storage, whereas in the present study citrate anticoagulated plasma was used that had 
been snap frozen in liquid nitrogen and that was used within 1-2 months. This implies that 
absolute numbers of cell-derived mP are likely to be dependent on conditions of collection and 
storage. however, especially the snap freezing of the plasma aliquots was noted to be important 
to reliably quantify mP. It emphasizes that appropriate samples from healthy controls should 
always be included in clinical studies, and conditions of collection, preparation and storage 
carefully noted in manuscripts. 
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In the present study the number of emP in the healthy controls using the anti-e-selectin antibody 
(64x106/l) is also much higher then in our previous report (18x106/l). The detection of emP is 
cumbersome due to the lack of appropriate antibodies. Combes et al. used antibodies directed against 
PeCAm-1 and α
v
β3, i.e. non-endothelial cell specific antibodies20. We used an antibody directed 
against e-selectin (CD62e), a protein only expressed on activated endothelial cells. This antibody 
was titrated on mP that strongly expose e-selectin, i.e. mP isolated from IL-1α stimulated human 
umbilical vein endothelial cells, to ensure a proper antibody concentration. Compared to IgG control 
antibody staining, mP bound this anti-e-selectin antibody although their fluorescence intensity was 
just above the fluorescence threshold of the IgG control. Although these mP may expose e-selectin, 
we question their endothelial cell origin. Very recently, we obtained plasma samples from 12 patients 
with SLe, and found subpopulations of mP strongly binding anti-e-selectin in 3 patients. Staining 
with an antibody directed against Ve-cadherin (CD144), like e-selectin a protein expressed only by 
endothelial cells, also showed a strong staining of a microparticle subpopulation in only these three 
patients, thus confirming their endothelial cell origin (data not shown). The anti CD144 data therefore 
seem more reliable than the anti-e-selectin data to estimate the number of emP. 
The numbers of annexin V positive emP and those exposing Tf were also reduced compared 
to controls, possibly via similar mechanisms as stated above. GmP (CD66b) were absent in 
plasma samples in healthy controls, but clearly present in the patients. By far the highest number 
of GmP did not stain for annexin V. The presence of these solely marker-positive events seems 
specific, since they are entirely absent in control plasma samples. At present, one can only 
speculate about the function and genesis of these distinct subpopulations. only the CD66b- and 
annexin V positive population correlated with elevated levels of elastase  (r=0.70, P=0.036), 
and not the annexin V negative population (r=0.41, P=0.273), but we presume both populations 
to originate from granulocytes. Previously, we reported circulating GmP in patients with 
meningococcal septic shock17 and the present study demonstrates that GmP are not restricted to 
those patients. The plasma concentrations of IL-6, CrP and elastase were elevated in (almost) 
all patients, but only elastase correlated to the number of GmP, strengthening the observation 
that circulating GmP indeed reflects activation of granulocytes in the circulation. 
The mP fractions from patients, containing mP of various cellular origins, generated on 
average less thrombin in normal plasma than mP from controls. Patients, however, clearly 
had enhanced coagulation activation in vivo, as reflected by increased concentrations of f1+2 
and TAT, and an inverse correlation was present between the numbers of mP and plasma TAT 
concentrations. This apparent discrepancy between thrombin generation in vitro and enhanced 
coagulation in vivo may be explained in two ways. first, the more extensive inhibition of the 
mP-induced thrombin generation by anti-factor XI may indicate that the mP in the patients, 
although present in low numbers, are in some way more capable of supporting the XI loop of 
coagulation activation43,44. Similarly, the extensive inhibition by anti-factor XII and anti-Tf in 
2 and 4 patients, respectively, points to different coagulation activation properties of the mP 
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in the patients versus healthy individuals. Second, (increased) adherence of mP to endothelial 
cells, monocytes or other circulating blood cells, resulting in a reduction of their circulating 
numbers, may initiate expression and production of Tf-alpha and cytokines. In vitro, leukocyte 
mP stimulates endothelial cells to produce Tf-alpha and IL-645, whereas PmP can stimulate 
monocytes46. As a consequence, the production of, for instance, Tf-alpha by target cells would 
result in enhanced coagulation activation in vivo and its reported Tf-alpha dependence25-28.
Taken together, the present study shows that in patients with moDS and sepsis the circulating 
numbers of mP are relatively low, and differ in cellular origin from those in healthy controls. 
These patient mP initiate thrombin generation via different mechanisms from those described 
previously for mP in pericardial blood of patients undergoing cardiopulmonary bypass and 
patients with meningococcal sepsis. 
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Abstract
Severe dengue virus infections are characterised by haemorrhagic manifestations. In afflicted 
patients, we observed a substantial decrease in platelet derived circulating microparticles with 
a nadir during acute illness and ongoing normalization during recovery. We suggest a causative 
role for platelet microparticle deficiency in dengue haemorrhagic fever. 
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1. Introduction
Dengue is the most important of arthropod-borne viral diseases1. At present, almost 30% of 
the world population is at risk for dengue virus infection and this number is expected to rise2. 
The haemorrhagic manifestations are characteristic to severe dengue virus infections and are 
thought to be due to thrombocytopenia and thrombocytopathy, but recent data suggest that other 
abnormalities in blood coagulation and fibrinolysis may also play an important role3-5. 
The coagulation system requires the presence of phospholipid cofactors that provide a surface 
to assemble the various complexes to activate clotting factors. microparticles are small, high 
phosphatidylserine expressing membrane vesicles, released from cells during activation or 
apoptosis that have a large number of (high affinity) binding sites for components of the X-ase 
and prothrombinase complexes6-10. microparticle formation is altered, most often increased, in 
several disease states. higher numbers of platelet derived microparticles have been described 
in patients with various underlying illnesses11-14, whereas a reduced ability to generate 
microparticles occurs in a congenital bleeding disorder (Scott syndrome)15. The primary cause 
of dengue associated bleeding is not yet clear, both hyper- and hypocoagulation have been 
implicated. Therefore, we investigated microparticle dynamics in the course of severe dengue 
infection. 
2. Patients and methods
Patients, aged 2 to 14 years, admitted to the paediatric intensive care unit and the paediatric 
ward of the Dr. Kariadi hospital in Semarang, Indonesia, with a clinical diagnosis of suspected 
dengue haemorrhagic fever or dengue shock syndrome were included. The controls were 
healthy school-aged Javanese children from 6 to 13 years of age (median age 10 years) who 
originated from the same geographical area as the cases. The ethics committee of the Dr. Kariadi 
hospital approved all clinical and laboratory aspects of this study. Blood samples were only 
taken from patients and controls provided that a parent or legal guardian gave informed consent. 
The presence of dengue was objectively confirmed by serological assays or by the detection 
of dengue antigen and rNA using a dot blot immunoassay and a dengue serotype reverse 
transcriptase PCr respectively16. 
for microparticle analysis, blood samples were centrifuged within 1-2 hours after retrieval and 
microparticle-rich plasma was snap frozen. microparticle analysis was performed upon  
thawing of the samples and preparation of microparticle suspensions, on a fACSCalibur 
flow cytometer with CellQuest-Pro software (Beckton Dickinson, San Jose, CA, USA), as 
described17. Briefly, microparticles were identified on fSC, SSC, binding of annexin V and cell-
specific antibodies or anti-Tf antibody (for a detailed description of the reagents and antibodies 
used see reference17).  
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3. Results
3.1 Patient characteristics
eight patients with a confirmed dengue virus infection from whom complete time series were 
available (day 0, 1, 2, 7 and 30), were randomly selected for this study. Three patients had 
evidence of circulatory failure on admission or during admission and were thus classified as 
suffering from dengue shock syndrome. one of the patients with circulatory failure had no 
evidence of vascular leakage and was classified as suffering from severe dengue fever. All other 
patients were classified as suffering from dengue fever. Platelet count was lower on days 1 and 
2 compared to day of admission (day of admission: 73.000 cells/mm3 (IQr 55.000-85.000); 
day 1:42.000 cells/mm3 (IQr 32.000-57.000); day 2:59.000 cells/mm3 (IQr 31.000-100.000)). 
Platelet count increased to near normal values on day 7 (168.000 cells/mm3 (IQr 65.000-
297.000)). All patients survived and the median stay in the hospital was 6 days (range 3 to 8 
days). 
Number and time course of circulating microparticles 
As shown in Table 1, on day of admission and on the first 2 days after admission the total 
number of microparticles in patients was decreased approximately 12-fold compared to 
microparticle numbers in healthy controls. Thereafter microparticle numbers gradually increased 
(friedman Test: P<0.01), though not yet reaching normal levels at 30 days. The tissue factor 
positive fraction of microparticles however was about 2-4 times higher in patients, rising from 
12% (IQr 7-25) to 24% (IQr 14-60) from day of admission to day 30, than in controls (6% 
(IQr 4-8)). No significant differences were observed between patients with circulatory failure 
and patients without circulatory failure (not shown). 
Number and time course of microparticles from various cell sources
Platelet derived microparticles were identified using an anti-CD61 (GPIIIA) mAb. Absolute 
numbers of CD61-positive microparticles were found to be decreased with respect to the 
numbers in controls particularly on day of admission (more than 35-fold decrease) and on 
days 1 and 2 (Table 1). After day 2 absolute numbers started to increase, although not reaching 
normal values during 30 day follow up (friedman Test: P<0.01). Dynamics of total microparticle 
count were mainly explained by the initial depletion and following rise in platelet microparticle 
numbers.
endothelial cell derived microparticles were identified by staining with an anti-CD62e 
(e-selectin) mAb. on all study days, endothelial cell derived microparticle numbers, though very 
low, tended to be higher in particular on day of admission and on days 7 and 30, compared to 
controls. In time however, endothelial cell derived microparticles did not change significantly 
opmaak karin joop_23147.indd   134 12-02-2009   08:47:08
eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIoN AND CoAGULATIoN  eNDoToXIN AND mICroPArTICLeS AS mArKS for INfLAmmATIo
135
Decrease number of platelet derived microparticles in severe dengu virus infections
(friedman Test: P=0.25). Absolute numbers of microparticles derived from monocytes (anti-
CD14), Th-cells (anti-CD4) and Ts-cells (anti-CD8) were somewhat higher than endothelial 
microparticle numbers and appeared significantly elevated both in the first three days of 
admission and at day 30. The numbers of microparticles derived from erythrocytes (anti-
Glycophorin A mAb), granulocytes (anti-CD66e mAb) and B-cells (anti-CD20 mAb) were 
comparable to controls (Table 1).
4. Discussion
This study shows that patients with a severe dengue virus infection have a significant decrease in 
absolute number of circulating microparticles. The decrease was found to be mainly caused by 
a deficiency in platelet-derived microparticles: a more than 35-fold reduction in CD61 (GPIIIA) 
positive microparticles, accompanied by a modest rise in absolute numbers of microparticles 
originating from some other cell populations like endothelial cells, monocytes, Th-cells and  
T
s
-cells. The decreased numbers of microparticles originating from platelets may provide a clue 
to the mechanism by which Dengue virus causes a potentially fatal haemorrhagic disease. 
Upon activation cells lose their asymmetric orientation of membrane phospholipids and 
form a procoagulant surface by exposing phosphatidylserine18. The transverse migration 
of phosphatidylserine generally coincides with the formation of phosphatidylserine-rich 
microparticles. Thus, in healthy individuals a significant number of cell derived microparticles 
Table 1. microparticle number in dengue virus infected patients during admission and in healthy controls.
Cell marker Day 0 Day 1 Day 2 Day 7 Day 30 Control
All Annexin V 205  216 222 612 608 2530
microparticles  (122-283) (115-332) (144-362) (323-1123)  (365-1348) (2399-3184)
endothelial e-selectin  10 1 2 14 5 1
cells (CD62e) (1-24) (0-5) (1-3) (0-37) (2-17)* (0-2)
Platelets GPIIIA  50 62 73 455 431 1814
 (CD61) (38-88)* (36-154)* (49-127)* (161-927)* (162-956)* (1177-2319)
erythrocytes Glyco A 40  55 48 54 48 33
  (28-149) (29-118) (22-174) (41-80) (29-80) (18-50)
Granulocyte CD66e 18 26 24 60 36 43
  (13-31)* (12-69) (11-34) (35-136) (15-78) (25-49)
monocyte CD14 11  2 11 12 3 1
  (6-20)* (2-7)*  (5-25)* (4-30)* (1-21) (0-2)
B-cell CD20 10 8 14 19 14 8
   (7-19) (4-18) (6-29) (5-68) (7-38) (3-13)
Th-cell CD4 16 9 4 12 9 4
   (8-18)* (3-18) (2-10)  (1-24) (3-18) (1-6)
TS-cell CD8 18 (7-40) 12 (8-20)* 16 (6-52) 18 (4-40) 24 (7-32) 7
       (2-9)
Data are expressed as median with corresponding interquartile range and represent number x106/l plasma.
*P<0.05 (mann-Whitney U test) for patients versus control
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has been found in the circulation that support low grade thrombin generation19. Under 
pathophysiological conditions, the number of microparticles is generally increased, allowing a 
potentially significant increase in the rate of thrombin formation by increasing the procoagulant 
surface. The significance of this process is illustrated in Scott syndrome, a clinical condition 
that is associated with a decreased surface exposure of plasma membrane phosphatidylserine 
and an impaired capacity to generate microparticles20. Patients typically suffer from a moderate 
to severe bleeding tendency and studies have demonstrated that the defect involves a protein 
(scramblase) which mediates the loss of membrane asymmetry with exposure of procoagulant 
phosphatidylserine on the outer membrane leaflet10,18,20. 
Severe dengue virus infections are characterized by a haemorrhagic tendency but only moderate 
thrombocytopenia. In our study, median values for platelet count varied from 73.000 cells/mm3 
on day of admission, 42.000 cells/mm3 on the first day after admission, to 59.000 cells/mm3 on 
the second day after admission. Interestingly, platelet derived microparticle deficiency was more 
pronounced than the thrombocytopenia itself, and we did not find an association between platelet 
numbers and levels of platelet derived microparticles (Spearman’s rho 0.08, (P=0.73)). This 
suggests that microparticle production from thrombocytes (or megakaryocytes,31,32 is inhibited 
directly by the virus infection instead of the infection having an indirect effect via suppression of 
platelet production21-26. 
In conclusion, our study demonstrates that Dengue virus infections may cause a near deficiency 
in absolute numbers of platelet-derived microparticles. Although relatively low numbers 
of microparticles have also been found in other acquired syndromes, this is the first report 
demonstrating a near deficiency of platelet-derived microparticles due to a severe infection 
resulting in a clinically significant haemorrhagic tendency. Although the primary mechanism 
that causes this deficiency remains to be determined, the decreased numbers of microparticles, 
especially those originating from platelets, could play an important role in dengue disease 
severity. The study of dengue virus associated abnormalities in microparticle number may give 
important insights in how viruses influence the complex coagulation cascade. 
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Abstract
objective: Type 2 diabetes is associated with increased plasma concentrations of markers of 
coagulation and inflammation. Different studies show that treatment with hmG-CoA reductase 
inhibitors (’statins’) is associated with anti-thrombotic and anti-inflammatory effects in addition 
to its cholesterol-lowering effect. our objective was to evaluate the effect of pravastatin (40  
mg/day) on markers of coagulation and inflammation in patients with type 2 diabetes. 
research design and methods: This was an open, randomized, cross over study, designed with an 
8 week intervention period. The study group was comprised  of 50 patients with type 2 diabetes 
(median hbA1c 7.1%) and serum total cholesterol of 5-10 mmol/l.  We evaluated plasma 
levels of fibrinogen, f1+2, D-dimer, soluble tissue factor (sTf), von Willebrand factor antigen 
(vWfag) and C-reactive protein (CrP) in blood samples drawn after fasting on day 1 and after 8 
and 16 weeks.
results: Significant reductions of total cholesterol (-22%, p<0.001), LDL-cholesterol (-32%, 
p<0.001) and triglycerides (-10%, p<0.05) were achieved after 8 weeks of treatment with 
pravastatin. In addition, significant reductions of plasma levels of f1+2 (-4.4%, p<0.05), vWfag 
(-5.3%, p<0.05) and sTf (-3.4%, p<0.05) were observed after treatment with pravastatin. 
furthermore, plasma levels of CrP were also significantly reduced (-13%, p<0.05). Levels of 
fibrinogen and D-dimer did not decrease after treatment with pravastatin. 
Conclusion: This study indicates that pravastatin reduces levels of markers of coagulation and 
inflammation in patients with type 2 diabetes. These anti-thrombotic and anti-inflammatory 
effects of treatment with statins could play a role in the reduction of cardiovascular 
complications in patients with type 2 diabetes. 
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1. Introduction
Type 2 diabetes is a leading cause of vascular morbidity and death. It is often complicated 
by other cardiovascular risk factors such as hypercholesterolemia, hypertension, obesity and 
increased markers of coagulation1 and inflammation2. It has therefore been recommended that 
therapeutic prevention of cardiovascular disease in type 2 diabetes focus not only on optimal 
regulation of hyperglycemia but also on treatment of other cardiovascular risk factors3,4. 
 A subgroup analysis of several large randomized clinical trials5,6 shows that the relative risk for 
cardiovascular complications in type 2 diabetic patients can be reduced by 25% using aggressive 
treatment of dyslipidemia with hydroxymethylglutaryl-CoA reductase inhibitors, also known as 
statins. Treatment with statins may be beneficial not only because of these agents’ lipid-lowering 
action, but also because of their effect on inflammation, endothelial function, adhesion of 
leucocytes to endothelium and thrombus formation7. Although statins have proven to be effective 
in the prevention of cardiovascular disease in type 2 diabetes, little is known about these so-
called pleiotropic effects in patients with type 2 diabetes. 
our objective was to determine if treatment with pravastatin has potential anti-thrombotic 
and anti-inflammatory effects in patients with well-controlled type 2 diabetes. Therefore, we 
evaluated the effect of pravastatin on coagulation and inflammation markers in patients with type 
2 diabetes and serum total cholesterol of 5-10 mmol/l. 
2. Research design and methods
In this crossover trial 50 type 2 diabetic patients were studied to evaluate the effect of pravastatin 
on plasma coagulation and inflammation markers. A cross over design was chosen to allow 
treatment comparisons in one subject rather than between subjects and because the sample size 
needed for detection of treatment effects is smaller. Patients were recruited from the outpatient 
clinic of the Slotervaart hospital (Amsterdam, The Netherlands). men and women aged 18-80 
years who were diagnosed with type 2 diabetes for at least one year and presented with serum 
cholesterol levels of 5.0-10.0 mmol/l were eligible for the study. Patients with acute medical 
conditions; surgery during the past 3 months; deep venous thrombosis or pulmonary embolism 
during the previous 3 months; significant renal, hepatic; metabolic or thyroid diseases; alcohol 
abuse or known familial hypercholesterolemia were excluded. Included patients were not 
concurrently receiving other lipid lowering, antithrombotic, or hormonal treatment, but were 
allowed to use an acetylsalicylic acid. Patients maintained their regular diet during the study 
period. 
An open-label, randomized, cross over design was used. one half of the subjects (group A) 
began with pravastatin (Selektine, Bristol myers Squibb, Woerden, The Netherlands, 40 mg/day), 
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and the other half (group B) began with no treatment. Patients visited the outpatient clinic on 
day one, after the first period of 8 weeks, at which time pravastatin or no treatment was crossed 
over for another 8-week period, and after 16 weeks at the end of the study. At each visit blood 
samples were taken and patients’ blood pressure was measured. The active treatment and its 
possible effects on the measured variables were presupposed to be washed out after 8 weeks. 
Laboratory outcomes at day 1 and at 8 and 16 weeks were compared, with each patient being his 
or her own control. All patients gave their informed consent, and the institutional ethical review 
Board of the Slotervaart hospital, Amsterdam, approved the study.
2.1 Blood sampling and laboratory methods
Blood samples were obtained by standard venepuncture between 9:00 and 11:00 A.m. after a 
12-h fast. Total, hDL, and LDL-cholesterol, triglycerides and fibrinogen were determined using 
standard laboratory procedures within 1 h after sampling. hDL cholesterol was determined 
using a direct assay. Safety parameters included creatinine, alanine amino transferase (ALT), 
aspartate amino transferase (AST), and creatine phosphokinase (CK) were measured with 
standard techniques. Glycemic control was monitored by evaluating fasting glucose, measured 
with standard techniques, and hbA1c, determined by high performance liquid chromatography, 
as described elsewhere8. Levels of high-sensitivity C- reactive protein (hs-CrP) were determined 
with a near infrared particle immunoassay rate methodology (Beckman, Brea, CA). Analytical 
sensitivity, defined as the lowest measurable concentration that can be distinguished from 
zero with 95% confidence, is 0.2 mg/ml. measurements of prothrombin fragment f1+2 (Dade 
Behring, marburg, Germany), the von Willebrand factor antigen (vWfag) (antibodies from 
Dako, Glostrup, Denmark), and soluble tissue factor (sTf) (American Diagnostica, Greenwich, 
CT) were performed by enzyme-linked immunosorbent assay (eLISA). D-dimers were 
Table 1. Patient characteristics.
 Type 2 diabetes patients (n=50)
Age (years) 59 (54-64)
Sex ratio (m/f) 25/25
Body mass index: BmI (kg/m²) 28.9 (26.8-33.1)
Diabetes duration (years) 6.0 (3.0-10.3)
hbA1c (%) 6.9 (6.4-7,7)
Insulin treatment, n 31
ACe-inhibitor, n 11
A2-antagonist, n  5
Acetyl-salicylic-acid, n 13
Current smokers, n 12
Plasma glucose (mmol/l) 9.7 (8.2-12.2)
Total cholesterol (mmol/l) 6.3 (5.7-6.9)
LDL cholesterol (mmol/l) 4.1 (3.6-4.6)
hDL cholesterol (mmol/l) 1.2 (1.0-1.5)
Triglycerides (mmol/l) 1.7 (1.4-2.8)
n indicates number of patients. Values are medians with 25th -75th percentile between brackets.
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measured with an automated quantitative latex particle immunoassay (Biomérieux, Durham, 
NC). Interleukin (IL)-12-p70, IL-1β, IL-6, IL-10 and IL-8 were measured by cytometric bead 
array analysis (Beckton Dickinson Biosciences, San Diego, CA). Tumor necrosis factor-alpha 
(TNf-alpha) and IL-6 were measured with a high sensitivity eLISA (Quantikine hS human 
TNf-alpha and IL-6 eLISA; r&D systems europe, Abingdon, oxon, U.K.).
2.2 Statistics
results are presented as medians with 25th and 75th percentiles. After testing for normality, 
Student’s paired t test or Wilcoxon’s signed-rank test was used to compare values after a 
treatment or no-treatment period. The main outcome data were tested for carryover effect 
by comparing treatment effects between the two patients groups (group A vs. group B)9.  No 
carryover effect was determined. Thus, we pooled data from patients after the treatment period, 
irrespective whether they started out or ended with the treatment period, and compared those 
with pooled data from the no-treatment period. Spearman’s rank correlation coefficient analysis 
was used to examine associations between measured parameters. A two-tailed P≤0.05 was 
considered to indicate statistical significance.
3. Results
A total of 56 patients were randomized to begin the study with an 8-week period of either 
pravastatin therapy or no treatment. of those 56, 50 patients completed the study; 4 patients 
stopped during the treatment period because of side effects attributed to the medication (skin 
and gastrointestinal complaints), 1 patient stopped during the treatment period because he had a 
myocardial infarction, and 1 patient stopped because lung carcinoma was detected. 
Baseline clinical characteristics of the 50 patients are presented in Table 1. The median age of the 
patients was 59 years. Patients were overweight, with a median BmI of 29 kg/m².  Patients’ diabetes 
was well controlled, with the median hbA1c being 7.1%. In all, 62% of the patients were treated with 
insulin alone or in combination with oral antidiabetic agents, whereas the other 38% were treated 
with oral medication alone. In addition, 42% of the patients used medication for hypertension and 
26% used acetyl-salicylic acid.
3.1 Serum lipids and safety parameters
The effects of therapy are shown in Table 2. Data are expressed as medians with 25th and 75th 
percentile. Statistically significant reductions of total cholesterol (-1.4 mmol/l (-1.9 to -1.0)), 
LDL cholesterol (-1.3 mmol/l (-1.74 to -0.95)) and triglycerides (-0.19 mmol/l (-0.55 to -0.08)) 
were achieved after treatment by pravastatin, indicating satisfactory compliance with the study 
medication. hDL levels did not change during drug treatment. Pravastatin did not influence 
glycemic control:  hbA1c and glucose levels remained unchanged during treatment. Treatment 
with pravastatin did not significantly change safety parameters CK, ALT and AST.
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3.2 Markers of coagulation and inflammation
The effects of therapy on the principal study outcome markers are summarized in table 2. A 
statistically significant reduction in plasma levels of hs-CrP (-0.52 mg/dL (-1.34 to 0.27)) was 
achieved by pravastatin treatment. The prothrombin activation marker f1+2 was slightly, but 
significantly lower (-0.04 nmol/L (-0.2 to 0.04)) after active treatment. The selected markers 
of endothelial dysfunction, vWfag (-7% (-12 to 3)) and sTf (-4 pg/ml (-45 to 4.5)) were 
also significantly reduced after pravastatin treatment. Despite the overall reduction in vWfag 
levels, the median concentration of vWfag was increased after treatment compared with before 
treatment (138% (103 to 175) vs. 131% (114 to 162)) because of the extreme nonnormal 
distribution (figure 1). 
Treatment did not significantly lower the levels of fibrinogen, D-dimer, IL-8 or TNf-alpha. 
In 20% of patients IL-12-p70, IL-1β, IL-6 and IL-10 levels were detected with the cytometric 
bead array analysis. In this group of patients, no changes were measured after treatment with 
pravastatin (data not shown). We repeated the measurements of IL-6 using a high-sensitivity 
eLISA (r&D systems europe) with a detection limit P0.05 pg/ml. IL-6 was still detectable 
only in 35% of patients. In the patients with detectable IL-6 levels, no changes were observed 
before and after pravastatin treatment (2.9 pg/ml (1.8 to 3.2) vs. 2.6 pg/ml (1.9 to 4.5) (P=0.3). 
To identify possible mechanisms for the decrease of CrP, f1+2, sTf and vWfag after 
pravastatin treatment, correlations with changes in other parameters were assessed. A 
statistically significant correlation was observed between change in f1+2 and degree of change 
of D-dimer (r=0.534; P<0.0001), a finding that fits the notion that thrombin generation (f1+2) 
is associated with fibrin formation and proteolytic cleavage (D-dimer). No correlation between 
change in f1+2 and changes in fibrinogen was observed. No correlations were found between 
Table 2. effect of pravastatin on lipids and coagulation and inflammation markers
 No treatment After pravastatin p-value g (after treatment – 
    after no-treatment)
Total cholesterol, mmol/l 6.3 (5.6, 7.0) 4.9 (4.1, 5.4) < 0.001* - 1.4 (-1.9, -1.0)
LDL cholesterol, mmol/l 4.0 (3.6, 4.6) 2.7 (2.4, 3.0) < 0.001* -1.3 (-1.74, -0.95)
hDL cholesterol, mmol/l 1.2 (1.0, 1.5) 1.2 (1.0, 1.4) 0.699*  0.03 (-0.11, 0.11)
hs-CrP, mg/dl 4.0 (2.0, 6.2) 3.3 (1.3, 4.7) 0.019† -0.52 (-1.34, 0.27)
TNf-alpha, pg/ml (2.6 (2.1, 3.8)  2.7 (2.2, 3.9)  0.967† +0.002 (-0.98, 1.5)
IL 8, pg/ml 6.2 (3.0, 11.7) 5.7 (3.0, 10.3) 0.956†   0 (-2.7, 3.9)
fibrinogen, g/l 3.2 (2.9, 3.9) 3.3 (2.8, 3.8) 0.231†   0 (-1.0, 3.0)
D-dimer, µg/ml 0.26 (0.19,0.39) 0.27 (0.19, 0.45) 0.104† -0.02 (-0.09, 0.05)
f1+2, nmol/l 0.92 (0.67, 1.29) 0.91 (0.63, 1.18) 0.007† -0.04 (-0.2, 0.04)
vWfag, % 131 (114, 162) 138 (103, 175) 0.027† -7 (-12, 3)
sTf, pg/ml 119 (87, 158) 104 (64, 146) 0.044∅ -4 (-45, 4.5)
Data are expressed as medians with 25th -75th percentile.  ∅ 
*Normal distributed variable.†Not- normal distributed variable.
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reductions of hs-CrP, f1+2, sTf and vWfag and changes in total, LDL or hDL cholesterol or 
triglycerides. A weak correlation was observed between degree of change of vWfag and the 
change of hs-CrP (r=0.312; P=0.031). No other correlations were found between the observed 
reductions in hs-CrP, f1+2, sTf and vWfag.
4. Discussion
Statins comprise a group of agents that are increasingly prescribed to counteract atherosclerosis 
and related cardiovascular complications. Statins also show marked clinical efficacy in 
individuals with type 2 diabetes. Several lines of evidence suggest that the beneficial effects of 
statins are attributable not only to their lipid-lowering action, but also the ’pleiotropic’ actions of 
statins. 
Current knowledge of such pleiotropic effects is largely derived from in vitro experiments and 
studies in patients with hypercholesterolemia. To specifically determine the effects of pravastatin 
on inflammation, coagulation, and endothelial activation markers in type 2 diabetic patients, we 
performed the present study. our data demonstrated that 2 months of treatment with pravastatin 
reduced the levels of CrP, f1+2, sTf, and vWfag. These biological alterations may have clinical 
significance, as type 2 diabetes is associated with increased inflammation and coagulation 
activity and impaired endothelial function.
CrP is a marker of inflammation; its plasma concentration levels correlate with the severity 
and extent of the atherosclerotic process in the arterial wall and is consistently associated with 
prognosis in ischemic heart disease. Several studies have shown that treatment with statins 
lowers CrP10-12 in hypercholesterolemic individuals and that patients with higher levels of CrP 
have greater benefit from treatment with statins than patients with lower concentrations13. In our 
study population of type 2 diabetic patients, we observed a significant reduction in plasma levels 
figure 1. The reduction of vWfag 
was -5.3 % after pravastatin 
treatment (dotted line) in spite of 
increased median concentration of 
vWfag (NT: 131% (114, 162) vs. 
PrAV: 138% (103, 175)) which is 
possible due to the extreme non-
normal distribution of vWfag. NT: 
after 8 weeks no- treatment; PrAV: 
after 8 weeks pravastatin treatment. 
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of CrP after treatment with pravastatin. This observation confirms previous observations14,15 and 
suggests that statins have anti-inflammatory properties in type 2 diabetic patients also. 
The anticoagulant potential of pravastatin was assessed by measuring two relevant markers, 
f1+2 and D-dimer. The f1+2 peptide fragment is released when prothrombin is converted into 
thrombin, with concentrations of f1+2 in plasma reflecting the amount of in vivo generated 
thrombin. Several studies have shown that statins reduce circulating levels of f1+216,17 and f1+2 
in samples from bleeding time wounds in patients with hypercholesterolemia18,19. Aoki et al.20 
showed that increased platelet-dependent thrombin generation in hypercholesterolemic patients 
normalizes after pravastatin treatment, whereas Szczeklik et al.18 found that simvastatin inhibits 
thrombin formation in bleeding time blood. Aspirin had no further effect on thrombin formation. 
Likewise, Dangas et al.19 showed that pravastatin reduced ex vivo thrombus formation, whereas 
the reduction was attenuated in patients on aspirin. The reduction in thrombin or thrombus 
formation in these studies may have been secondary to an antiplatelet effect of statins21. our 
study extends the above findings to patients with type 2 diabetes, in whom we observed that 
pravastatin lowered levels of f1+2. A possible explanation for this reduction of in vivo thrombin 
formation in these diabetic patients with mild hypercholesterolemia is that like in the previous 
described studies with hypercholesterolemic patients, platelet-mediated thrombin formation 
is reduced by statin treatment. In contrast, aspirin did not diminish thrombin production in 
these patients. The mechanism by which statins might influence platelet-mediated thrombin 
production remains unknown. In contrast to f1+2, we observed no significant reduction of the 
level of D-dimer after pravastatin treatment.  on the basis of our study we were not able to 
unravel the pathophysiological mechanism behind this observation.
Theoretically, a lowered cellular sTf production or exposure may also be responsible for 
reduced thrombin production. At this stage, it remains uncertain whether a reduced level of sTf, 
as observed in our study, may translate into lower thrombin production, because the role of sTf 
as a stimulus of coagulation has not been established. The small decrease in sTf should probably 
be interpreted as diminished proteolytic cleavage from injured endothelial cells, which would 
support the concept of stabilization of endothelial cell function by statins22.
The level of circulating vWfag is another marker that is considered to reflect endothelial 
injury. VWf is a glycoprotein stored in endothelial cells and secreted into the circulation. It 
increases in parallel with the degree of endothelial cell damage. In our patients the basal levels 
of vWfag were quite high (median 131%), a finding that might reflect the longer-term vascular 
perturbation inflicted by type 2 diabetes (median duration of type 2 diabetes in these patients 
was 6 years). The observed decrease of vWfag during treatment, confirming observations 
on statins in patients with hypercholesterolemia17; 23; 24, could be explained by an endothelial 
improving-effect of pravastatin. Data on endothelial cell-improving effects of statins in type 2 
diabetic patients are scarce and conflicting. endothelial cell-mediated vasoreactivity improves in 
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diabetic rats after treatment with pravastatin or cerivastatin25,26. In a study with diabetic patients, 
vasoreactivity improved as soon as after 3 days of treatment with cerivastatin.  In addition, 
the plasma level of soluble vascular adhesion molecule-1, a plasma marker for endothelial 
dysfunction, was decreased in these patients after 3 months of treatment14. however, another 
study reported the absence of any effect on nitric oxide-dependent vasoreactivity in type 2 
diabetic patients after 4 weeks of aggressive lipid-lowering treatment with atorvastatin27. To our 
knowledge, our study is the first to show that pravastatin reduces levels of vWfag and sTf in 
diabetes patients. 
fibrinogen has been claimed as an independent cardiovascular risk factor, and increased levels 
of fibrinogen have been observed in patients with various atherosclerotic diseases. one study 
in patients with poorly controlled diabetes showed a decrease of fibrinogen after treatment with 
pravastatin28. In the present study no change of fibrinogen was found after two months treatment. 
This finding is in line with the majority of studies in hypercholesterolemic patients, where no 
reduction in fibrinogen levels after statin treatment has been observed.
Some of the effects of pravastatin on thrombin formation and endothelial function may be 
induced by an anti-inflammatory action of this class of agents. Statins are able to block the 
synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety 
of intracellular signaling molecules. To identify a mechanism for the observed changes in 
inflammation, coagulation, and endothelial function after pravastatin treatment, correlations with 
reduction of lipids were assessed.  The fact that no significant correlation was found between 
reductions in CrP, f1+2, vWfag and sTf and the reduction of lipids, supports the concept that 
effects other than lipid-lowering action play a role in these changes. In addition, the change of 
vWfag after pravastatin treatment was associated with the degree of change of CrP, suggesting 
that the endothelial cell-improving effect was attributable to an anti-inflammatory and not a 
cholesterol-lowering effect of pravastatin. We speculated that the regulation of vWfag and sTf 
were related, both being markers of endothelial cell dysfunction. however, we did not find an 
association between changes of both parameters. This might be explained by a different pattern 
of cleavage, secretion or elimination from the circulation. 
In conclusion, our data demonstrate that treatment with pravastatin for 2 months induces anti-
inflammatory, anti-thrombotic and endothelial-improving actions in patients with type 2 diabetes 
and mild hypercholesterolemia. These findings provide an additional biological basis for the 
presumed importance of pleiotropic effects of statin treatment in patients with type 2 diabetes 
and cardiovascular disease.
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1. Introduction
Bacterial infection and particularly sepsis is associated with major complications like multiple 
organ failure, contributing to a persistent high mortality rate. In the management of patients with 
suspicion of gram negative sepsis, a major problem remains to be the timely diagnosis. Bacterial 
cultures require too much time and although novel PCr based techniques may help to establish 
an earlier identification of specific micro-organisms, rapid diagnosis remains a real challenge.  
In addition, patients with sepsis and other diseases associated with systemic activation of the 
immune system show signs of activated blood coagulation. This activated coagulation also 
involves the generation of microparticles (mP) that have become the subject of increasing 
interest because of their presumed involvement in the pathophysiology of inflammation and 
coagulation crosstalk. hence, an impact of mP in processes like sepsis related multi organ 
failure and thrombosis has been proposed. Thus, the quantification of mP and identification 
of their cellular source become of diagnostic interest in the management of diverse patient 
populations. 
2. Outline of this thesis 
The work presented in this thesis deals with both aspects of the pathophysiology of 
inflammation. first, the bacterial component endotoxin and its consequences in vivo; second, the 
generation of mP as part of the host response to inflammation. 
having outlined the general features of endotoxin and its analysis in chapter 1, we describe the 
applications of endotoxin testing in relation to outcomes in different settings. It should be noted 
that the development of the endotoxin assay in plasma as well as other fluids like cerebrospinal 
fluid, has been the subject of previous studies by the defendant in collaboration with other 
investigators1. The previous studies provide the basis for the application and validation of 
endotoxin assays in practice and the results of a number of such studies are included in this 
thesis.
3. Endotoxin 
The general idea underlying endotoxin measurement in biological material is that it confirms 
or rules out the presence of significant numbers of gram negative bacteria and for this purpose 
endotoxin assay by LAL test is a widely applied screening test. one relevant and widely used 
application is the screening of any biologically used products for endotoxin contamination. 
The second potential use of the endotoxin test is the determination of significant endotoxin 
concentrations in blood (plasma) as an indication of infection (clinical) or as a research tool, 
eg in studies where specific inflammatory stimuli are being investigated such as the intake of a 
high fat meal2. Several technical issues are important in this regard and have been the topic of 
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much discussion in the past decades. As outlined in chapter I endotoxins are bound to different 
molecules upon entry of the bloodstream. Compounds like BPI (Bactericidal Permeability 
Increasing Protein), LBP (LPS (endotoxin) Binding Protein) and different lipoproteins all bind 
and modify the biologic activity of endotoxin in blood. furthermore, neutralizing antibodies are 
generated and these act as important modifiers of endotoxin activity as well. Different methods 
have been and are being applied to optimize sensitivity and to maintain specificity for particular 
endotoxins. Without having to discuss all technical issues related to the quality of the assays, the 
aspect of analytical sensitivity is relevant to address shortly. 
4. The endotoxin  LAL assay
Independent of methodology all LAL assays are standardized using samples in water. Therefore, 
unless the sample is water some components of the solution may interfere with the LAL test 
such that the recovery of endotoxin is affected. The LAL assay is dependent on the proper 
activation of the cascade of serine protease that makes up the lysate. In a gel clot assay, the 
final step of the cascade involves the cleavage of the clotting protein, coagulogen, and its 
polymerization into a solid gel. The last step in a chromogenic assay is the cleavage of a 
chromogenic substrate and the resulting release of the chromophore pNA. Without the proper 
concentration of divalent cations, the enzymes in the lysate cannot function properly and this 
will not yield a readable signal. At extreme ph gel formation may be impaired; on the other hand 
highly basic solutions may cause non-enzymatic chromogenic substrate cleavage, suggesting 
more contamination than is actually present. In order to overcome LAL interference, heating4, 
dilution4, and chloroform extraction of serum/plasma were all found to be efficient in removing 
inhibition. Besides the interfering constituents in blood (plasma) an inhibitory effect of the 
anticoagulant in which the blood was collected, was noted. The same experiments suggested 
that higher levels of endotoxin were found in platelet rich plasma compared with platelet poor 
plasma5. 
4.1 Introduction of the international endotoxin standard
To further optimize the LAL assay the international standard was introduced and endotoxin 
levels expressed in endotoxin units (eU). This standardization makes it possible to compare 
LAL assay data from different laboratories, which was previously debated because of the 
difference in potencies of the standard endotoxin used to prepare the calibration curve. The eU 
is defined by the reference standard endotoxin eC-5 (escherichia coli-5). furthermore, LAL 
from different manufacturers and/or different lot numbers of LAL may have different potencies 
with the same standard of endotoxin. Therefore standard and lysate together are responsible for 
the eU of standards calibrated against the reference standard (eC-5).  
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4.2 Sensitive assay to determine levels endotoxin
The concentration of endotoxin measured with the gel-clot test has a detection range of 0.03-0.5 
eU/ml in water and the turbidimetric assay is sensitive down to 0.001 eU/ml3.  In comparison, 
with the chromogenic assay in blood in which the neutralizing capacity of blood elements is 
circumvented by heating the platelet rich plasma to 75°C, we could accomplish a detection 
limit of 0.0036 eU/ml4. A highly sensitive test may be relevant for excluding the presence 
of endotoxin in blood and indeed during the past decade a whole blood assay for endotoxin 
has been successfully applied to exclude gram-negative infection in patients admitted to the 
intensive care6. for this indication, the endotoxin activity assay has been approved by the 
fDA7,8. however, this particular assay was less suited for predicting subsequent morbidity, 
since there were no major differences in organ failure among those patients with a low, 
intermediate or high endotoxin level in this activity assay9. Thus, with the fDA approved 
endotoxin test low endotoxin levels fairly good rule out gram negative infection, but the host 
response to inflammation is less well predicted. The latter limitation does not seem odd given 
the array of host response molecules not directly associated with endotoxin that are involved in 
inflammation.
4.3 Neutralizing endotoxine antibodies
our studies involving the endotoxin assay confirm that the LAL based assay does not contribute 
much to the diagnosis of gram-negative infections. In cases of localized infections such as in the 
cattle study (chapter II) no systemic endotoxin activity was detected which may for a large part 
be explained by the presence of neutralizing antibodies. An argument supporting the importance 
of such antibodies is the observation that post-operative patients developing SIrS had lower 
serum Ig endotoxin antibodies levels than those who did not12.  In the study of Braun et al. 
decreased plasma endotoxin core antibodies in patients undergoing cardiac surgery are reported 
and the concentrations of these antibodies were significantly lower in patients developing moDS 
and were also predictors of long-term mortality10-11,13. Alternatively, there is little dissemination 
from localized infections to the systemic circulation, explaining low endotoxin levels in blood of 
these cows.
essentially, a similar question was tackled in the chapter on endurance performance.      
4.4 Endotoxin in healthy athletes
The initial hypothesis was that the gut barrier function for bacterial endotoxins and potentially 
for fungal beta glucans would be disturbed during severe prolonged exercise and would be a 
contributor to gastro-intestinal (GI) complaints10. 
As stated, the ironman distance triathlon in embrun in france is one of the most challenging 
long distance triathlons, hence we assumed that this would be an ’ideal’ trigger of inflammation. 
Although in 74% of the athletes a low level of endotoxemia was observed in the hours after 
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exercise, there was no correlation between systemic endotoxemia and GI complaints. In contrast, 
there was a clear cytokine response immediately after exercise and an acute phase response the 
day after exercise and both positive correlated with severe GI complaints. This study supports 
the leakage of endotoxin to the systemic blood compartment due to increased gut permeability 
and/or translocation of a.o. gram negative bacteria.  The fact that there was no correlation with 
systemic complaints after endurance training does not rule out a causal relation, which may be 
masked due to the fact that most inflammatory reactions are due to secondary messengers rather 
than direct endotoxin effects. The latter fits with the observation that cytokine releases as well 
as acute phase reactions were linked to systemic complaints. It should be noted that the transfer 
of endotoxin into the circulation might be an ongoing event also under physiological conditions. 
A number of papers have reported the presence of low levels of LPS in apparently normal 
individuals14-18. relative mild challenges such as the intake of a fat meal or smoking and minimal 
invasive procedures like colonoscopy may indeed raise the systemic level of endotoxin in blood. 
The reason for this phenomenon may be the relatively large amounts of endotoxin present in the 
gut (estimated as about 1 gram of LPS derived from 100 trillion commensal microorganisms), 
allowing for a trivial fraction of LPS to pass into the blood circulation occasionally. 
Under provoked conditions such as exercise and fatty meal intake, the fraction that passes to the 
blood may also be temporarily increased due to increased barrier permeability of the gut.  
It is known from previous studies that the prolonged severe exercise challenge in men is 
associated with ischemia of parts of the intestines that promote direct passage of bacteria  
and/or endotoxin to blood. The recent fatty meal study shows that even without gross intestinal 
disruption translocation of endotoxin occurs. A similar mechanism has been experimentally 
observed in hyperphagic leptin-deficient ob/ob mice as well as in hyperleptinemic db/db mice19. 
In addition, apo e -/- mice also had increased endotoxin levels in portal blood after a fatty 
meal as compared to normal mice20. Based on these observations the transfer (or translocation, 
or leakage) of endotoxin into the portal blood may be a relatively common phenomenon and 
the clearance function of the liver and other reticular endothelial compartments as well as the 
presence of neutralizing antibodies will then determine the persistence of endotoxin in blood. 
The clinical relevance of these physiological perturbations may be quite substantial. Prolonged 
exposure to endotoxin and the generated inflammatory mediators may be a contributor to 
atherosclerosis. The relation with such long term diseases may be postulated on the basis of 
prolonged and repeated challenges with endotoxin from the gut after fatty meals or in conditions 
such as chronic infection during periodontitis21. These pathophysiological connections merit 
more thorough experimental and clinical studies. 
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4.5 PCT sensitive marker for bacterial infections
In addition, a new marker, procalcitonin (PCT), was measured. PCT levels appeared to be 
more sensitive and specific than C-reactive protein (CrP) and interleukin 6 (IL-6) in the 
differentiation between bacterial infection and other inflammatory processes. The PCT levels 
before exercise were low and increased 4-fold after exercise, however they did not correlate 
with endotoxin or creatine kinase (as indicator of muscle damage) levels. Nevertheless, PCT 
levels correlated with the acute phase reaction indicated by CrP and IL-6 rises in blood. hence, 
it appeared that PCT measurements did not give an early indication of inflammation, but were 
probably induced by exercise induced cytokine release. 
5. Endotoxin and procalcitonin assays in inflammatory disease
To determine whether in a setting of community acquired infection the endotoxin assay would be 
helpful in predicting outcomes we performed the study described in chapters VI. here, we also 
tested a rapid bedside test for endotoxin in comparison with the traditional LAL assay (chapter V). 
The two assays did not match well in detecting endotoxin levels, moreover neither test predicted 
a complicated course in patients with a community-acquired infection. We found that in patients 
that were clinically stable on admission the main factors associated with fatal outcome were high 
age and co-morbidity, while endotoxin, cytokines (IL-6, TNf-alpha, IL-10) and PCT levels were 
not sufficiently predictive. recent data suggest that the prognostic value of PCT testing may be 
improved by serial measurements in combination with determination of lactate. The rising trend 
of both lactate and PCT, especially between day 1 and 2, had superior prognostic value for 28 
day mortality compared with absolute levels22. PCT is also investigated in the context of other 
inflammatory diseases. An example is the observation of high levels of PCT in patients with critical 
illness in heatstroke and the further validation of this biomarker may be of interest23.  
Nevertheless, in our study (chapter V) in patients that were in shock upon admission the 
endotoxin assay was the best predictor of fatal outcome. In summary, in clinical practice, 
endotoxin testing in patients suspected from infection is only warranted to exclude a poor 
outcome in those already hospitalized at the intensive care department. In patients already in 
shock, the endotoxin assay may predict a poor outcome. In practice, it is our impression that 
the endotoxin assays are  not widely used for either purpose, because of the limited specificity 
coupled to many technical problems in performing such tests at the bedside or at a rapid 
laboratory basis. however, in clinical medicine the endotoxin assay is not the only laboratory 
test that performs poorly. In patients with inflammatory diseases such as sepsis, there is no single 
test that predicts outcomes sufficiently well to guide management decisions. 
The choice of antibiotics for instance remains based primarily on detection of the 
microorganism, either by culture or nowadays increasingly by PCr based methods that safe 
time, rather than on indirect markers such as endotoxin, CrP or PCT. 
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6. Microparticles
During sepsis DIC is supposed to be one of the main contributors to multi organ failure. This 
association between an activated coagulation system and a systemic inflammatory state led 
to a number of experimental studies of the underlying mechanisms, involving coagulation 
and fibrinolysis in relation to inflammation and its mediators. one of the elements that drew 
attention of clinical researchers was the microparticle (mP) fraction released upon activation 
of intravascular cells. Indeed, over the past years the interest in mP has substantially increased. 
The first studied mP was from platelets and early studies showed that these platelet derived mP 
were highly procoagulant. In addition, it became clear that all vascular cells could contribute 
to the circulating mP fraction, although platelets are the abundant fraction in plasma from 
normal individuals24 as well as plasma from patients with diverse conditions.  Since sepsis is 
a microvascular disorder involving large vascular beds it could be expected that mP would 
be a potentially relevant contributor to procoagulant activity in blood.  one of the postulated 
mechanisms was that monocytes that induced tissue factor at their surface during endotoxemia25 
would also provide tissue factor enriched mP as a trigger of DIC. Indeed this was confirmed 
by the study of meningococcal sepsis in which thrombin generation in plasma was initiated by 
microparticles in a factor VII/tissue factor dependent way26. We studied platelet, granulocyte, 
erythrocyte and endothelial mP and their tissue factor expression in 9 patients with sepsis 
and multiple organ failure. This analysis provided some surprising data. first, in contrast 
to the expectation that mP would be increased in concentration during sepsis, the numbers 
of particles were reduced compared to healthy controls and differed in their cellular origin. 
Second, thrombin generation triggered by mP from the plasma of these patients occurred only 
partially in a factor VII/tissue factor dependent way. In fact in 8/9 of these patients thrombin 
was generated in a factor XI dependent way and in 2 patients there was evidence of factor 
XII mediated thrombin generation. The blood from 2 patients in whom the contribution of 
factor XII was largest (based on the strongest inhibition of thrombin generation by anti-factor 
XII antibodies) contained both the largest number of granulocyte derived mP and the highest 
elastase concentration. In this regard it is of interest that recent studies provide a novel role 
for the contact activation system. In particular factor XII appears to be involved in collagen 
stimulated platelet dependent thrombin generation in vitro27,28 and this may be the mechanism 
by which factor XII contributes to arterial thrombus formation and stability29 . The liberation of 
mP carrying factor XII would point to a mechanism by which contact activation indeed supports 
thrombin generation and potentially arterial thrombosis.  
6.1 General hypothesis of MP in sepsis
The difference between thrombin formation in meningococcal sepsis by a factor VII/tissue 
factor dependent way and in postoperative sepsis by a factor XII dependent way, merits further 
investigation.
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In general, the interpretation of mP fractions in plasma should be regarded with caution. It was 
quite surprising to note that the concentration of mP was lower in patients with sepsis than in 
normals. however, if we assume that mP are actively involved in processes like thrombosis 
one would indeed expect that mP’s with greatest coagulation potency are being scavenged in 
ongoing thrombotic processes. The studies from the furie group have in detail revealed that 
mPs’contribute to thrombus formation in experimental models30-32. The tissue factor bearing 
mP are probably a major source of ’blood borne’ tissue factor activity33,34 and the finding of 
low or absent tissue factor bearing mP in plasma cannot be seen as an indication of the absence 
of such particles in blood. In fact, the opposite may be the case, where mP carrying factor XII 
antigen may not be active participants in thrombosis, however this remains highly speculative.  
In addition, mP of any cellular origin are captured in atherosclerotic plaques33, thus mP that still 
circulate reflect merely the process of mP formation. 
6.2 MP in Dengue virus infection 
To further investigate the involvement of mP in a systemic inflammatory condition we studied 
mP during severe Dengue virus infection. Severe Dengue virus infection is characterized by 
a haemorrhagic tendency and thrombocytopenia. Assuming mP as active participants in the 
pathophysiology of haemostasis and thrombosis it was anticipated that both mP concentrations and 
characteristics would be altered as compared to normal individuals. In our study 2 patients suffered 
from uncomplicated dengue fever (Df), 4 patients suffered from the potentially life-threatening 
dengue haemorrhagic fever (Dhf) and 2 patients suffered from dengue shock syndrome (DSS). All 
of these patients had a significant decrease in absolute number of circulating mP, with a striking 
deficiency in platelet-derived mP. The latter may be explained by a lack of circulating platelets due 
to impaired bone marrow production, although the scavenging of platelet mP in leaky vessels (to 
prevent bleeding) may also be a relevant protective mechanism. In this study we did not detect an 
association between mP and severity of disease.  We observed a rise in absolute numbers of mP 
originating from other cell populations like endothelial cells, monocytes, Th-cells and Ts-cells, and a 
relatively large percentage of mP exposing tissue factor. Patterns of mP and associated tissue factor 
should also be regarded with caution, since the cellular association not necessarily reflects the source 
of tissue factor. This issue has since many years been a topic of controversy in the case of tissue 
factor on neutrophils36-38. however, studies now indicate that blood cells and their mP may not only 
be involved in production of molecules such as tissue factor but are also able to scavenge (or absorb) 
molecules perhaps as a means of transportation36.
6.3 Sources of tissue factor during infections
The primary source of cellular tissue factor is uncertain in most diseases.  endothelial cells 
probably do not express tissue factor in vivo. Platelets are able to generate tissue factor as 
demonstrated in recent studies39.  monocytic tissue factor may be transferred to activate platelets. 
In plasma from healthy subjects tissue factor-like activity, identified via partial inactivation 
by anti-tissue factor antibodies, is found. In addition to mP-bound tissue factor, plasma tissue 
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factor also comprises the alternatively spliced, truncated human tissue factor, but its function, 
if any, remains to be established. Both truncated and full-length tissue factor are present in 
experimental thrombi, hence a function of truncated tissue factor may be postulated. Since the 
truncated form of tissue factor does not have procoagulant activity it may in fact inhibit full 
length tissue factor and act as a natural anticoagulant40,41. 
As a hypothetical mechanism we postulate that during infections monocytes/macrophages 
provide the primary source of tissue factor. When monocytes/macrophages shed mP with tissue 
factor activity, they may transfer this tissue factor to activated platelets. To further transfer 
tissue factor to endothelial cells by platelets and/or mP shed from platelets the presence of 
P-selectin glycoprotein ligand-1 (PSGL-1) on activated platelets and endothelial cells, also 
known as CD62P, plays a critical role. P-selectin is an adhesion molecule which interacts 
between platelets and endothelial cells.  Platelet P-selectin also acts in concert with PSGL-1 
in monocytic synthesis of tissue factor. Tissue factor gene expression is transiently induced in 
human adherent monocytes, reaching maximal tissue factor protein levels between days 3 and 
542-44. This may explain the time path we observed in Dengue virus infection where there was 
a trend for enhanced tissue factor exposure on monocytic particles at day 2 and on endothelial 
derived particles at day 3. Secondly, a near deficiency in absolute numbers of platelet-derived 
microparticles may have been caused by the interaction between activated vascular endothelial 
cells and platelet derived mP.
We have not addressed the thrombin generating capacity of Dengue virus associated mP yet 
and we therefore are uncertain whether the circulating mP fraction has pro-hemostatic activity, 
which might potentially control bleeding in patients with Dengue hemorrhagic fever. The 
observation that infusion of either desmopressin or recombinant activated factor VIIa in patients 
with a bleeding tendency increases mP number and procoagulant activity45,46 is suggestive of 
a contributing effect of mP induced by these prohemostatic agents in patients suffering from 
severe Dengue virus infection48-50. 
6.4 MP in diabetes Mellitus type 2
In the last chapter we explore some characteristics of mP in a cross-over study in diabetes 
mellitus type 2 (Dm2) patients treated with statins. Several studies indicate that enhanced 
platelet activation is a relevant phenomenon in patients with Dm2 and the degree of platelet 
activation (measured as tromboxane B2 in serum) is correlated with degree of glycemic control 
(hbA1c)47. Whether platelet activity is also associated with clinical disease such as degree of 
atherosclerosis and cardiovascular outcomes is uncertain. With regard to therapy, inhibition of 
platelets with aspirin is only indicated in patients with additional cardiovascular risk factors and 
not as primary prevention.  
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An increased level of circulating mP has been suggested to be one of the procoagulant 
determinants in patients with Dm2 and high levels of mP have been observed in such 
patients. Statins are a group of cholesterol lowering drugs with potential pleiotropic effects 
including modulation of inflammatory and procoagulant activity49 A number of studies have 
shown that statin treatment has an influence on platelet activation50,51 and platelet membrane 
composition52,53. In our study pravastatin clearly reduced cholesterol levels, however the total 
number of mP and mP expressing tissue factor was not different after 8 weeks of treatment. 
Pravastatin did however affect the platelet membrane composition suggested by a reduction 
of GPIIb/IIIa density on platelet-derived microparticles. GPIIb/IIIa, known as the fibrinogen 
receptor on platelets, is released from the platelet’s storage pool and transported to the cell 
membrane upon platelet activation54. Interestingly, there was no significant correlation between 
cholesterol levels and GPIIb/IIIa density of the mP suggesting that processes other than lipid 
metabolism are involved in mP formation in patients with Dm2. The functional implications of 
attenuation of GPIIb/IIIa receptors may be of some importance, since in patients with Dm2, the 
parentally used GPIIb/IIIa inhibitors have been shown to be more effective in reducing coronary 
occlusion after percutaneous coronary interventions than in patients without diabetes55,56. 
7. Future
Taken together it appears from experimental studies that mP are contributing factors to 
thrombosis due to their procoagulant activity, mainly characterized by expression of tissue 
factor, but also in part by other proteins such as factor XII. mP may be critical messengers 
among cells and be involved in cell-cell communication by exchanging specific proteins like 
tissue factor and P-selectin. The membrane composition, as eg indicated by density of specific 
receptors like GPIIb/IIIa, may contribute to specific features of the prothrombotic nature of mP. 
In addition to participating in thrombosis, mP may be regulators of hemostasis and the finding of 
lowered mP in hemorrhagic disorders like dengue hemorrhagic fever suggests a pro-hemostatic 
function. That way mP may be both helpful (hemostasis) and detrimental thrombosis players in 
the delicate hemostatic balance in health as well as disease. 
from a diagnostic point of view it should be noted that the detectable fraction of mP in blood 
may not be the pathophysiologically relevant fraction in situations where mP are thought to 
be absorbed in (thrombosis) or on atherosclerotic lesions. recent studies point to a potentially 
clinically relevant diagnostic application, ie in malignancies. here, elevated mP in blood has 
been detected in cancers, and in some cases the number has been associated with the severity of 
disease. however, both their diagnostic utility and pathophysiological relevance in cancer and 
thrombosis remains to be determined.  
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Summary
Inflammation, either bacterial or nonbacterial, coagulation and the determinants of their 
interplay are longstanding topics of research. The present thesis describes the application of 
laboratory diagnostic and research tools in various disease states and models relating to this 
interplay, as discussed in Chapter 1.  
Chapter II: Eelationship between intra-uterine bacterial contamination, endotoxin levels 
and the development of endometritis in postpartum cows with dystocia or retained placenta
This study investigated the relationship between intra-uterine bacterial contamination, endotoxin 
levels and the development of endometritis in cows that experienced a dystocia or retained 
their placenta. from a total of 59 cows plasma and uterine lochia samples were collected to 
determine lipopolysaccharide (LPS) and the plasma IgG anti-LPS concentrations. of these 
cows, 15 were healthy, 31 suffered from retained placenta (rP) and 13 had dystocia, All were 
clinically examined 1 or 2 days after parturition. rP cows had significantly higher LPS levels in 
uterine lochia as compared to cows with dystocia and healthy postpartum cows. high LPS levels 
in lochia at 1 or 2 days postpartum were significantly related to abnormal cervical discharge. 
Nevertheless, LPS was not detectable in blood in any group, also no significant difference 
was measured in anti-LPS IgG levels in plasma. We concluded that the presence of e. coli and 
LPS (endotoxins) in lochia early postpartum favors the development of uterine infections by 
A. pyogenes and gram-negative anaerobes later postpartum. LPS was not observed in plasma, 
suggesting that either it is not absorbed into the blood, or IgG anti-LPS or other detoxification 
mechanisms efficiently detoxify them. 
Chapter III: Relationship between gastro-intestinal complaints and endotoxemia, cytokine  
release and the acute-phase reaction during and after a long-distance triathlon in highly trained 
men
This study was performed to establish whether the gastro-intestinal (GI) complaints observed 
during and after ultra-endurance exercise are related to gut ischaemia-associated leakage 
of endotoxins into the circulation and subsequent cytokine production. We collected blood 
samples from 29 athletes before, immediately after, and at 1, 2 and 16 hours after a long-
distance triathlon. most participants (93%) had gastro-intestinal symptoms, and even 7% of the 
participants abandoned the race because of severe gastro-intestinal distress. endotoxin levels 
were detectable in 68% of the athletes, associated with a reduction in IgG anti-LPS antibody 
levels. We observed immediately after the race an increased plasma level of IL-6 reflective of 
an acute phase response, associated with an increase in CrP and a decrease in pre-albumin 
concentrations. Nevertheless, we could not establish any significant correlation between 
the extent of endotoxemia and the gastro-intestinal symptoms. Although LPS does enter the 
circulation after ultra-endurance exercise, LPS leakage does not seem to be responsible for the 
observed gastro-intestinal problems in these athletes. 
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Chapter IV: Plasma procalcitonin before and after ultra endurance exercise 
To investigate whether levels of plasma procalcitonin are indicative for bacterial translocation 
and are not elevated by muscle damage, we have determined plasma levels of procalcitonin, 
endotoxin and creatininekinase before and after ultra endurance exercise. There was (mild) 
endotoxemia and significant muscle damage detectable in some, but not all (29), athletes, even 
before and at 1, 2 and 16 hours after the exercise. Plasma procalcitonin concentrations before 
exercise were low, and increased after the exercise. Plasma procalcitonin concentrations did 
not significantly correlate with endotoxin levels or with increasing plasma concentrations of 
creatinekinase (muscle damage). Nevertheless, the maximum procalcitonin concentrations 
correlate with maximum IL-6 levels and with the acute phase reactant CrP. We concluded that 
during and after ultra endurance exercise the rise in procalcitonin is likely to be induced by 
exercise-induced cytokine alterations.
Chapter V: Predictive values for fatal outcome in septic patients: A comparison between the 
SIMPLY RED®- and the chromogenic LPS-assays
The presence of LPS in the systemic circulation is an important predictor of for fatal outcome. 
The detection of LPS by the regular chromogenic Limulus amoebocyte lysate (LAL) assay is 
too expensive and labour intensive to perform on only a few patient samples per day. A simple 
bedside test applied on a whole blood sample, the SimplireD® endotoxin (Sre) assay, has been 
reported to be of clinical value in critically ill patients. In the present study we evaluated the 
LAL and Sre assays for their ability to predict mortality in patients clinically suspected to have 
sepsis.
74 Patients were included; out of 61 septic patients 6 died as result of sepsis, while in 13 
patients sepsis could not be confirmed by bacterial culture. of the 55 survivors, samples of 5 
were positive for the LAL, 12 for the Sre and 2 for both assays. Both the positive and negative 
predictive values were low for both assays in all septic patients. even when considering 
APAChe II score selected patients the positive and negative predicted value remained too low 
for clinical use. The performance of the blood and local cultures were similar to the results of 
the both endotoxin assays. We conclude that neither the Sre nor the LAL assay is useful in 
predicting or excluding mortality in patients clinically suspected of having sepsis.  
Chapter VI: Endotoxin, cytokines and procalcitonin in febrile patients admitted to hospital: 
identification of subjects with high mortality risk
We prospectively examined 464 febrile patients (median age, 61 years) for predictors of in-
hospital death. We measured clinical data (age, underlying disease, duration of fever, chills, 
and shock on admission) and plasma endotoxin, TNf-alpha, IL-6, IL-10, and procalcitonin 
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levels. The mortality rate was higher in patients with shock on admission (n=31; 7nonsurvivors) 
compared to patients not in shock at admission (n=433; 26 nonsurvivors). The endotoxin 
concentration showed the strongest association with mortality risk, predicting 5 of the 7 deaths 
with a 5% false-positive rate. for patients without shock on admission, mortality was associated 
with age and underlying disease: clinical data predicted 30% of the deaths, whereas IL-6 and 
procalcitonin levels identified an extra 10%.
When febrile patients are screened on hospital admission to identify those with a high risk 
for mortality, clinical judgment (age, underlying disease, and recent history) outweighs the 
predictive value of endotoxin, cytokine, and procalcitonin levels. only in patients who present 
with shock measurement of endotoxin levels may help to predict a fatal outcome.
Chapter VII: Microparticles from patients with Multiple Organ Dysfunction Syndrome and 
Sepsis support coagulation through multiple mechanisms
We investigated the number and cellular origin of mP in patients with multiple organ 
dysfunction syndrome (moDS) and sepsis. 9 Patients and 14 healthy controls were included. 
Number and cellular origin of the mP were determined with flow-cytometry. The coagulation 
activation status in vivo was quantified by plasma prothrombin fragment f1+2- and thrombin-
antithrombin (TAT) measurements. 
Annexin V-positive mP in the patients originated predominantly from platelets (PmP), and to a 
lesser extent from erythrocytes, endothelial cells (emP) and granulocytes (GmP). 
Compared to healthy controls, the numbers of annexin V-positive PmP and Tf-exposing mP 
were decreased, emP were decreased or found equal, erythrocyte-derived mP were equal and 
GmP were increased. GmP numbers correlated with plasma concentrations of elastase, but not 
with CrP or IL-6 concentrations. Patient mP triggered thrombin formation, which was reduced 
compared to the healthy controls and strongly inhibited by an anti-factor XII moAb (n=2), by 
anti-factor XI moAb (n=8) or by anti-Tf moAb (n=4). Concentrations of f1+2 and TAT were 
elevated and correlated inversely proportional with the number of circulating mP and their 
thrombin generation capacity.
Chapter VIII: Decreased number of microparticles in severe dengue virus infection possible 
involment in disease pathogenesis.
Severe dengue virus infections are characterized by haemorrhagic manifestations that are 
thought to be due to a combination of thrombocytopenia and thrombocytopathia. recent data 
suggest that abnormalities in blood coagulation and fibrinolysis also play a role in disease 
severity. In view of the evidence for a role of mP in coagulation, we investigated the presence 
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and cellular source of circulating mP in patients suffering from a severe dengue virus infection. 
This study demonstrated a near deficiency of mP (especially platelet derived mP) during a 
severe infection. 
Chapter IX: Pravastatin reduces levels of the glycoprotein IIIa subunit from the fibrinogen 
receptor on platelet derived microparticles in patients with type 2 diabetes
A major clinical problem in patients with diabetes is the high risk for cardiovascular diseases.  
Different studies show that statins (hmG-CoA reductase inhibitors) reduce cardiovascular 
complications in patients with diabetes. This anti-thrombotic effect is primarily ascribed to its 
cholesterol lowering effect, however other so called pleiotropic effects have also be proposed. 
The objective in this study was to study the effect of pravastatin, in patients with diabetes (type 
2), on the number, cellular origin and antigenic composition of mP.
Patients (n=48) with type 2 diabetes were treated for 8 weeks in a cross over study with 
pravastatin or no medication. The number of mP was determined as annexin V positive 
signal determined with flow-cytometry, and the antigen composition of the mP with mean 
fluorescence. We found that the number, cellular origin and the tissue factor exposure on mP 
was unaffected by pravastatin. Nevertheless there was a reduction, during Pravastatin treatment, 
of Glycoprotein IIIa (CD61) on platelet mP. reduced expression of the fibrinogen receptor and 
may be responsible in part for the risk reduction of cardiovascular event by statin treatment.
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In dit proefschrift wordt een aantal aspecten beschreven welke samenhangen met de reactie van 
het lichaam op ontsteking. Twee aspecten spelen een hoofdrol in het proefschrift: ten eerste, 
de meting in lichaamsvloeistoffen van bacterieel endotoxine (lipopolysaccharide, LPS), als 
belangrijke mediator van bacteriële infectie in mens en dier. Ten tweede, de reactie van de 
bloedstolling op ontsteking en hiermee gepaard gaande ziektebeelden. Specifiek werd onderzoek 
gedaan naar het vrijkomen in bloed van micropartikels (mP) en dan met name naar de cellulaire 
afkomst en relevantie van deze mP. In hoofdstuk 1 wordt de achtergrond van dit onderzoek 
geschetst en wordt ingegaan op de opbouw van het proefschrift, omvattende twee verschillende 
onderdelen. 
Hoofdstuk II: Relatie tussen bacteriële baarmoeder ontsteking, endotoxine concentraties en het 
ontwikkelen van baarmoederslijmvliesontsteking in runderen na een moeilijke bevalling of bij 
het achterblijven van de placenta.
Deze studie bestudeert de relatie tussen bacteriële baarmoederontsteking en endotoxine 
concentraties enerzijds, en het ontwikkelen van baarmoederslijmvliesontsteking nadat de koe 
een moeilijke bevalling heeft gehad of wanneer de placenta achterblijft anderzijds. Van de 
59 runderen werden plasma en baarmoeder slijmmonsters verzameld, waarin de endotoxine 
concentraties werden bepaald. In het plasma werd ook de IgG anti-endotoxine concentratie 
gemeten. 
Van deze 59 runderen waren 15 gezond met een normale bevalling, 31 waarbij de placenta was 
achtergebleven (’retained placenta’, rP) en 13 hadden dystocia. Alle runderen werden klinisch 
onderzocht 1 of 2 dagen na baring. De runderen met rP hadden beduidend hogere niveaus 
LPS in het baarmoederslijm vergeleken met dystocia en gezonde postpartum koeien. De hoge 
niveaus LPS in baarmoederslijm bij 1 of 2 dagen post partum hadden een duidelijke relatie met 
betrekking tot abnormale cervicale vloeiing. Desalniettemin, was er geen LPS aantoonbaar in 
het plasma van deze drie groepen runderen, ook werden geen significante verschillen gemeten 
in niveaus van anti-LPS IgG in plasma. Concluderend uit deze studie, zou de aanwezigheid van 
e. coli en LPS (endotoxinen) in baarmoederslijm postpartum een aanwijzing kunnen zijn voor 
het ontwikkelen van bacteriële baarmoederontsteking post partum. het niet aantoonbaar zijn 
van LPS in plasma zou verklaard kunnen worden, doordat  LPS niet de baarmoederwand kan 
passeren, of doordat  anti-LPS antistoffen het LPS efficiënt binden en klaren. 
Hoofdstuk III: Verband tussen gastro-intestinale klachten en endotoxemia, cytokinen en de 
acuut-fase reactie tijdens en na een triatlon, bij zeer getrainde atleten.
Deze studie werd uitgevoerd om vast te stellen of de gastro-intestinale (GI) klachten die tijdens 
en na zeer extreme inspanningen worden waargenomen in relatie kon worden gebracht met 
darm ischemie geassocieerde lekkage van endotoxine in de circulatie met bijbehorende cytokine 
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productie. Bij 29 atleten werd bloed afgenomen voor de triatlon, onmiddellijk daarna, en 1, 2 en 
16 uur na de triatlon. De meeste deelnemers (93%) hadden gastro-intestinale symptomen, en 7%  
van de deelnemers verlieten de race wegens gastro-intestinale problemen. endotoxines waren 
aantoonbaar in 68% van de atleten, in relatie met verlaagde anti IgG anti-LPS concentraties in 
het bloed. ook werd onmiddellijk na de race een verhoogde acuut fasereactie waargenomen 
met een duidelijk verhoogde IL-6 concentratie, gepaard gaande met een verhoogd  CrP en een 
daling van de pre-albumine concentraties. er werd geen significante correlatie aangetoond tussen 
endotoxemia en de gastro-intestinale klachten. hoewel bekend is dat LPS  vanuit de darmen naar 
de systemische circulatie kan passeren gedurende extreme inspanningen, kon er geen verband 
worden aangetoond tussen de gastro-intestinale klachten en het aangetoonde LPS in het bloed.
Hoofdstuk IV: Plasma procalcitonine  concentratie voor en na extreme inspanning
om te onderzoeken of verhoogde concentraties procalcitonine in plasma van atleten indicatief zijn 
voor bacteriële translocatie en verklaard worden door spierschade, zijn plasmaconcentraties van 
procalcitonine, endotoxine en creatininekinase voor en na extreme inspanning bepaald. er waren 
(milde) endotoxemie en significante spierschade aantoonbaar in de meeste, maar niet alle atleten 
(29), vóór en na, 1, 2 en 16 uren van inspanning. Concentraties van het plasma procalcitonine vóór 
waren laag, en stegen na de inspanning. Concentraties van het plasma procalcitonine correleerden 
niet met endotoxine concentraties of met stijgende plasmaconcentraties van creatinekinase (maat 
voor spierschade). Wel correleerden de maximale procalcitonine concentraties met maximale IL-6 
concentraties en met de acuut fase reactant CrP. Concluderend, tijdens en na extreme inspanning 
stijgt de procalcitonine concentratie in bloed, hetgeen waarschijnlijk samenhangt met pro-
inflammatoire cytokine productie en niet door lekkage van endotoxines.
Hoofdstuk V: Voorspellende waarden voor septische patiënten met hoge mortaliteit: Een 
vergelijking tussen de SIMPLY RED® en de LAL LPS-bepaling.
De aanwezigheid van LPS in de circulatie is een belangrijke voorspeller van een slechte 
prognose bij patiënten. De bepaling van LPS door de chromogene amoebocyte Limulus lysate 
(LAL) analyse is duur en arbeidsintensief om dagelijks uit te voeren. een eenvoudige bedside 
test die rechtstreeks op volbloed kan worden toegepast is de endotoxine SImPLY reD®  (Sre) 
test, een potentieel klinisch waardevolle test in patiënten met sepsis. In de huidige studie 
vergelijken wij de chromogene LAL en Sre test en bepalen we de voorspellende waarde in 
patiënten met een  klinisch beeld van sepsis. 
Vierenzeventig patiënten werden geincludeerd; waarvan 61 bewezen sepsis hadden.  6 patiënten  
stierven als gevolg van sepsis, en  in 13 patiënten kon sepsis niet worden bevestigd door een 
positieve bacteriële kweek. Van de 55 overlevenden, waren er 5 positief in de LAL, 12 in de Sre 
en 2 in beide testen.
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Zowel de positieve als negatieve voorspellende waarden voor beide analyses, in alle septische 
patiënten, waren laag. ook wanneer de APAChe II score van de patiënten werd meegenomen 
in overweging bleven de positieve en negatieve voorspellende waarden te laag voor klinisch 
gebruik van een van beide tests. De voorspellende waarden van de bloed- en de lokale kweken 
waren gelijk aan de resultaten van de beide endotoxine analyses. In deze studie  kon voor zowel 
de  Sre als de LAL test niet worden aangetoond dat deze  te gebruiken is als voorspeller van 
mortaliteit in patiënten met klinisch bewezen sepsis. 
Hoofdstuk VI: Endotoxine, cytokinen en procalcitonine in koortsachtige patiënten opgenomen in 
het ziekenhuis: identificatie van patiënten met een hoog mortaliteitsrisico.
Wij onderzochten in 464 koortsachtige patiënten (gemiddelde leeftijd 61 jaar) de voorspellers 
van mortaliteit. 
Naast anamnestische factoren (leeftijd, onderliggende ziekte, duur van koorts, rillingen, en shock 
bij opname) werden TNf-alpha waarden,  plasma endotoxine, IL-6, IL-10, en procalcitonine 
concentraties in bloed gemeten. De mortaliteit was hoger in patiënten die in shock waren bij 
opname (n=31; 7 overleden) vergeleken bij patiënten die dat niet waren bij opname (n=433; 26 
overleden). De endotoxine concentratie was de beste voorspeller van het  mortaliteitsrisico, deze 
voorspelde 5 van de 7 overleden patiënten. Voor patiënten die niet in shock waren bij opname, 
was de mortaliteit geassocieerd met hogere leeftijd en onderliggende ziekte: de klinische 
gegevens verzameld bij de anamnese voorspelden 30% van de sterfgevallen, terwijl IL-6 en 
procalcitonine concentraties een additionele 10% identificeerden.
Wanneer patiënten met koorts in het ziekenhuis worden opgenomen,  is het klinische oordeel (leeftijd, 
onderliggende ziekte, en recente medische geschiedenis)  een betere voorspeller  voor mortaliteit 
dan de waarden bij opname van endotoxine, cytokine, en procalcitonine. Bij patiënten  die zich 
presenteren in shock is de endotoxine-waarde ook een voorspeller voor een slechte prognose.
Hoofdstuk VII: Micropartikels van patiënten met meervoudig orgaan falen en sepsis bevorderen 
de stolling via meerdere wegen
Wij onderzochten het aantal en de cellulaire oorsprong van micropartikels (mP) in patiënten 
met  meervoudig orgaan falen (mof) en sepsis. 9 Patiënten en 14 gezonde controles werden 
onderzocht op de aanwezigheid van mP in bloedmonsters. het aantal en de cellulaire oorsprong 
van de mPs werden bepaald met behulp van flowcytometrie. De stollingsstatus werd bepaald 
door plasma protrombine fragment f1+2- en trombine-antitrombine complex (TAT) metingen.
De meeste Annexine V positieve mPs  waren afkomstig van plaatjes (PmP) en in mindere mate 
van erytrocyten, endotheel cellen (emP) en granulocyten (GmP). 
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Vergeleken met gezonde controles, waren de aantallen PmP die Annexin V en tissue factor 
positief waren verlaagd,  emP waren gelijk of verlaagd,  emP waren gelijk en GmP waren 
verhoogd. GmP aantallen correleerden met plasmaconcentraties van elastase, maar niet met 
CrP of IL-6 concentraties.
 mP afkomstig van de patiënten bevorderden de trombine vorming, die vergeleken met de 
gezonde controles sterk rembaar was door toevoeging van anti-factor XII monoklonaal (n=2), 
anti-factor XI monoklonaal (n=8), of anti-Tf monoklonaal (n=4). De concentraties f1+2 en TAT 
waren verhoogd en correleerden omgekeerd evenredig met het aantal circulerende mP en hun 
trombone-vormende capaciteit.
Hoofdstuk VIII: Verlaagd aantal micropartikels in ernstige  knokkelkoorts infectie: mogelijke rol 
in   pathogenese? 
Knokkelkoorts (dengue hemorrhagic fever) infectie wordt in de ernstige fase van de ziekte 
ondermeer gekenmerkt door bloedingen,  hetgeen wordt toegeschreven aan thrombocytopenie 
en thrombocytopathie. recente studies suggereren dat de abnormale bloedstolling en fibrinolyse 
een rol spelen in de bloedingsneiging in dit ziektebeeld. omdat er aanwijzingen zijn voor een 
rol van de mP  in de stolling, bestudeerden wij de aanwezigheid van mP en hun cellulaire 
oorsprong in patiënten met een ernstige knokkelkoortsinfectie.
Kinderen met verdenking van knokkelkoorts in de leeftijd van 2 tot 14 jaar, die werden 
opgenomen in de intensive care van het kinderziekenhuis Dr. Kariadi hospital in Semarang, 
Indonesia, werden in deze studie opgenomen. Gezonden schoolgaande  kinderen in de leeftijd 
categorie 6 tot 13 jaar, en uit hetzelfde gebied als de zieken kinderen waren de controle groep. 
De diagnose knokkelkoorts werd via een serologische antigeen test en rNA immuun blot test 
bevestigd. Van acht willekeurige patientjes met een bewezen knokkelkoorts infectie werd van de 
tijdserie, dag 0 (opname),dag 1,2,7 en 30 o.a. mP bepaald.
het aantal thrombocyten was lager op dag 1 en 2 dan op de dag van opname en op dag 7 was het 
aantal genormaliseerd. het aantal mP was bij opname en de eerste 2 dagen verlaagd en bereikten 
normale aantallen op dag 30 in vergelijking met de controles. Deze studie toonde een verlaagd 
aantal mP (m.n. mP afkomstig van plaatjes) gedurende ernstige infectie aan.
Hoofdstuk IX: Pravastatine vermindert glycoproteïne IIIa, de fibrinogeen receptor op 
micropartikels afkomstig van bloedplaatjes in patiënten met type 2 diabetes.
een belangrijk klinisch probleem in patiënten met diabetes is het risico van cardiovasculaire 
complicaties. De verschillende studies tonen aan dat statines (hmG-CoA reductase remmers) 
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het risico op cardiovasculaire complicaties in patiënten met diabetes kunnen verminderen. 
Dit beschermende effect wordt hoofdzakelijk toegeschreven aan het cholesterol verlagend 
vermogen, hoewel andere, zogenaamd pleiotrope effecten van statines ook worden gepostuleerd. 
De doelstelling in deze studie was om het effect van pravastatine, in patiënten met diabetes (type 
2), op het aantal, cellulaire oorsprong en antigene samenstelling van mP te bestuderen.  
Patiënten (n=48) met type diabetes 2 werden in een cross-over studie, 8 weken behandeld met 
pravastatine en 8 weken zonder.
met behulp van flowcytometrie werd het totaal aantal, de cellulaire oorsprong en de antigeen 
samenstelling van de mP bepaald.
Wij vonden dat het aantal, de cellulaire oorsprong en de tissue factor expressie op de mP niet 
door pravastatine werden beïnvloed. Wel was er een verlaging van Glycoproteïne IIIa (CD61) 
op mP afkomstig van bloedplaatjes tijdens de behandeling met pravastatine. De verminderde 
fibrinogeen receptor  zou theoretisch een bijdrage kunnen leveren aan het gunstige effect van 
statine-behandeling bij patiënten met diabetes, maar meer onderzoek is ook hier aangewezen.  
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Dit proefschrift heeft vele dieptepunten en hoogtepunten gekend. het is een periode geweest 
waar in ik veel  geleerd maar ook afgeleerd heb, compromissen leren maken en mijn idealen heb 
leren bijstellen. Ik heb met zeer veel mensen samengewerkt waarvan ik verre weg de meeste een 
warm hart toedraag. helaas kan ik niet ontkennen dat er toch ook enkele teleurstellingen waren.  
Niet te min is het proefschrift een rugzak geweest die ik lange tijd heb gedragen. Ik ben dan ook 
trots en dankbaar dat de promotie een feit geworden is, hoewel het zonder die rugzak vreemd zal 
voelen.
hoewel het proefschrift mijn naam draagt, hebben er velen aan bijgedragen. Guus Sturk wil 
ik bedanken, omdat hij degene geweest is die de eerste kans heeft geboden om zelfstandig 
onderzoek te doen in het LUmC te Leiden. helaas heb ik mijn proefschrift niet bij jouw groep 
afgemaakt, omdat wij zo verschillend in het leven staan. rienk Nieuwland wil ik bedanken voor 
zijn bijdrage bij het schrijven van hoofdstuk VIII.
Aan de afdeling infectie-ziekten ben ik veel dank verschuldigd, met name professor van Dissel, 
voor het leveren van plasmamonsters en klinische gegevens van koortsige patiënten (hoofdstuk 
VI). Twee andere medewerkers van deze afdeling waren mijn steun en toeverlaat. Lieve Paul en 
hanneke  jullie hebben mij de kliniek leren verkennen en mij ook laten inzien dat het recruiteren 
van patiënten voor ons onderzoek een tijdrovende zaak is. Ik heb zeer veel van jullie geleerd.
De hele groep medewerkers van de klinische chemisch laboratorium in het LUmC heb ik als 
zeer sympathieke en hulpvaardige groep ervaren en wil deze daarvoor bedanken. Toch wil 
ik een paar mensen met wie ik nauw samen hebt gewerkt er uitlichten; margo en marja voor 
het overnemen en verder opzetten van de volbloed stimulatie. marry en margreth voor het 
overnemen van de endotoxine bepaling. Als er een reeks creatinine kinase bepalingen moest 
worden gedaan was dat geen moeite om het te regelen met ‘Wimmie’ en als ze dan gedaan 
werden stond henny in zijn avonddienst klaar om alles te bepalen. Buiten de inhoudelijke 
bijdrage zijn sociale oppeppraatjes zeker zeer belangrijk. Lieve Conny tegen jouw kon ik altijd 
aanzeuren als dingen niet zo lekker gingen. op jouw luisterend oor kon ik altijd rekenen, we 
hebben samen ook heel wat afgelachen. Philiph ook jij had altijd een luisterend oor wanneer 
het niet zo lekker ging. Bij eef kon ik altijd terecht voor goede raad. Als echte gebruiker van de 
computer stuit je op allerlei problemen en dan was mijn noodkreet: ‘Urban!’ Jij was altijd weer 
bereid om mij uit de computerproblemen te helpen.
De mensen van het research lab LUmC wil ik bedanken voor hun bijdragen; Lieve fred, jij met 
je altijd goeie humeur hebt me geholpen met het analyseren van de mof monsters. ook  Anita, 
ria, marianne en rené bedank ik voor hun ondersteuning en hulp.
een van die hoogtepunten was absoluut de triatlon-studie in samenwerking met de universiteit 
van maastricht samen met Ton Wagenmakers, Asker Jeukendrup, Joan Senden en Jos Stegen. 
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het lab was in een tent in embrun. het meemaken van onderzoek doen op locatie was een 
ervaring om nooit te vergeten. 
Toen ik in het oLVG ging werken heb ik mijn rugzakje weer mee genomen en zijn de laatste 
twee hoofdstukken ontstaan. Samen met Anja Leyte was het opzetten van research op de een 
diagnostisch lab een ware uitdaging. Anja, jij was degene die mij weer aangemoedigd heb 
om het proefschrift af te ronden. Jij heb me kennis laten maken met ronne en Dirkje. het 
samen werken met jou, ronne, was zeer inspirerend, ik heb je leren kennen als een echte 
wetenschapper: gedreven en enthousiast. Jouw Dengue-studie gaf weer een nieuwe dimensie 
aan de betekenis van mPs. We hebben heel wat gepuzzeld om een overzicht te krijgen in alle 
gegevens. Wat uiteindelijk toch geresulteerd heeft in een mooi artikel. De diabetes-studie samen 
met Dirkje was een verrassende studie. Jij, Dirkje, hoogzwanger in die tijd, was super om samen 
mee te werken. 
De mensen van het oLVG lab waren een geweldige groep mensen, een aantal wil ik met name 
bedanken. Dik(el), jij hebt heel wat getallen een tweede controle-ronde gegeven. Verder de 
samenwerking met frans, Cieleke, martijn en Wendy waren meer voor mij dan gewoon collega’s 
zijn. Daarom ook  lieve Wendy was jij bereid om naast mij te staan tijdens de promotie, wat ik 
enorm waardeer.
Lieve hugo, jouw steun en wijze woorden zijn onmisbaar geweest. Als ik met andere over jouw 
praat zeg ik altijd het is zo’n ‘schatje’. Jij bent degene die me iedere keer stimuleerde om verder 
te gaan. Zonder jouw zou dit boekje er niet zijn geweest. We kennen elkaar al vanaf 1981 en 
hebben zo ieder onze eigen weg bewandeld. Jij bent hoogleraar geworden in maastricht, en hebt 
Amsterdam achter je gelaten. onze wegen kruisten elkaar weer toen ik werkzaam was in het 
oLVG. De oude gekke verhalen uit de WG tijd kwamen weer boven. Dat jij mijn promotor wou 
zijn en in mij geloofde is een enorme eer.
De overstap naar de farmaceutische industrie was voor mij zeker een ‘eye opener’. Lieve 
Sarianne, jij als Pietje Precies hebt heel wat van mijn slordigheden zoals verschillen in 
lettertypes in het zelfde document gecorrigeerd. Ik die gewend was snel SoPs te lezen en 
daarom onderaan begon was voor jouw onbegrijpelijk! ook tijdens het schrijven van de 
bedelbrieven en andere stukjes was het jouw kritische blik die alle foutjes eruit haalden. Ik heb 
heel veel geleerd, misschien ben ik nu ook zo’n Pietje Precies?
Naast alle mensen in de werkomgeving zijn er ook mensen in de privé-sfeer, de zogenoemde 
‘sponsors’ (zie stelling). Lieve edith, ik wil je bedanken voor al die oppas-uurtjes. Ik kon je 
altijd bellen als er onverwachts een bespreking was. ook Carla jouw wil ik bedanken voor de 
tijd die je op maikel hebt gepast. 
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Lieve Pa en ma geen woorden zijn de juiste om mijn gevoel te beschrijven, maar jullie weten het 
wel………..
Wat mijn mannen betreft, jullie steun is natuurlijk onmisbaar geweest. Dit heb ik in ‘ode aan de 
mannen’ geprobeerd onder woorden te brengen. maar in hoeverre kan dat? Jullie hebben deze 
rugzak samen met mij gedragen.
Ik zal ongetwijfeld mensen zijn vergeten maar het zal duidelijk zijn dat deze rugzak door vele is 
gevuld. en ieder die mij kent weet wel dat ik ze een warm hard toedraag ook al ben ik je naam 
vergeten.
Zonder jullie………….
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ode aan mijn mannen
Ode aan mijn mannen 
Ik loop met jullie langs het strand 
Denk aan wat is geweest in tijden van vreugde en verdriet 
Kijk jullie één voor één aan 
En weet: zonder jullie ben ik niets 
Ik zie acht voeten op een rij, vier grote en vier kleine 
Vier grote zeer bedeesd, vier kleine aan het draven 
De vier kleine nemen mij zonder het te weten 
Bij de hand en laten mij zweven 
De twee grote trekken mij voorzichtig weer naar beneden 
Acht voeten maken afdrukken in het zand zonder het te weten 
Ik stop en kijk achter mij 
Maar als ik de afdrukken goed bekijk zie ik langs onze baan 
Daar waar het juist het moeilijkst was, maar zes afdrukken 
staan 
Verward kijk ik om me heen, waar zijn die van mij gebleven 
Juist toen ik jullie nodig had op het zwaarste deel van mijn 
pad 
Zes ogen kijken mij vol liefde aan en vier zeggen tegelijk: 
maar mamma 
Weet je dat dan niet! Toen het moeilijk was hebben we jou 
gedragen. 
Gebaseerd op het engelse gedicht uit 1936 ‘Foorprints in the sand’ van Mary Stevenson (1922-1999)  
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Karin Joop werd geboren op 26 maart 1962 te Zaandam. In 1978 deed zij mAVo-4 eind 
examen en in datzelfde jaar  werd aangevangen met de dag opleiding mBo Klinisch-
Chemie te Amsterdam. In 1981 werd het diploma behaald en is zij begonnen in het 
Wilhelmina Gasthuis  op de afdeling hematologie als analiste.  Na de verhuizing in 1983 
van het Wilhelmina gasthuis naar het Academisch medisch Centrum (AmC) behaalde zij 
in 1984 in de avonduren  het hBo-A diploma klinische chemie en was reeds werkzaam 
op gelijknamige afdeling. In 1988 werd eveneens in de avonduren het hBo-B medische-
Biologie gehaald en in 1989 werd zij hoofd-analiste op het fertiliteitslaboratorium in het 
AmC. In het kader van het fertiliteitsonderzoek schreef zij in het vakblad voor analisten 
en won daarmee in 1991 de Anna Wichers prijs. Na anderhalf jaar ging zij weer onderzoek 
doen op de afdeling hematologie waar zij in 1993 het hLo diploma klinische chemie 
avond-opleiding behaalde. ook doceerde zij van 1989 tot 1992 aan de hogeschool van 
Amsterdam. In 1994 is zij met de hoogleraar en een groep mensen uit het AmC naar het 
Leids Universitair medisch Centrum (LUmC) gegaan om daar onderzoek te doen naar 
infecties en coagulatie. Tussen 2001 tot eind 2005 is zij werkzaam geweest in het onze 
Lieve Vrouwe Gasthuis, waar zij de beenmerg diagnostiek heeft helpen opzetten. In 2006 
heeft zij beenmerg morfologie verricht, op de afdeling celdiagnostiek. in het Utrecht 
medisch Centrum. In 2007 heeft zij de overstap gemaakt naar de farmaceutische industrie. 
Na 1 jaar via Quintiles bij Centocor, Leiden te hebeen gewerkt als Clinical Trial Assistent. 
Is zij via Covance nu werkzaam bij merck Sharp & Dohme BV. te haarlem als Clinical 
research Associate.
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